<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0812222997
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Rosgan
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ROSUVASTATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        87.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Aurobindo Pharma Limited Unit VII" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Limited Unit VII
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 3103]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Saudi Arabia Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Saudi Arabia Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AA07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Rosgan belongs to a group of medicines called statins.<br />You have been prescribed Rosgan because:<br />&bull; You have a high cholesterol level. This means you are at risk from a heart attack or stroke.<br />Rosgan is used in adults, adolescents and children 6 years or older to treat high cholesterol.<br />&bull; You have been advised to take a statin, because changing your diet and doing more exercise were<br />not enough to correct your cholesterol levels. You should continue with your cholesterollowering<br />diet and exercise while you are taking Rosgan.<br />Or<br />&bull; You have other factors that increase your risk of having a heart attack, stroke or related health<br />problems. Heart attack, stroke and other problems can be caused by a disease called<br />atherosclerosis. Atherosclerosis is due to build-up of fatty deposits in your arteries.<br />Why it is important to keep taking Rosgan?<br />Rosgan is used to correct the levels of fatty substances in the blood called lipids, the most common of<br />which is cholesterol.<br />There are different types of cholesterol found in the blood &ndash; &lsquo;bad&rsquo; cholesterol (LDL-C) and &lsquo;good&rsquo;<br />cholesterol (HDL-C).<br />&bull; Rosgan can reduce the &lsquo;bad&rsquo; cholesterol and increase the &lsquo;good&rsquo; cholesterol.<br />&bull; It works by helping to block your body&rsquo;s production of &lsquo;bad&rsquo; cholesterol. It also improves your body&rsquo;s<br />ability to remove it from your blood.<br />For most people, high cholesterol does not affect the way they feel because it does not produce any<br />symptoms. However, if it is left untreated, fatty deposits can build up in the walls of your blood vessels<br />causing them to narrow.<br />Sometimes, these narrowed blood vessels can get blocked which can cut off the blood supply to the<br />heart or brain leading to a heart attack or a stroke. By lowering your cholesterol levels, you can reduce<br />your risk of having a heart attack, a stroke or related health problems. You need to keep taking<br />Rosgan, even if it has got your cholesterol to the right level, because it prevents your cholesterol<br />levels from creeping up again and causing build-up of fatty deposits.<br />However, you should stop if your doctor tells you to do so, or you have become pregnant.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not take Rosgan</strong><br />&bull; If you are allergic to rosuvastatin or any of the other ingredients of this medicine (listed in<br />section 6).<br />&bull; If you are pregnant or breastfeeding. If you become pregnant while taking Rosgan stop taking it<br />immediately and tell your doctor. Women should avoid becoming pregnant while taking Rosgan<br />by using suitable contraception.<br />&bull; If you have liver disease.<br />&bull; If you have severe kidney problems.<br />&bull; If you have repeated or unexplained muscle aches or pains.<br />&bull; If you take a drug combination of sofosbuvir/velpatasvir/voxilaprevir (used for viral infection of<br />the liver called hepatitis C).<br />&bull; If you take a drug called ciclosporin (used, for example, after organ transplants)<br />&bull; If you have ever developed a severe skin rash or skin peeling, blistering and/ or mouth sores after<br />taking Rosgan or other related medicines.<br />If any of the above applies to you (or you are in doubt), please go back and see your doctor.<br />In addition, do not take Rosgan 40 mg (the highest dose):<br />&bull; If you have moderate kidney problems (if in doubt, please ask your doctor).<br />&bull; If your thyroid gland is not working properly.<br />&bull; If you have had any repeated or unexplained muscle aches or pains, a personal or family<br />history of muscle problems, or a previous history of muscle problems when taking other<br />cholesterol-lowering medicines.<br />&bull; If you regularly drink large amounts of alcohol.<br />&bull; If you are of Asian origin (Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).<br />&bull; If you take other medicines called fibrates to lower your cholesterol.<br />If any of the above applies to you (or you are in doubt), please go back and see your doctor.</p><p dir="ltr"><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before taking Rosgan.<br />&bull; If you have problems with your kidneys.<br />&bull; If you have problems with your liver.<br />&bull; If you have had repeated or unexplained muscle aches or pains, a personal or family history of<br />muscle problems, or a previous history of muscle problems when taking other cholesterol-lowering<br />medicines. Tell your doctor immediately if you have unexplained muscle aches or pains especially if<br />you feel unwell or have a fever. Also tell your doctor or pharmacist if you have a muscle weakness<br />that is constant.<br />&bull; If you regularly drink large amounts of alcohol.<br />&bull; If your thyroid gland is not working properly.<br />&bull; If you take other medicines called fibrates to lower your cholesterol. Please read this leaflet<br />carefully, even if you have taken other medicines for high cholesterol before.<br />&bull; If you take medicines used to treat the HIV infection e.g. ritonavir with lopinavir and/or<br />atazanavir, please see &ldquo;Other medicines and Rosgan&rdquo;.<br />&bull; If you are taking or have taken in the last 7 days a medicine called fusidic acid (a medicine for<br />bacterial infection), orally or by injection. The combination of fusidic acid and Rosgan can lead to<br />serious muscle problems (rhabdomyolysis), please see &ldquo;Other medicines and Rosgan&rdquo;.<br />&bull; If you are over 70 (as your doctor needs to choose the right start dose of Rosgan to suit you)<br />&bull; If you have severe respiratory failure.<br />&bull; If you are of Asian origin &ndash; that is Japanese, Chinese, Filipino, Vietnamese, Korean and Indian.<br />Your doctor needs to choose the right start dose of Rosgan to suit you.<br />&bull; Serious skin reactions including Stevens-Johnson syndrome and drug reaction with eosinophilia<br />and systemic symptoms (DRESS) have been reported in association with Rosgan treatment. Stop<br />using Rosgan and seek medical attention immediately if you notice any of the symptoms described<br />in section 4.<br />If any of the above applies to you (or if you are not sure):<br />&bull; Do not take Rosgan 40 mg (the highest dose) and check with your doctor or pharmacist<br />before you actually start taking any dose of Rosgan.<br />In a small number of people, statins can affect the liver. This is identified by a simple test which looks<br />for increased levels of liver enzymes in the blood. For this reason, your doctor will usually carry out this<br />blood test (liver function test) before and during treatment with Rosgan.<br />While you are on this medicine your doctor will monitor you closely if you have diabetes or are at risk of<br />developing diabetes. You are likely to be at risk of developing diabetes if you have high levels of sugars<br />and fats in your blood, are overweight and have high blood pressure..<br /><strong>Children and adolescents</strong><br />&bull; If the patient is under 6 years old: Rosgan should not be given to children younger than 6 years.<br />&bull; If the patient is below 18 years of age: The Rosgan 40 mg tablet is not suitable for use in<br />children and adolescents below 18 years of age.</p><p dir="ltr"><strong>Other medicines and Rosgan</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<br />Tell your doctor if you are taking any of the following:<br />&bull; ciclosporin (used for example, after organ transplants),<br />&bull; warfarin or clopidogrel (or any other drug used for thinning the blood),<br />&bull; fibrates (such as gemfibrozil, fenofibrate) or any other medicine used to lower cholesterol (such as<br />ezetimibe),<br />&bull; indigestion remedies (used to neutralise acid in your stomach),<br />&bull; erythromycin (an antibiotic), fusidic acid (an antibiotic &ndash; please see below and Warnings and<br />precautions),<br />&bull; an oral contraceptive (the pill),<br />&bull; regorafenib (used to treat cancer),<br />&bull; darolutamide (used to treat cancer),<br />&bull; hormone replacement therapy<br />&bull; any of the following drugs used to treat viral infections, including HIV or hepatitis C infection, alone<br />or in combination (please see Warnings and precautions): ritonavir, lopinavir, atazanavir, sofosbuvir,<br />voxilaprevir, simeprevir, ombitasvir, paritaprevir, dasabuvir, velpatasvir, grazoprevir, elbasvir,<br />glecaprevir, pibrentasvir.<br />The effects of these medicines could be changed by Rosgan or they could change the effect of Rosgan.<br />If you need to take oral fusidic acid to treat a bacterial infection you will need to temporarily<br />stop using this medicine.<br />Your doctor will tell you when it is safe to restart Rosgan. Taking Rosgan with fusidic acid may<br />rarely lead to muscle weakness, tenderness or pain (rhabdomyolysis). See more information<br />regarding rhabdomyolysis in Section 4.<br /><strong>Pregnancy, breast-feeding and fertility</strong><br />Do not take Rosgan if you are pregnant or breast-feeding. If you become pregnant while taking Rosgan<br />stop taking it immediately and tell your doctor. Women should avoid becoming pregnant while taking<br />Rosgan by using suitable contraception.<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask<br />your doctor or pharmacist for advice before taking this medicine.<br /><strong>Driving and using machines</strong><br />Most people can drive a car and operate machinery while using Rosgan &ndash; it will not affect their ability.<br />However, some people feel dizzy during treatment with<br />Rosgan. If you feel dizzy, consult your doctor before attempting to drive or use machines.<br />Rosgan contains lactose. If you have been told by your doctor that you have an intolerance to some<br />sugars, contact your doctor before taking this medicinal product.<br />Rosgan film-coated tablets contain allura red AC and sunset yellow FCF, which may cause allergic<br />reactions.<br />For a full list of ingredients, please see Contents of the pack and other information.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if<br />you are not sure.<br />Recommended doses in adults if you are taking Rosgan for high cholesterol:<br />Starting dose<br />Your treatment with Rosuvastatin must start with the 5 mg or the 10 mg dose, even if you have taken<br />a higher dose of a different statin before. The choice of your start dose will depend upon:<br />&bull; Your cholesterol levels.<br />&bull; The level of risk you have of experiencing a heart attack or stroke.<br />&bull; Whether you have a factor that may make you more sensitive to possible side effects.<br />Please check with your doctor or pharmacist which start dose of Rosgan will best suit you.<br />Your doctor may decide to give you the lowest dose (5 mg) if:<br />&bull; You are of Asian origin (Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).<br />&bull; You are over 70 years of age.<br />&bull; You have moderate kidney problems.<br />&bull; You are at risk of muscle aches and pains (myopathy).<br />Increasing the dose and maximum daily dose<br />Your doctor may decide to increase your dose. This is so that you are taking the amount of<br />Rosuvastatin that is right for you. If you started with a 5 mg dose, your doctor may decide to double<br />this to 10 mg then 20 mg and then 40 mg if necessary.<br />If you started on 10 mg, your doctor may decide to double this to 20 mg and then 40 mg if necessary.<br />There will be a gap of four weeks between every dose adjustment.<br />The maximum daily dose of Rosuvastatin is 40 mg. It is only for patients with high cholesterol levels<br />and a high risk of heart attacks or stroke whose cholesterol levels are not lowered enough with 20 mg.<br />If you are taking Rosgan to reduce your risk of having a heart attack, stroke or related health<br />problems:<br />The recommended dose is 20 mg daily. However, your doctor may decide to use a lower dose if you<br />have any of the factors mentioned above.<br />Use in children and adolescents aged 6&ndash;17 years<br />The dose range in children and adolescents aged 6 to 17 years is 5 to 20 mg once daily. The usual start<br />dose is 5 mg per day and your doctor may gradually increase your dose to find the right amount of<br />Rosuvastatin for you. The maximum daily dose of Rosuvastatin is 10 mg or 20 mg for children aged 6 to<br />17 years depending on your underlying condition being treated.<br />Take your dose once a day. Rosgan 40 mg tablet should not be used by children.</p><p dir="ltr">Taking your tablets<br />Swallow each tablet whole with a drink of water.<br />Take Rosgan once daily. You can take it at any time of the day with or without food.<br />Try to take your tablet at the same time every day to help you to remember it.<br />Regular cholesterol checks<br />It is important to go back to your doctor for regular cholesterol checks, to make sure your cholesterol<br />has reached and is staying at the correct level.<br />Your doctor may decide to increase your dose so that you are taking the amount of Rosgan that is right<br />for you.<br />If you take more Rosgan than you should<br />Contact your doctor or nearest hospital for advice.<br />If you go into hospital or receive treatment for another condition, tell the medical staff that you&rsquo;re taking<br />Rosgan.<br />If you forget to take Rosgan<br />Don&rsquo;t worry, just take your next scheduled dose at the correct time.<br />Do not take a double dose to make up for a forgotten dose.<br />If you stop taking Rosgan<br />Talk to your doctor if you want to stop taking Rosgan. Your cholesterol levels might increase again if<br />you stop taking Rosgan.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />It is important that you are aware of what these side effects may be. They are usually mild and<br />disappear after a short time. Stop taking Rosgan and seek medical help immediately<br />If you have any of the following allergic reactions:<br />&bull; Difficulty in breathing, with or without swelling of the face, lips, tongue and/or throat<br />&bull; Swelling of the face, lips, tongue and/ or throat, which may cause difficulty in swallowing<br />&bull; Severe itching of the skin (with raised lumps).<br />&bull; Reddish non-elevated, target-like or circular patches on the trunk, often with central blisters, skin<br />peeling, ulcers of mouth, throat, nose, genitals and eyes. These serious skin rashes can be<br />preceded by fever and flu-like symptoms (Stevens-Johnson syndrome).<br />&bull; Widespread rash, high body temperature and enlarged lymph nodes (DRESS syndrome or drug<br />hypersensitivity syndrome).<br />Also, stop taking Rosgan and talk to your doctor immediately<br />&bull; If you have any unusual aches or pains in your muscles which go on for longer than you might<br />expect. Muscle symptoms are more common in children and adolescents than in adults. As with<br />other statins, a very small number of people have experienced unpleasant muscle effects and<br />rarely these have gone on to become a potentially life threatening muscle damage known as<br />rhabdomyolysis.<br />&bull; If you experience muscle rupture.<br />&bull; If you have lupus-like disease syndrome (including rash, joint disorders and effects on blood cells).<br />Common possible side effects: may affect up to 1 in 10 people<br />&bull; Headache<br />&bull; Stomach pain<br />&bull; Constipation<br />&bull; Feeling sick<br />&bull; Muscle pain<br />&bull; Feeling weak<br />&bull; Dizziness<br />&bull; An increase in the amount of protein in the urine &ndash; this usually returns to normal on its own without<br />having to stop taking your Rosuvastatin tablets (only Rosuvastatin 40 mg)<br />&bull; Diabetes. This is more likely if you have high levels of sugars and fats in your blood, are<br />overweight and have high blood pressure. Your doctor will monitor you while you are taking this<br />medicine.<br />Uncommon possible side effects: may affect up to 1 in 100 people<br />&bull; Rash, itching or other skin reactions<br />&bull; An increase in the amount of protein in the urine &ndash; this usually returns to normal on its own without<br />having to stop taking your Rosuvastatin tablets (only Rosuvastatin 5 mg, 10 mg and 20 mg).<br />Rare possible side effects: may affect up to 1 in 1,000 people<br />&bull; Severe allergic reaction &ndash; signs include swelling of the face, lips, tongue and/ or throat, difficulty in<br />swallowing and breathing, a severe itching of the skin (with raised lumps). If you think you are<br />having an allergic reaction, then stop taking Rosgan and seek medical help immediately<br />&bull; Muscle damage in adults &ndash; as a precaution, stop taking Rosgan and talk to your doctor<br />immediately if you have any unusual aches or pains in your muscles which go on for longer<br />than expected<br />&bull; A severe stomach pain (inflamed pancreas)<br />&bull; Increase in liver enzymes in the blood<br />&bull; Bleeding or bruising more easily than normal due to low level of blood platelets<br />&bull; Lupus-like disease syndrome (including rash, joint disorders and effects on blood cells).<br />Very rare possible side effects: may affect up to 1 in 10,000 people<br />&bull; Jaundice (yellowing of the skin and eyes)<br />&bull; Hepatitis (an inflamed liver)<br />&bull; Traces of blood in your urine<br />&bull; Damage to the nerves of your legs and arms (such as numbness)<br />&bull; Joint pain<br />&bull; Memory loss<br />&bull; Breast enlargement in men (gynaecomastia)</p><p dir="ltr">Side effects of not known frequency may include:<br />&bull; Diarrhoea (loose stools)<br />&bull; Cough<br />&bull; Shortness of breath<br />&bull; Oedema (swelling)<br />&bull; Sleep disturbances, including insomnia and nightmares<br />&bull; Sexual difficulties<br />&bull; Depression<br />&bull; Breathing problems, including persistent cough and/or shortness of breath or fever<br />&bull; Tendon injury<br />&bull; Muscle weakness that is constant</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">- Keep this medicine out of the sight and reach of children.<br />- Do not use this medicine after the expiry date which is stated after EXP on the blister and carton.<br />The expiry date refers to the last day of the month.<br />- Store below 30&deg;C.<br />- Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to<br />throw away medicines no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">What Rosgan contains<br />The active substance is Rosuvastatin. Each film-coated tablet contains 10 mg/20 mg/40 mg of Rosuvastatin<br />(as Rosuvastatin calcium).<br />The other ingredients are:<br />Tablet core: Lactose monohydrate, calcium hydrogen phosphate anhydrous, microcrystalline cellulose,<br />Crospovidone (type B), magnesium stearate.<br />Tablet film-coat: Hypromellose (15cP) (E464), lactose monohydrate, titanium dioxide (E171), sunset<br />yellow FCF (E110), allura red AC aluminium lake (E129), indigo carmine aluminium lake (E132),<br />triacetin.<br /><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Rosgan film-coated tablets 10 mg:
Pink coloured, round shaped, biconvex film-coated tablets, debossed with ‘J’ on one side and ‘54’ on
the other side.
Rosgan film-coated tablets 20 mg:
Pink coloured, round shaped, biconvex film-coated tablets, debossed with ‘J’ on one side and ‘55’ on
the other side.
Rosgan film-coated tablets 40 mg:
Pink coloured, oval shaped, biconvex film-coated tablets, debossed with ‘J’ on one side and ‘56’ on the
other side.
Rosgan Tablets are supplied in 30’s pack (10’s blister x 3)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Manufacturing Site:<br />Aurobindo Pharma Limited,<br />Unit VII, SEZ, TSIIC, Plot No. S1,<br />Survey No&rsquo;s: 411/P, 425/P, 434/P, 435/P &amp; 458/P,<br />Green Industrial Park, Polepally village, Jedcherla Mandal,<br />Mahaboobnagar District, Telangana State, India.<br />Marketing Authorization Holder:<br />Aurobindo Pharma Saudi Arabia Limited,<br />Jeddah, Saudi Arabia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last Revised in 08/2022, Version number is 00.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي روسجان لمجموعة من الأدوية تُسمى الستاتينات.<br />وُصف لك روسجان:<br />&bull; لأن مستوى الكوليستيرول لديك مرتفع. وهذا يعني أنك عرضة للإصابة بأزمة قلبية أو سكتة دماغية. يُستخدم روسجان لدي البالغين والمراهقين<br />والأطفال من عمر 6 سنوات أو أكثر لعلاج ارتفاع الكوليستيرول.<br />&bull; لأنك قد نُصحت بأخذ الستاتينات؛ وذلك لأن تغيير نظامك الغذائي وبذل المزيد من الجهد لم يكن كافيًا لتصحيح مستويات الكوليستيرول. يجب أن<br />تواظب على نظامك الغذائي المُخفض للكوليسترول وبذل المجهود البدني أثناء أخذ روسجان.<br />أو<br />&bull; لأنك تملك عوامل خطورة أخرى للإصابة بأزمة قلبية أو سكتة دماغية أو مشاكل صحية أخرى. يُمكن لمرض يُسمى تصلب الشرايين أن يُسبب<br />الأزمة القلبية أو السكتة الدماغية أو مشاكل أخرى. ويحدث تصلب الشرايين نتيجة تراكم الترسبات الدهنية بالشرايين.<br />لماذا من المهم الاستمرار في أخذ روسجان?<br />يُستخدم روسجان لتصحيح مستويات مواد دهنية توجد في الدم تُسمى الليبيدات، وأكثرها شيوعًا هو الكوليستيرول.<br />.(HDL-C) &ldquo; والكوليستيرول &rdquo;الجيد (LDL-C) &ldquo; توجد أنواع مختلفة من الكوليستيرول في الدم -الكوليستيرول &rdquo;السيء<br />&bull; يُمكن لروسجان خفض الكوليستيرول &rdquo;السيء&ldquo; وزيادة الكوليستيرول &rdquo;الجيد&ldquo;.<br />&bull; يعمل عن طريق منع تكوين الجسم للكوليسترول &rdquo;السيء&ldquo;، كما يُحسن من قدرة جسدك على إزالته من الدم.<br />لا يؤثر الكوليستيرول المرتفع على إحساس معظم الناس؛ لأنه ليست لديه أية أعراض. ومع ذلك، إن تُرك دون علاج، قد تتراكم الترسبات الدهنية في<br />جدران الأوعية الدموية متسببة في ضيقها.<br />وفي بعض الأحيان، قد تنسد تلك الأوعية الدموية الضيقة متسببة في قطع إمداد الدم للقلب أو الدماغ، مما يؤدي بدورة إلى الأزمات القلبية أو السكتات<br />الدماغية. يُمكن خفض خطر الإصابة بالأزمة القلبية أو السكتة الدماغية أو المشاكل الصحية الأخرى عبر خفض مستويات الكوليستيرول. أنت في حاجة<br />إلى الاستمرار في أخذ روسجان حتى إن وصل الكوليستيرول للمستوى الصحيح؛ لأنه يمنع ارتفاع مستويات الكوليستيرول مرة أخرى، والذي يتسبب<br />في تراكم الترسبات الدهنية.<br />ومع ذلك، يجب أن تتوقف إن طلب منك الطبيب ذلك، أو إن أصبحتِ حاملًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تأخذ روسجان<br />.( &bull; إذا كانت لديك حساسية تجاه روزوفاستاتين أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6<br />&bull; إن كنتِ حاملًا أو ترضعين. وإن حملتي أثناء أخذ روسجان، توقفي عن أخذه فورًا، وأعلمي طبيبك. يجب على النساء تجنب الحمل أثناء أخذ<br />روسجان عن طريق استخدام وسائل منع الحمل المناسبة.<br />&bull; إن كنت مصابًا بمرض كبدي.<br />&bull; إن كنت تعاني من مشاكل كلوية حادة.<br />&bull; إن كنت مصابًا بآلام أو أوجاع متكررة أو غير مُفسرة بالعضلات.<br />.(C &bull; إذا كنت تأخذ المزيج الدوائي سوفوسبوفير/فيلباتاسفير/فوكسيلابريفير (يُستخدم مع عدوى فيروسية للكبد تُسمى الالتهاب الكبدي<br />&bull; .إن كنت تأخذ دواءً يُسمى سيكلوسبورين (يُستخدم على سبيل المثال بعد زراعة الأعضاء<br />&bull; إن عانيت من طفح جلدي شديد أو تقشر بالجلد أو بثور و/أو قرح بالفم بعد أخذ روسجان أو أي أدوية مماثلة أخرى.<br />إن انطبق أي مما سبق عليك (أو إن شعرت بالشك)، من فضلك استشر طبيبك.<br />بالإضافة إلى ذلك، لا تأخذ روسجان 40 مجم (الجرعة القصوى):<br />&bull; إن كنت مصابًا بمشاكل كلوية متوسطة (إن شعرت بالشك، استشر طبيبك).<br />&bull; إن كانت غدتك الدرقية لا تعمل جيدًا.<br />&bull; إن أُصبت قبلًا بأية آلام أو أوجاع متكررة أو غير مُفسرة بالعضلات، أو كان لديك أو لدي عائلتك تاريخ للإصابة بمشاكل العضلات، أو تاريخ<br />سابق للإصابة بمشاكل العضلات عند أخذ مُخفضات أخرى للكوليسترول.<br />&bull; إذا كنت تشرب كميات كبيرة من الكحول بصورة منتظمة<br />&bull; إن كنت أسيويًا (ياباني، صيني، فلبيني، فيتنامي، كوري، هندي).<br />&bull; إن كنت تأخذ أدوية أخرى تُسمى الفيبرات لخفض الكوليستيرول.<br />إن انطبق أي مما سبق عليك (أو إن شعرت بالشك)، من فضلك استشر طبيبك.<br />التحذيرات والاحتياطات<br />تحدث مع طبيبك أو الصيدلي قبل أخذ روسجان<br />&bull; إن كنت مصابًا بمشاكل في الكلى.<br />&bull; إن كنت مصابًا بمشاكل في الكبد.<br />&bull; إن أُصبت قبلًا بآلام أو أوجاع متكررة أو غير مُفسرة بالعضلات، أو كان لديك أو لدي عائلتك تاريخ للإصابة بمشاكل العضلات، أو تاريخ سابق<br />للإصابة بمشاكل العضلات عند أخذ مُخفضات أخرى للكوليسترول. أعلم طبيبك على الفور إن أُصبت بآلام أو أوجاع غير مُفسرة بالعضلات،<br />خاصة إن شعرت بالإعياء أو أُصبت بحمى. أعلم طبيبك أو الصيدلي أيضًا إن كنت مصابًا بضعف عضلي ثابت.<br />&bull; إذا كنت تشرب كميات كبيرة من الكحول بصورة منتظمة<br />&bull; إن كانت غدتك الدرقية لا تعمل جيدًا.<br />&bull; إن كنت تأخذ أدوية أخرى تُسمى الفيبرات لخفض الكوليستيرول. من فضلك اقرأ هذه النشرة بعناية حتى إن أخذت مسبقًا أدوية أخرى للكوليسترول<br />المرتفع.<br />مثل ريتونافير مع لوبينافير و/أو أتازانافير، من فضلك انظر &rdquo;الأدوية (HIV) &bull; إن كنت تأخذ أدوية لعلاج عدوى فيروس نقص المناعة البشرية<br />الأخرى وروسجان&ldquo;.<br />&bull; إذا كنت تأخذ أو أخذت خلال السبعة أيام الماضية دواءً يُدعى حامض الفيوسيديك (دواء للعدوات البكتيرية) فمويًا أو عن طريق الحقن؛ فقد يؤدي<br />المزج ما بين حامض الفيوسيديك وروسجان إلى مشاكل عضلية خطيرة (انحلال الربيدات). من فضلك انظر &rdquo;الأدوية الأخرى وروسجان&ldquo;.<br />&bull; إن كنت أكبر من 70 عامًا (لأن طبيبك سيختار الجرعة المبدئية التي تناسبك من روسجان)<br />&bull; إذا كنت مصابًا بقصور تنفسي حاد.<br />&bull; إن كنت أسيويًا -ياباني، فلبيني، فيتنامي، كوري، هندي. سيختار طبيبك الجرعة المبدئية التي تناسبك من روسجان.<br />(DRESS) &bull; أُبلغ عن تفاعلات جلدية شديدة تتضمن متلازمة ستيفنز-جونسون والتفاعلات الدوائية مع كثرة اليوزينيات والأعراض الجهازية<br />. بالتزامن مع العلاج بروسجان. توقف عن استخدام روسجان والجأ للعناية الطبية على الفور إن لاحظت أي من الأعراض المذكورة في القسم 4<br />إن انطبق أي من المذكور أعلاه عليك (أو إن لم تكن متأكدًا):<br />&bull; لا تأخذ روسجان 40 مجم (الجرعة القصوى)، واستشر طبيبك أو الصيدلي قبل أخذ أية جرعة من روسجان.<br />قد تؤثر الستاتينات على الكبد لدي أعداد قليلة من الأشخاص، ويمكن تحديد ذلك عبر اختبار بسيط للكشف عن زيادة مستويات إنزيمات الكبد في الدم.<br />ولهذا السبب، سيطلب منك طبيبك في العادة إجراء هذا الاختبار للدم (اختبار وظائف الكبد) قبل العلاج بروسجان وأثناء العلاج.<br />أثناء أخذك لهذا الدواء، سيفحصك طبيبك عن كثب إذا كنت مصابًا بالسكري أو عرضة للإصابة بالسكري. يمكن أن تكون عرضة لخطر الإصابة<br />بالسكري إذا كانت مستويات السكر والدهون بدمك مرتفعة، وإذا كان وزنك زائدًا وضغط دمك.</p><p>الأطفال والمراهقون<br />&bull; إن كان المريض أقل من 6 سنوات: يجب عدم إعطاء روسجان للأطفال الأقل من 6 سنوات.<br />&bull; إن كان المريض أقل من 18 عام: أقراص روسجان 40 غير مناسبة للاستخدام مع الأطفال والمراهقين الأقل من 18 عام.<br />الأدوية الأخرى وروسجان<br />أعلم طبيبك إن كنت تأخذ أو أخذت حديثًا أو قد تأخذ أي أدوية أخرى؛<br />أعلم طبيبك إن كنت تستخدم أي من الأدوية التالية:<br />&bull; سيكلوسبورين (يُستخدم على سبيل المثال بعد زرع الأعضاء)<br />&bull; وارفارين أو كلوبيدوجريل (أو أي دواء آخر يُستخدم لترقيق الدم)<br />&bull; الفيبرات (مثل جيميفيبروزيل، فينوفيبرات) أو أي دواء آخر لخفض الكوليستيرول (مثل إيزيتيميب)<br />&bull; علاجات عسر الهضم (تُستخدم لمعادلة الحامض المعوي)<br />&bull; إريثرومايسين (مضاد حيوي)، حامض الفيوسيديك (مضاد حيوي -يرجى النظر أدناه وكذلك &rdquo;التحذيرات والاحتياطات&ldquo;)<br />&bull; موانع الحمل الفموية (الأقراص)<br />&bull; ريجورافينيب (لعلاج السرطان)<br />&bull; دارولوتاميد (لعلاج السرطان)<br />&bull; علاج الاستبدال الهرموني<br />أو الالتهاب الكبدي، سواء (HIV) &bull; أي من الأدوية التالية المستخدمة لعلاج العدوات الفيروسية، بما في ذلك عدوى فيروس نقص المناعة البشري<br />كان استخدامه منفردًا أو متزامنًا (من فضلك انظر &rdquo;التحذيرات والاحتياطات&ldquo;): ريتونافير، لوبينافير، أتازانافير، سوفوزبوفير، فوكسيلابريفير،<br />سيميبريفير، أومبيتاسفير، باريتابريفير، دازابوفير، فيلباتاسفير، جرازوبريفير، إلباسفير، جليكابريفير، بيبرينتاسفير.<br />قد يُغير روسجان من تأثيرات تلك الأدوية، أو قد تُغير من تأثير روسجان.<br />في حالة احتياجك لأخذ حامض الفيوسيديك فمويًا لعلاج عدوى بكتيرية، ستحتاج لإيقاف استخدام هذا الدواء مؤقتًا.<br />سيخبرك طبيبك بموعد إعادة العلاج بروسجان بصورة آمنة. أخذ روسجان مع حامض الفيوسيديك قد يؤدي بصورة نادرة إلى ضعف العضلات أو<br />ليونتها أو آلامها (انحلال الربيدات). انظر القسم 4 لمزيد من المعلومات عن انحلال الربيدات.<br />الحمل والرضاعة الطبيعية والخصوبة<br />لا تأخذي روسجان إن كنتِ حاملًا أو ترضعين. وإن حملتي أثناء أخذ روسجان، توقفي عن أخذه فورًا، وأعلمي طبيبك. يجب على النساء تجنب الحمل<br />أثناء أخذ روسجان عن طريق استخدام وسائل منع الحمل المناسبة.<br />إذا كنتِ حاملًا أو تقومين بالإرضاع، أو يُحتمل أن تصبحين حاملًا أو تخططين لإنجاب طفل، يجب عليكِ أخذ مشورة طبيبك أو الصيدلي قبل استعمال<br />هذا الدواء.<br />القيادة واستخدام الآلات<br />يستطيع معظم الناس قيادة السيارات وتشغيل الآلات أثناء استعمال روسجان -لن يؤثر على قدرتهم. ومع ذلك، قد يشعر بعض الأشخاص بالدوخة أثناء<br />العلاج بروسجان.<br />إن شعرت بالدوخة، استشر طبيبك قبل محاولة القيادة أو استخدام الآلات.<br />يحتوي روسجان على اللاكتوز. إذا أخبرك طبيبك بعدم قدرتك على تحمل بعض السكريات، فعليك الاتصال بطبيبك قبل أخذ هذا المنتج الطبي.<br />أصفر غروب الشمس، والتي قد تتسبب في تفاعلات تحسسية. FCF أحمر و AC تحتوي أقراص روسجان المغلفة على ألورا<br />لمعرفة كافة المكونات، من فضلك انظر محتويات العبوة ومعلومات أخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>خذ هذا الدواء دائمًا كما أخبرك طبيبك، وتحقق من طبيبك أو الصيدلي إن لم تكن متأكدًا.<br />الجرعات الموصي بها للبالغين إن كنت تأخذ روسجان لعلاج ارتفاع الكوليستيرول:<br />جرعة البدء<br />يجب بدء العلاج بروزوفاستاتين باستخدام جرعة مقدارها 5 مجم أو 10 مجم، حتى إن أخذت جرعة أعلى من ستاتين مختلف سابقًا. سيعتمد اختيار<br />الجرعة المبدئية على:<br />&bull; مستويات الكوليستيرول.<br />&bull; مدى خطر الإصابة بأزمة قلبية أو سكتة دماغية.<br />&bull; إن كانت لديك عوامل تجعلك أكثر عرضة للإصابة بالآثار الجانبية المحتملة.<br />من فضلك استشر الطبيب أو الصيدلي حول أكثر الجرعات المبدئية المناسبة لك من روسجان.<br />قد يرغب الطبيب في إعطاءك جرعة أقل ( 5 مجم):<br />&bull; إن كنت أسيويًا (ياباني، صيني، فلبيني، فيتنامي، كوري، هندي).<br />&bull; إذا كان عمرك أكبر من 70 عام.<br />&bull; إن كنت تعاني من مشاكل متوسطة بالكلى.<br />&bull; إن كنت عرضة للإصابة بآلام وأوجاع العضلات (اعتلال العضلات).<br />زيادة الجرعة والجرعة اليومية القصوى<br />قد يرغب الطبيب في زيادة الجرعة حتى تأخذ كمية روزوفاستاتين المناسبة لك. إن بدأت بجرعة 5 مجم، قد يرغب الطبيب بمضاعفة الجرعة لتصبح<br />10 مجم، ثم 20 مجم، وبعدها 40 مجم عند الضرورة.<br />إن بدأت بجرعة 10 مجم، قد يرغب الطبيب بمضاعفة الجرعة لتصبح 20 مجم، ثم 40 مجم عند الضرورة. يجب وجود فترة زمنية مقدارها أربعة<br />أسابيع ما بين كل تعديل للجرعات.<br />أقصى جرعة يومية من روزوفاستاتين هي 40 مجم، وتُعطى فقط للمرضى ذوي مستويات الكوليستيرول المرتفعة، والمعرضين للإصابة بأزمات قلبية<br />أو السكتات الدماغية، والذين لم تنخفض مستويات الكوليستيرول لديهم بشكل كاف عند استخدام 20 مجم.<br />إن كنت تأخذ روسجان لخفض خطر الإصابة بأزمة قلبية أو سكتة دماغية أو مشاكل صحية:<br />الجرعة الموصي بها هي 20 مجم يوميًا. ومع ذلك، قد يرغب الطبيب في استخدام جرعة أقل إن كانت لديك أي من العوامل المذكورة أعلاه.<br />17 عام &ndash; الاستخدام مع الأطفال والمراهقين ما بين 6<br />مدى الجرعة المستخدمة مع الأطفال والمراهقين ما بين 6 إلى 17 عام هو 5 إلى 20 مجم مرة واحدة يوميًا. جرعة البدء المعتادة هي 5 مجم يوميًا،<br />وقد يُزيد الطبيب من الجرعة تدريجيًا حتى الوصول لجرعة روزوفاستاتين المناسبة لك. أقصى جرعة يومية من روزوفاستاتين هي 10 مجم أو 20<br />مجم للأطفال من عمر 6 إلى 17 عام، بناءً على الحالة المبدئية الواجب علاجها.<br />خذ جرعتك مرة واحدة يوميًا. لا يجب استخدام روسجان 40 مجم مع الأطفال.<br />أخذ الأقراص<br />ابتلع كل قرص كاملًا مع بعض الماء.<br />خذ روسجان مرة واحدة يوميًا. ويمكنك أخذه في أي وقت أثناء اليوم مع الطعام أو بدونه.<br />حاول أخذ الأقراص في نفس الموعد كل يوم للمساعدة على تذكر أخذها.<br />فحوصات الكوليستيرول الدورية<br />من المهم أن ترجع إلى طبيبك لإجراء فحوصات دورية للكوليسترول، وذلك للتحقق من وصول الكوليستيرول للمستوى الصحيح واستمراره بذلك<br />المستوى.<br />قد يرغب الطبيب في زيادة الجرعة حتى تأخذ الكمية المناسبة لك من روسجان.<br />إذا أخذت أكثر مما يجب من روسجان<br />اتصل بطبيبك أو أقرب مستشفى من أجل النصح.<br />إن ذهبت للمستشفى أو تلقيت علاجًا لحالة أخرى، أعلم الطاقم الطبي بأنك تأخذ روسجان.<br />إذا نسيت تناول روسجان<br />لا تقلق، فقط تناول جرعتك التالية في موعدها الصحيح.<br />لا تأخذ جرعة مزدوجة للتعويض عن الجرعة المنسية.</p><p>إذا توقفت عن أخذ روسجان<br />تحدث مع طبيبك إن كنت ترغب في إيقاف روسجان، فقد تزداد مستويات الكوليستيرول مرة أخرى إن توقفت عن أخذ روسجان.<br />تحدث مع طبيبك أو الصيدلي إن كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، قد يتسبب هذا الدواء بآثار جانبية، بالرغم من عدم إصابة الجميع بها.<br />من المهم أن تعلم ماهية تلك الآثار الجانبية، وغالبًا ما تكون بسيطة وتختفي بعد فترة وجيزة. توقف عن أخذ روسجان واطلب الرعاية الطبية على الفور<br />إن عانيت من أي من التفاعلات التحسسية التالية:<br />&bull; صعوبة بالتنفس، قد يصاحبها تورم بالوجه أو الشفتين أو اللسان أو الحلق أو<br />&bull; تورم بالوجه أو الشفتين أو اللسان أو الحلق أو جميعهم، قد يؤدي إلى صعوبة<br />&bull; حكة شديدة بالجلد (تصاحبها كتل مرتفعة).<br />&bull; رقع مستوية محمرة دائرية أو بشكل الهدف على الجذع، وغالبًا ما يصاحبها بثور متمركزة وتقشر بالجلد وقرح بالفم والحلق والأنف والأعضاء<br />التناسلية والعينين. غالبًا ما يسبق هذا الطفح الجلدي الشديد حمى وأعراض شبيهة بالأنفلونزا (متلازمة ستيفنز-جونسون).<br />أو متلازمة فرط الحساسية الدوائية). DRESS &bull; طفح منتشر وارتفاع بدرجة حرارة الجسم وتضخم بالغدد الليمفاوية (متلازمة<br />&bull; وكذلك توقف عن أخذ روسجان وتحدث مع طبيبك على الفور إن عانيت من أي آلام أو أوجاع بالعضلات، واستمرت لأكثر مما تتوقع. تزداد<br />احتمالية حدوث الأعراض العضلية لدي الأطفال والمراهقين مقارنة بالبالغين. وكما يحدث مع الستاتينات الأخرى، عانى عدد ضئيل جدًا من<br />الأشخاص من آثار غير مرغوبة بالعضلات، ونادرًا ما تطورت تلك الآثار لتلف عضلي مُهدد للحياة يُدعى انحلال الربيدات.<br />&bull; تمزق بالعضلات.<br />&bull; صورة مرضية مشابهة للذئبة (تتضمن الطفح واضطرابات المفاصل وآثار على الخلايا الدموية)<br />آثار جانبية شائعة: قد تُصيب 1 لكل 10 أشخاص<br />&bull; صداع<br />&bull; ألم المعدة<br />&bull; إمساك<br />&bull; شعور بالإعياء<br />&bull; ألم بالعضلات<br />&bull; شعور بالضعف<br />&bull; دوخة<br />&bull; زيادة كمية البروتين في البول&ndash; عادة ما يعود لطبيعته دون الحاجة إلى إيقاف أقراص روزوفاستاتين (فقط مع روزوفاستاتين 40 مجم)<br />&bull; السكري. وتزداد احتماليته إذا كانت مستويات السكر والدهون بالدم مرتفعة، وإذا كنت زائد الوزن، وضغط دمك مرتفعًا. سوف يتابعك الطبيب<br />أثناء أخذك لهذا الدواء.<br />آثار جانبية غير شائعة: قد تُصيب 1 لكل 100 شخص<br />&bull; طفح أو حكة أو تفاعلات جلدية أخرى<br />&bull; زيادة كمية البروتين في البول&ndash; عادة ما يعود لطبيعته دون الحاجة إلى إيقاف أقراص روزوفاستاتين (فقط مع روزوفاستاتين 5 مجم و 10 مجم<br />و 20 مجم).<br />آثار جانبية نادرة: قد تُصيب 1 لكل 1,000 شخص<br />&bull; تفاعلات تحسسية شديدة -تتضمن العلامات تورم بالوجه أو الشفتين أو اللسان أو الحلق أو جميعهم، صعوبة في البلع والتنفس، حكة شديدة بالجلد<br />(تصاحبها كتل مرتفعة). إن ظننت أنك تعاني من تفاعل تحسسي، توقف عن أخذ روسجان واطلب المساعدة الطبية على<br />&bull; تلف العضلات بالبالغين -كإجراء احترازي، توقف عن أخذ روسجان وتحدث مع طبيبك على الفور إن عانيت من أي آلام أو أوجاع بالعضلات،<br />واستمرت لأكثر مما<br />&bull; ألم شديد بالمعدة (التهاب البنكرياس)<br />&bull; زيادة الإنزيمات الكبدية في الدم<br />&bull; حدوث نزف أو كدمات بصورة أسهل من الطبيعي نتيجة انخفاض مستوى الصفيحات<br />&bull; صورة مرضية مشابهة للذئبة (تتضمن الطفح واضطرابات المفاصل وآثار على الخلايا الدموية)<br />آثار جانبية شديدة الندرة: قد تُصيب 1 لكل 10,000 شخص<br />&bull; يرقان (اصفرار الجلد والعينين)<br />&bull; التهاب كبدي<br />&bull; آثار للدم في البول<br />&bull; تلف بأعصاب القدمين واليدين (مثل التنميل)<br />&bull; آلام المفاصل<br />&bull; فقدان الذاكرة<br />&bull; تضخم الثديين لدي الرجال (التثدي)</p><p>الآثار الجانبية غير معلومة التكرارية قد تتضمن:<br />&bull; إسهال (براز رخو)<br />&bull; سعال<br />&bull; صعوبة التنفس<br />&bull; وذمة (تورم)<br />&bull; اضطرابات النوم، تتضمن الأرق والكوابيس<br />&bull; مشاكل جنسية<br />&bull; اكتئاب<br />&bull; مشاكل تنفسية تتضمن السعال و/أو صعوبة التنفس المستمرين أو الحمى<br />&bull; إصابة الأوتار<br />&bull; ضعف ثابت بالعضلات</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- ابق هذا الدواء بعيدا عن نظر الأطفال ومتناول أيديهم.<br />يشير تاريخ انتهاء الصلاحية إلى آخر يوم بالشهر.&nbsp;لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على الشريط والكرتون.<br />- يُحفظ في درجة حرارة أقل من 30 مئوية.<br />- لا تتخلص من أي أدوية عن طريق الصرف الصحي أو النفايات المنزلية. واسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها.<br />هذه التدابير تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي روزوفاستاتين. يحتوي كل قرص مُغلف على 10 مجم/ 20 مجم/ 40 مجم من روزوفاستاتين (في صورة روزوفاستاتين كالسيوم).<br />المكونات الأخرى هي:</p><p>جسم القرص: لاكتوز أحادي الماء، فوسفات كالسيوم هيدروجينية لا مائية، سيليولوز دقيق التبلور، كروسبوفيدون (النوعB&nbsp;),&nbsp;ستيرات ماغنسيوم.&nbsp;<br />غلاف القرص: هيبروميلوز (E464) (15cP)،لاكتوز أحادي الماء، ثاني أكسيد التيتانيوم ( 171 ) EFCF أصفر غروب الشمس ( 110 E)</p><p>صبغة ألورا أحمر AC&nbsp;الألمونيومية الترسيبية E129 ,&nbsp;صبغة إنديجو كارمين الألمونيومية الترسيبية ( 132 E) ,&nbsp;ترياسيتين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كيف يبدو روسجان ومحتويات العبوة</p><p>روفاست 10 : أقراص مغلفة زهرية اللون ، مستديرة ، محدبة الوجهين، محفور عليها<br />أقراص روسجان المغلفة 20 مجم:<br />و&rdquo; 55 &ldquo; على الجانب الآخر. ،&ldquo;J&rdquo; أقراص مستديرة مغلفة وردية ثنائية التحدب، محفور على أحد جانبيها<br />أقراص روسجان المغلفة 40 مجم:<br />و&rdquo; 56 &ldquo; على الجانب الآخر. ،&ldquo;J&rdquo; أقراص بيضاوية مغلفة وردية ثنائية التحدب، محفور على أحد جانبيها<br />تُورد أقراص روسجان في عبوة تحتوي على 30 قرص ( 3 أشرطة يحتوي كل منها على 10 أقراص)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>موقع التصنيع:<br />أوروبيندو فارما المحدودة،<br />،S المنطقة الاقتصادية الخاصة)، شركة البنية التحتية الصناعية بولاية تيلانجانا، قطعة رقم 1 ) VII- الوحدة<br />،P/458 ،P/435 ،P/434 ،P/425 ،P/ مسح رقم: 411<br />الحديقة الصناعية الخضراء، قرية بوليبالي، منطقة جيدشيرلا،<br />حي ماهابوباجار، ولاية تيلانجانا، الهند.<br />حامل ترخيص التسويق:<br />أوروبيندو فارما السعودية المحدودة،<br />جدة، المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             تمت مراجعة هذه النشرة في 08.2022 ، رقم الإصدار هو 00 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rosgan (Rosuvastatin Tablets 10 mg, 20 mg & 40 mg)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rosuvastatin Tablets 10 mg:
Each film-coated tablet contains 10 mg of Rosuvastatin (as Rosuvastatin calcium).
Excipients with known effect
Each 10 mg tablet contains 44.918 mg lactose monohydrate.
Rosuvastatin Tablets 20 mg:
Each film-coated tablet contains 20 mg of Rosuvastatin (as Rosuvastatin calcium).
Excipients with known effect
Each 20 mg tablet contains 91.755 mg lactose monohydrate.
Rosuvastatin Tablets 40 mg:
Each film-coated tablet contains 40 mg of Rosuvastatin (as Rosuvastatin calcium).
Excipients with known effect
Each 40 mg tablet contains 183.510 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Rosuvastatin Tablets 10 mg: Pink coloured, round shaped, biconvex film-coated tablets, debossed
with 'J' on one side and '54' on the other side.
Rosuvastatin Tablets 20 mg: Pink coloured, round shaped, biconvex film-coated tablets, debossed
with 'J' on one side and '55' on the other side.
Rosuvastatin Tablets 40 mg:Pink coloured, round shaped, biconvex film-coated tablets, debossed
with 'J' on one side and '56' on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Treatment of hypercholesterolaemia<br />Adults, adolescents and children aged 6 years or older with primary hypercholesterolaemia (type<br />IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an<br />adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise,<br />weight reduction) is inadequate.<br />Adults, adolescents and children aged 6 years or older with homozygous familial<br />hypercholesterolaemia as an adjunct to diet and other lipid lowering treatments (e.g. LDL<br />apheresis) or if such treatments are not appropriate.<br />Prevention of Cardiovascular Events<br />Prevention of major cardiovascular events in patients who are estimated to have a high risk for a<br />first cardiovascular event (see Section 5.1), as an adjunct to correction of other risk factors.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Posology<br />Before treatment initiation the patient should be placed on a standard cholesterol-lowering diet that<br />should continue during treatment. The dose should be individualised according to the goal of<br />therapy and patient response, using current consensus guidelines.<br />Rosuvastatin may be given at any time of day, with or without food.<br />Treatment of hypercholesterolaemia<br />The recommended start dose is 5 or 10 mg orally once daily in both statin-na&iuml;ve or patients<br />switched from another HMG CoA reductase inhibitor. The choice of start dose should take into<br />account the individual patient&#39;s cholesterol level and future cardiovascular risk as well as the<br />potential risk for adverse reactions (see below). A dose adjustment to the next dose level can be<br />made after 4 weeks, if necessary (see Section 5.1). In light of the increased reporting rate of<br />adverse reactions with the 40 mg dose compared to lower doses (see Section 4.8), a final titration<br />to the maximum dose of 40 mg should only be considered in patients with severe<br />hypercholesterolaemia at high cardiovascular risk (in particular those with familial<br />hypercholesterolaemia), who do not achieve their treatment goal on 20 mg, and in whom routine<br />follow-up will be performed (see Section 4.4). Specialist supervision is recommended when the 40<br />mg dose is initiated.<br />Prevention of cardiovascular events<br />In the cardiovascular events risk reduction study, the dose used was 20 mg daily (see Section 5.1).<br />Paediatric population<br />Paediatric use should only be carried out by specialists.<br />Children and adolescents 6 to 17 years of age (Tanner Stage II-V)<br />Heterozygous familial hypercholesterolaemia<br />In children and adolescents with heterozygous familial hypercholesterolaemia the usual start dose<br />is 5 mg daily.<br />&bull; In children 6 to 9 years of age with heterozygous familial hypercholesterolaemia, the usual dose<br />range is 5-10 mg orally once daily. Safety and efficacy of doses greater than 10 mg have not been<br />studied in this population.</p><p dir="ltr">&bull; In children 10 to 17 years of age with heterozygous familial hypercholesterolaemia, the usual<br />dose range is 5-20 mg orally once daily. Safety and efficacy of doses greater than 20 mg have not<br />been studied in this population.<br />Titration should be conducted according to the individual response and tolerability in paediatric<br />patients, as recommended by the paediatric treatment recommendations (see Section 4.4). Children<br />and adolescents should be placed on standard cholesterol-lowering diet before rosuvastatin<br />treatment initiation; this diet should be continued during rosuvastatin treatment.<br />Homozygous familial hypercholesterolaemia<br />In children 6 to 17 years of age with homozygous familial hypercholesterolaemia, the<br />recommended maximum dose is 20 mg once daily. A starting dose of 5 to 10 mg once daily<br />depending on age, weight and prior statin use is advised.<br />Titration to the maximum dose of 20 mg once daily should be conducted according to the<br />individual response and tolerability in paediatric patients, as recommended by the paediatric<br />treatment recommendations (see section 4.4).<br />Children and adolescents should be placed on standard cholesterol-lowering diet before<br />rosuvastatin treatment initiation; this diet should be continued during rosuvastatin treatment. There<br />is limited experience with doses other than 20 mg in this population.<br />The 40 mg tablet is not suitable for use in paediatric patients.<br />Children younger than 6 years<br />The safety and efficacy of use in children younger than 6 years has not been studied. Therefore,<br />Rosuvastatin is not recommended for use in children younger than 6 years.<br />Use in the elderly<br />A start dose of 5 mg is recommended in patients &gt;70 years (see Section 4.4). No other dose<br />adjustment is necessary in relation to age.</p><p dir="ltr">Dosage in patients with renal insufficiency<br />No dose adjustment is necessary in patients with mild to moderate renal impairment. The<br />recommended start dose is 5 mg in patients with moderate renal impairment (creatinine clearance<br />&lt;60 ml/min). The 40 mg dose is contraindicated in patients with moderate renal impairment. The<br />use of rosuvastatin in patients with severe renal impairment is contraindicated for all doses (See<br />sections 4.3 and 5.2).<br />Dosage in patients with hepatic impairment<br />There was no increase in systemic exposure to rosuvastatin in subjects with Child-Pugh scores of 7<br />or below. However, increased systemic exposure has been observed in subjects with Child-Pugh<br />scores of 8 and 9 (see Section 5.2). In these patients an assessment of renal function should be<br />considered (see Section 4.4). There is no experience in subjects with Child-Pugh scores above 9.<br />Rosuvastatin is contraindicated in patients with active liver disease (see Section 4.3).<br />Race<br />Increased systemic exposure has been seen in Asian subjects (see Section 4.3, 4.4 and 5.2). The<br />recommended start dose is 5 mg for patients of Asian ancestry.<br />Genetic polymorphisms<br />Specific types of genetic polymorphisms are known that can lead to increased rosuvastatin<br />exposure (see Section 5.2).<br />For patients who are known to have such specific types of polymorphisms, a lower daily dose of<br />rosuvastatin is recommended.<br />Dosage in patients with pre-disposing factors to myopathy<br />The recommended start dose is 5 mg in patients with predisposing factors to myopathy (see Section<br />4.4).</p><p dir="ltr">Concomitant therapy<br />Rosuvastatin is a substrate of various transporter proteins (e.g. OATP1B1 and BCRP). The risk of<br />myopathy (including rhabdomyolysis) is increased when rosuvastatin is administered<br />concomitantly with certain medicinal products that may increase the plasma concentration of<br />rosuvastatin due to interactions with these transporter proteins (e.g. ciclosporin and certain protease<br />inhibitors including combinations of ritonavir with atazanavir, lopinavir, and/or tipranavir; see<br />Sections 4.4 and 4.5). Whenever possible, alternative medications should be considered, and, if<br />necessary, consider temporarily discontinuing rosuvastatin therapy. In situations where<br />coadministration of these medicinal products with rosuvastatin is unavoidable, the benefit and the<br />risk of concurrent treatment and rosuvastatin dosing adjustments should be carefully considered<br />(see Section 4.5).</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rosuvastatin is contraindicated:
- In patients with hypersensitivity to the active substance or to any of the excipients listed in
section 6.1
- In patients with active liver disease including unexplained, persistent elevations of serum
transaminases and any serum transaminase elevation exceeding 3 times the upper limit of
normal (ULN).
- In patients with severe renal impairment (creatinine clearance <30 ml/min).
- In patients with myopathy.
- In patients receiving concomitant combination of sofosbuvir/velpatasvir/voxilaprevir (see
section 4.5).
- In patients receiving concomitant ciclosporin.
During pregnancy and lactation and in women of childbearing potential not using appropriate
contraceptive measures.
The 40 mg dose is contraindicated in patients with pre-disposing factors for myopathy/
rhabdomyolysis. Such factors include:
- Moderate renal impairment (creatinine clearance < 60 ml/min)
- Hypothyroidism
- Personal or family history of hereditary muscular disorders
- Previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate
- Alcohol abuse
- Situations where an increase in plasma levels may occur
- Asian patients
- Concomitant use of fibrates. (see Sections 4.4, 4.5 and 5.2).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Renal Effects<br />Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients<br />treated with higher doses of rosuvastatin, in particular 40 mg, where it was transient or intermittent<br />in most cases. Proteinuria has not been shown to be predictive of acute or progressive renal disease<br />(see Section 4.8). The reporting rate for serious renal events in post-marketing use is higher at the<br />40 mg dose. An assessment of renal function should be considered during routine follow-up of<br />patients treated with a dose of 40 mg.<br />Skeletal Muscle Effects<br />Effects on skeletal muscle e.g. myalgia, myopathy and, rarely, rhabdomyolysis have been reported<br />in rosuvastatin - treated patients with all doses and in particular with doses &gt; 20 mg. Very rare<br />cases of rhabdomyolysis have been reported with the use of ezetimibe in combination with HMGCoA<br />reductase inhibitors. A pharmacodynamic interaction cannot be excluded (see Section 4.5)<br />and caution should be exercised with their combined use.<br />As with other HMG-CoA reductase inhibitors, the reporting rate for rhabdomyolysis associated<br />with rosuvastatin in postmarketing use is higher at the 40 mg dose.<br />Creatine Kinase Measurement<br />Creatine Kinase (CK) should not be measured following strenuous exercise or in the presence of a<br />plausible alternative cause of CK increase which may confound interpretation of the result. If CK<br />levels are significantly elevated at baseline (&gt;5xULN) a confirmatory test should be carried out<br />within 5 &ndash; 7 days. If the repeat test confirms a baseline CK&gt;5xULN, treatment should not be<br />started.<br />Before Treatment<br />Rosuvastatin, as with other HMG-CoA reductase inhibitors, should be prescribed with caution in<br />patients with predisposing factors for myopathy/rhabdomyolysis. Such factors include:<br />&bull; renal impairment</p><p dir="ltr">&bull; hypothyroidism<br />&bull; personal or family history of hereditary muscular disorders<br />&bull; previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate<br />&bull; alcohol abuse<br />&bull; age &gt;70 years<br />&bull; situations where an increase in plasma levels may occur (see Sections 4.2, 4.5 and5.2)<br />&bull; concomitant use of fibrates.<br />In such patients the risk of treatment should be considered in relation to possible benefit and<br />clinical monitoring is recommended. If CK levels are significantly elevated at baseline (&gt;5xULN)<br />treatment should not be started.<br />Whilst on Treatment<br />Patients should be asked to report inexplicable muscle pain, weakness or cramps immediately,<br />particularly if associated with malaise or fever. CK levels should be measured in these patients.<br />Therapy should be discontinued if CK levels are markedly elevated (&gt;5xULN) or if muscular<br />symptoms are severe and cause daily discomfort (even if CK levels are &le; 5x ULN). If symptoms<br />resolve and CK levels return to normal, then consideration should be given to re-introducing<br />rosuvastatin or an alternative HMG-CoA reductase inhibitor at the lowest dose with close<br />monitoring. Routine monitoring of CK levels in asymptomatic patients is not warranted. There<br />have been very rare reports of an immune-mediated necrotising myopathy (IMNM) during or after<br />treatment with statins, including rosuvastatin. IMNM is clinically characterised by proximal<br />muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of<br />statin treatment.<br />In clinical trials, there was no evidence of increased skeletal muscle effects in the small number of<br />patients dosed with rosuvastatin and concomitant therapy. However, an increase in the incidence of<br />myositis and myopathy has been seen in patients receiving other HMG-CoA reductase inhibitors<br />together with fibric acid derivatives including gemfibrozil, ciclosporin, nicotinic acid, azole<br />antifungals, protease inhibitors and macrolide antibiotics. Gemfibrozil increases the risk of<br />myopathy when given concomitantly with some HMG-CoA reductase inhibitors. Therefore, the<br />combination of Rosuvastatin and gemfibrozil is not recommended. The benefit of further<br />alterations in lipid levels by the combined use of Rosuvastatin with fibrates or niacin should be<br />carefully weighed against the potential risks of such combinations. The 40 mg dose is<br />contraindicated with concomitant use of a fibrate. (See Section 4.5 and 4.8).</p><p dir="ltr">Rosuvastatin must not be co-administered with systemic formulations of fusidic acid or within 7<br />days of stopping fusidic acid treatment. In patients where the use of systemic fusidic acid is<br />considered essential, statin treatment should be discontinued throughout the duration of fusidic acid<br />treatment. There have been reports of rhabdomyolysis (including some fatalities) in patients<br />receiving fusidic acid and statins in combination (see section 4.5). Patients should be advised to<br />seek medical advice immediately if they experience any symptoms of muscle weakness, pain or<br />tenderness. Statin therapy may be re-introduced seven days after the last dose of fusidic acid. In<br />exceptional circumstances, where prolonged systemic fusidic acid is needed, e.g. for the treatment<br />of severe infections, the need for co-administration of Rosuvastatin and fusidic acid should only be<br />considered on a case by case basis and under close medical supervision.<br />Rosuvastatin should not be used in any patient with an acute, serious condition suggestive of<br />myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (e.g.<br />sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders;<br />or uncontrolled seizures).</p><p dir="ltr">Liver Effects<br />As with other HMG-CoA reductase inhibitors, rosuvastatin should be used with caution in patients<br />who consume excessive quantities of alcohol and/or have a history of liver disease.<br />It is recommended that liver function tests be carried out prior to, and 3 months following, the<br />initiation of treatment.<br />Rosuvastatin should be discontinued or the dose reduced if the level of serum transaminases is<br />greater than 3 times the upper limit of normal. The reporting rate for serious hepatic events<br />(consisting mainly of increased hepatic transaminases) in post-marketing use is higher at the 40 mg<br />dose.<br />In patients with secondary hypercholesterolaemia caused by hypothyroidism or nephrotic<br />syndrome, the underlying disease should be treated prior to initiating therapy with rosuvastatin.<br />Race<br />Pharmacokinetic studies show an increase in exposure in Asian subjects compared with Caucasians<br />(see Section 4.2, 4.3 and 5.2).<br />Protease inhibitors<br />Increased systemic exposure to rosuvastatin has been observed in subjects receiving rosuvastatin<br />concomitantly with various protease inhibitors in combination with ritonavir. Consideration should<br />be given both to the benefit of lipid lowering by use of rosuvastatin in HIV patients receiving<br />protease inhibitors and the potential for increased Rosuvastatin plasma concentrations when<br />initiating and up titrating rosuvastatin doses in patients treated with protease inhibitors.<br />The concomitant use with certain protease inhibitors is not recommended unless the dose of<br />rosuvastatin is adjusted (see Sections 4.2 and 4.5).<br />Interstitial lung disease<br />Exceptional cases of interstitial lung disease have been reported with some statins, especially with<br />long-term therapy (see Section 4.8). Presenting features can include dyspnoea, non-productive<br />cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected a patient<br />has developed interstitial lung disease, statin therapy should be discontinued.</p><p dir="ltr">Diabetes Mellitus<br />Some evidence suggests that statins as a class raise blood glucose and in some patients, at high risk<br />of future diabetes, may produce a level of hyperglycaemia where formal diabetes care is<br />appropriate. This risk, however, is outweighed by the reduction in vascular risk with statins and<br />therefore should not be a reason for stopping statin treatment. Patients at risk (fasting glucose 5.6 to<br />6.9 mmol/L, BMI&gt;30 kg/m2, raised triglycerides, hypertension) should be monitored both<br />clinically and biochemically according to national guidelines.<br />In the JUPITER study, the reported overall frequency of diabetes mellitus was 2.8% in rosuvastatin<br />and 2.3% in placebo, mostly in patients with fasting glucose 5.6 to 6.9 mmol/L.<br />Severe cutaneous adverse reactions<br />Severe cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and drug reaction<br />with eosinophilia and systemic symptoms (DRESS), which could be life-threatening or fatal, have<br />been reported with rosuvastatin. At the time of prescription, patients should be advised of the signs<br />and symptoms of severe skin reactions and be closely monitored. If signs and symptoms suggestive<br />of this reaction appears, Rosuvastatin should be discontinued immediately and an alternative<br />treatment should be considered.<br />If the patient has developed a serious reaction such as SJS or DRESS with the use of Rosuvastatin,<br />treatment with Rosuvastatin must not be restarted in this patient at any time.</p><p dir="ltr">Paediatric population<br />The evaluation of linear growth (height), weight, BMI (body mass index), and secondary<br />characteristics of sexual maturation by Tanner staging in paediatric patients 6 to 17 years of age<br />taking rosuvastatin is limited to a two-year period. After two years of study treatment, no effect on<br />growth, weight, BMI or sexual maturation was detected (see Section 5.1).<br />In a clinical trial of children and adolescents receiving rosuvastatin for 52 weeks, CK<br />elevations&gt;10xULN and muscle symptoms following exercise or increased physical activity were<br />observed more frequently compared to observations in clinical trials in adults (see Section 4.8).<br />Lactose: This product contains lactose. Patients with rare hereditary problems of galactose<br />intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this<br />medicine.<br />Azo colouring agents: This product also contains azo colouring agents, allura red AC (E129) and<br />sunset yellow FCF (E110) which may cause allergic reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Effect of coadministered medicinal products on rosuvastatin<br />Transporter protein inhibitors: Rosuvastatin is a substrate for certain transporter proteins<br />including the hepatic uptake transporter OATP1B1 and efflux transporter BCRP. Concomitant<br />administration of rosuvastatin with medicinal products that are inhibitors of these transporter<br />proteins may result in increased rosuvastatin plasma concentrations and an increased risk of<br />myopathy (see Sections 4.2, 4.4 and 4.5 Table 1).<br />Ciclosporin: During concomitant treatment with rosuvastatin and ciclosporin, rosuvastatin AUC<br />values were on average 7 times higher than those observed in healthy volunteers (see Table 1).<br />Rosuvastatin is contraindicated in patients receiving concomitant ciclosporin (see Section 4.3).<br />Concomitant administration did not affect plasma concentrations of ciclosporin.<br />Protease inhibitors: Although the exact mechanism of interaction is unknown, concomitant<br />protease inhibitor use may strongly increase rosuvastatin exposure (see Table 1). For instance, in a<br />pharmacokinetic study, co-administration of 10 mg rosuvastatin and a combination product of two<br />protease inhibitors (300 mg atazanavir / 100 mg ritonavir) in healthy volunteers was associated<br />with an approximately three--fold and f seven-fold increase in rosuvastatin AUC() and Cmax<br />respectively. The concomitant use of rosuvastatin and some protease inhibitor combinations may<br />be considered after careful consideration of rosuvastatin dose adjustments based on the expected<br />increase in rosuvastatin exposure (see Sections 4.2, 4.4 and 4.5 Table 1).</p><p dir="ltr">Gemfibrozil and other lipid-lowering products: Concomitant use of rosuvastatin and<br />gemfibrozil resulted in a 2-fold increase in rosuvastatin C max and AUC (see Section 4.4).<br />Based on data from specific interaction studies no pharmacokinetic relevant interaction with<br />fenofibrate is expected, however a pharmacodynamic interaction may occur. Gemfibrozil,<br />fenofibrate, other fibrates and lipid lowering doses (&gt; or equal to 1 g/day) of niacin (nicotinic acid)<br />increase the risk of myopathy when given concomitantly with HMG-CoA reductase inhibitors,<br />probably because they can produce myopathy when given alone. The 40 mg dose is contraindicated<br />with concomitant use of a fibrate (see Sections 4.3 and 4.4). These patients should also start with<br />the 5 mg dose.<br />Ezetimibe: Concomitant use of 10 mg rosuvastatin and 10 mg ezetimibe resulted in a 1.2-fold<br />increase in AUC of rosuvastatin in hypercholesterolaemic subjects (Table 1). A pharmacodynamic<br />interaction, in terms of adverse effects, between rosuvastatin and ezetimibe cannot be ruled out (see<br />Section 4.4).<br />Antacid: The simultaneous dosing of rosuvastatin with an antacid suspension containing<br />aluminium and magnesium hydroxide resulted in a decrease in rosuvastatin plasma concentration<br />of approximately 50%. This effect was mitigated when the antacid was dosed 2 hours after<br />rosuvastatin. The clinical relevance of this interaction has not been studied.<br />Erythromycin: Concomitant use of rosuvastatin and erythromycin resulted in a 20% decrease in<br />AUC and a 30% decrease in Cmax of rosuvastatin. This interaction may be caused by the increase<br />in gut motility caused by erythromycin.</p><p dir="ltr">Cytochrome P450 enzymes: Results from in vitro and in vivo studies show that rosuvastatin is<br />neither an inhibitor nor an inducer of cytochrome P450 isoenzymes. Therefore, drug interactions<br />resulting from cytochrome P450 mediated metabolism are not expected. In addition, rosuvastatin is<br />a poor substrate for these isoenzymes. No clinically relevant interactions have been observed<br />between rosuvastatin and either fluconazole (an inhibitor of CYP2C9 and CYP3A4) or<br />ketoconazole (an inhibitor of CYP2A6 and CYP3A4).<br />Interactions requiring rosuvastatin dose adjustments (see also Table 1): When it is necessary<br />to co-administer rosuvastatin with other medicinal products known to increase exposure to<br />rosuvastatin, doses of rosuvastatin should be adjusted. Start with a 5 mg once daily dose of<br />rosuvastatin if the expected increase in exposure (AUC) is approximately 2-fold or higher. The<br />maximum daily dose of rosuvastatin should be adjusted so that the expected rosuvastatin exposure<br />would not likely exceed that of a 40 mg daily dose of rosuvastatin taken without interacting<br />medicinal products, for example a 20 mg dose of rosuvastatin with gemfibrozil (1.9-fold increase),<br />and a 10 mg dose of rosuvastatin with combination atazanavir/ritonavir (3.1fold increase).<br />If medicinal product is observed to increase rosuvastatin AUC less than 2-fold, the starting dose<br />need not be decreased but caution should be taken if increasing the rosuvastatin dose above 20 mg</p><p dir="ltr">Cytochrome P450 enzymes: Results from in vitro and in vivo studies show that rosuvastatin is<br />neither an inhibitor nor an inducer of cytochrome P450 isoenzymes. Therefore, drug interactions<br />resulting from cytochrome P450 mediated metabolism are not expected. In addition, rosuvastatin is<br />a poor substrate for these isoenzymes. No clinically relevant interactions have been observed<br />between rosuvastatin and either fluconazole (an inhibitor of CYP2C9 and CYP3A4) or<br />ketoconazole (an inhibitor of CYP2A6 and CYP3A4).<br />Interactions requiring rosuvastatin dose adjustments (see also Table 1): When it is necessary<br />to co-administer rosuvastatin with other medicinal products known to increase exposure to<br />rosuvastatin, doses of rosuvastatin should be adjusted. Start with a 5 mg once daily dose of<br />rosuvastatin if the expected increase in exposure (AUC) is approximately 2-fold or higher. The<br />maximum daily dose of rosuvastatin should be adjusted so that the expected rosuvastatin exposure<br />would not likely exceed that of a 40 mg daily dose of rosuvastatin taken without interacting<br />medicinal products, for example a 20 mg dose of rosuvastatin with gemfibrozil (1.9-fold increase),<br />and a 10 mg dose of rosuvastatin with combination atazanavir/ritonavir (3.1fold increase).<br />If medicinal product is observed to increase rosuvastatin AUC less than 2-fold, the starting dose<br />need not be decreased but caution should be taken if increasing the rosuvastatin dose above 20 mg</p><p dir="ltr"><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAzIAAAOpCAYAAADBlBKtAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAFiUAABYlAUlSJPAAAP+lSURBVHhe7P0/qKbdmt4HVuCwjRkQBkMnpoJuByMcSAaDMHJUgZPGyA32CVq0nRQdTCfiGMGgg52oAg2caZ9oaLcnKs4EFg4UTCSGAncqNUwgmBqGCdwwUnfjcxqdQFbXfL/q7/rOVdd3r+d53l3v3vt99nv9YPG+a6173etea933+rN3/Xn1qZRSSimllFJORh8ypZRSSimllNPRh0wppZRSSinldPQhU0oppZRSSjkdfciUUkoppZRSTkcfMqWUUkoppZTT0YdMKaWUUkop5XT0IVNKKaWUUko5HX3IlFJKKaWUUk5HHzKllFJKKaWU09GHTCmllFJKKeV09CFTSimllFJKOR19yJRSSimllFJORx8ypZRSSimllNPRh0wppZRSSinldPQhU0oppZRSSjkdfciUUkoppZRSTkcfMqWUUkoppZTT0YdMKaWUUkop5XT0IVNKKaWUUko5HX3IlFJKKaWUUk5HHzKllFJKKaWU09GHTCmllFJKKeV09CFTSimllFJKOR19yJRSSimllFJORx8ypZRSSimllNPRh0wppZRSSinldPQhU0oppZRSSjkdfciUUkoppZRSTkcfMqWUUkoppZTT0YdMKaWUUkop5XT0IVNKKaWUUko5HX3IlFJKKaWUUk5HHzKllFJKKaWU09GHTCmllFJKKeV09CFTSimllFJKOR19yBzk3bt3n169enUoffjw4dtW26TOFe/fvz8kdynoQvclMDa3ZZVev379bYtfkm0Z/1b5rfHmzZsv7Lx1WIPHsFfz8PHjx29LjvM1bZ+Lx5rHryH3BI8ZxdPbt2+/LdnnIW2O4vvctC/cAre4xuV8nHF/e0kQx+xlE6zNan/L/dSTyPJpjVNG+x2yt3qveQl0xz4ITkggCAJCzqrHAM5KfhVIE65ni6Nye8hGpUsfMsIvJ6kDW/PC4o8Vt2FVfg2uuXnogEKf1uIMG9O1/Eb4Gl06/oe2xUce6qfX4trzeA1W8/kQWx97fIqfW33IwFOs8S34cvklX7Me2fZr9sbydegesZp3X5stfA9AZ8J6T32s2tUnnobbOZVvHJwQpxTuuL6Z8X0KgBVHD89rHbLSofTQTZz52NLhjz5I+/nkUrMqvwbYcI3NIzcjjf2hc/eUXMtvHF1KPR6O8pC2+MNzz/VjzOPXsjokdahj81Ee0uYS+pD5S27Bl8sv+Zr1mNp+zd5YHob2wa2z3mN7a71dbrrHUZbtj+wb17qLlJnbOZVPxtHA2OPo4XlU7gi6tJAearsu866Dzyn4YWX/Ncfl6EC5xuaxujCegcea36eCywK2f02MXYNbnMcz+WUfMrfjy+Uv+Zr16FreDkcej9QrIb/C94AjDxm/S23twcid7e5wJs55u7kB3OG3NjOcV3Ik2jmp54ic422yboUH30M3Yh+XdLC5T8GvjcYTcqtyocOCNG0CXs934eVKl6yR9+VzpbS1EcLKLuG6SEfxi+uqrdtL35PfuH2M1ddBY3cZXxOVkTSnXkb7S9pOY1KbLPc68HJfXx8P4/c5cVRGSv/wNqt5TNAhGZLrIKXM5Efui/Sb5Fr5d9hq73UkzeXUJmX37Pb5IckeIbunMUH6wdY4jqxv6pv6PbLGypOYg5yXxOt8nrxcif63/H9FzrX77qXr5lxjXo/G82ous0z6vZw+YOrLOWpL1u3pzTqSzxVJa+JljIHxKK/+tvBx+1z7WqXvktDtZch7G/cZseVXkPXyp8lGl6Meco6YZ9kkGViNeUI6ZcuEfM3HLx9KfIzT+lDm87Inv2Iad3k439+JyyHcgadNASSjoJG8O6/r4TvsyQkFvOQI+r3AB99QVrbvob4zrYJ5sh9W5V6GjXx3W1XP3MoWNgfyPj6fwwm11dxnHtB5VJ/k0i7h9VN+hcak/jVvvt4+bnC7VQZZTjvNsRIye31oPVIfeW3Ue22RcxnyyCmlPKg/tdM8Iy/UDhl0yh5k9tp7v5Dj28L9mT6BflRGvevzcamtyvguHaAxpA94GUjO51WyyHn/fIetNiS+r9ZDbWE1tkl/grzaIg+yQXkhOfRRJ/2+viTIPBxd42nMPi8i+5CM5m1r7nxOyCO7QnrTB3z93T71r7z3PSG5h87r1ngmO9xW4WX0IShXXrpyHrLvyRYl9eFzsqf3SFsv9zkikdecum0T6lu6+E5bgY3S6/Pp0IdksM/tIS/U18qvNDb1Q95tyTF5P9IBbjOyykvX3pgTyee4HdpjDzqR3ZKXPpLPj6BMtoHPL30cwedmzwfKMX65e5SLcId3x3YyyCTvge16hMrcySc55RVwklnZI7QpHZFd4RuSdGDvFPww2Q9TeW5uCnzNR9ZrPClP8rmekJzG4HOjjemovj27VO/rSh1lzMMWbhdo3iZd6g+m+Z3Gw/hVpjWc2rodmrNJ32Tf1JZ6b+dM8iDdfILkfNxqpzKND/baH53HiUlOY5S+ab68jO8gO7DP54LvMOkBtdPcT7plU/bl65VjcT2+HmqLDXsyrj/RGpE0Rh+3bAWVoRem9VUdaLyaJ9njMtPaef8azySnMj5B9ig/6YG0awufW82Pz5lI+1ZrMiG5h87r1niOziWoTPPHGFyn6wLpcf+61BY4ovdIW5X73MuOSWfi7fgO8ln6ESpb6dMc+Jqpjc+tdEi31p005RPplA3TuIHvKldftKH86Jgd1U9rDOjxsUs/aUJrQ5r6pMzXXPNLks1H2LO7XMa8mmUXd3h37AmcX7IkbSDgesSRstTpaS84vO2e7St8Q5IOPqfgh2lMMJUryKfk9b5BOatNNPF5kN3T3BzVt2fXVK+y6RBa4ZsnSaicORXT/E7jYawq01xMbY/Oz9G2Xkbyw2CShxy/ks+hynwuxF77o/M4MclJn9Z9b/4zUef1mqNJD6RPTW2TyQ9zLKv+RI5hy6YJby8fXPmAyrbW1+tyDSaZae2m/ie5SZ+zGoeXk1brAz4/kpvmLO3bWzdHctM4jszr1niOziVkOXav5kY2pJ5LbUmO6F2tpcqnuV+N2fF1zeR97q1trg9kLHpfmiMvY1ygdqT0j9S5sovvKvf1gKNjdjS+aeyAnd7W537S6fUat0OZt/M5meTL07COpLLJXkAIBRpI3jcB1yOOlPmmeWkAedst27fwDWmlw8unMcFUrs2Bz4ncNJO9zV1MczjNzVF9e3ZN48o26seT0Jxj1zRv8jXqxCQ3jQedKtNcTG2Pzs/RtkK2e91KfhpnonaTzF77o/M4MclJn9Z9b/6pT6b6SQ+kT3lbrW2SbSDHsuoP1PaoTROTnSsfUNm0hppvr1OZ1mCSmdZu6n+SS/3JahxC7Vf14PMjH/AyzVnat7VuieR8XsSReRXTeI7OJbjNyE72MBavn/TAUVvEnt5V26l8mvstWwXtJaO1XuH6UnZan4zFqS8vk1+Bl6s9pM5p3KC5JaWtl4xZaHzehyN9U5pi1efSxy2wcTUfKxvK47OOpLKJOzzOPKHgRhYkrzy4HqGyLbnVRnGE1UYMCkzfpCZ8Q5rGTx9u1zRO2Bp/ygqvX214qt+aG59DbU4+N9J9dK737FL9dKhQt4VvmDDNkXS5/kluGo/r11xMbSffmfQdbevIBtnvel1e49zyUbWb5nWv/dF5nJjkdNhO49J87c2N12t9Jj2Q4/O2K/+d5iTHsupP46PsqE0TWn+Sxui2o1uobGt9vc5tBMnwKaa18/FoXSY56fMyZ9KTaPxukzPNhc+ZOLpuE5J76Lw6OZ6jcyl8TuUPIse9pQeO2AJH9K7a+vqofJr7PVth0rXC9fHd0fq4T+U6HvUrR3q1LrJB8T2NG/iucvUlLhmz0FhW/pfzAbJ9ssHHPdmAvmzj+lagS3MFajPZXS5nPfNlEwXuyuFB9ch6kHpwuR4FSObB5YRv9JLFlr3g2NowXKcHXuIbUvYn/a57sh+m8tVcTZukb9CqB9VjGyk3H6FxqJ/Mg/eXY3UusUv2ZH5FztO0eTLfKkv9JNk0jcfbat331kbrO+k72hab1B9Qp7l3vcir3G319ZjmWW2cvfZevzWPE9O4tVZb8w/TmlKvuVK9xkSd5EmaR/oh7/OhMpLG5LqnNjmWye4sW83tpD/xthqjbNDciZRz3KYpD0fXeBqzywn3bbdJ43U99C0Z+ln5/4TmQ7ZkHlRGgmkMKyQ32ZDzmHnYGs/RuRRao8lncozIpJ6jtvh6HNG7aus+QDlMY84+Vkx9oyN1A+WS9TV2Hci7PT43siltVB5Zj0H1hz7IMa3s8XK1dfbGnEif1kBoLaY+0KU+6C+ZbAD68rE4ks82wLy5fe4nk3y5nM7ihaQTeko8uHFmkvIKCGQILA8ukgdg1nnwuU5SBrTjm1gm9ae+pgCHrfFnQhbSRtWtymHqx+dkGstqzlabj9BmOMlPdmD3ij27IOuPkHa4zb5WORb5oNvgG7XLbJWpDy8jreYn86u29OPyObc+HtZUZEyQxKp/Z6s9HJnHJHUyZ2nLNNc+rlwb90XwOuniU6TdPva0RbqnNlOZ50msH3gdtvgYGNuWTY7Pn8+TfE+kLZO+jMPUAWmX+sw1XsmRvO8pFhzXozVHl49nNTeO9++64JJ1S1J2smVvXvfGc3QuBeW0SXKuXa9susQWzeERvTC1VV5p8ge3R/kt6NPlNReuJ/1BZaD2yLsu9xmRelyGsWR9+pHXTbLTfKQOWI15Qjp9Hn1tsm6aK1LGvM+v0pYdMI2PtDfGrTOlHOPYLaqUUkp5RLg4bR3+pZTL8IfMS0WPjjM+CFif8vX0IVNKKeXZ6UOmlOtyDw8Z/ZZQv4U6C6zJ9Juxcjl9yJRSSnl2+pAp5brcw0MG9Me6zvIwYF26x12PPmRKKaU8K/l3L0h7fya9lLJm+vsgL50+EO6TPmRKKaWUUkopp6MPmVJKKaWUUsrp6EOmlFJKKaWUcjr6kCmllFJKKaWcjj5kSimllFJKKaejD5kL0D/xd6v/Xrn+qcVb+xdK3C6+73Gr47gGZ/7Pux6bx44v/+d9SUf/VayHrFf29dL/vwD/F5K2Ytz/122Xu2Tt83/uvhYP9Y8J1+Nr/zXx/xh7x8rOa/GQmF75SCmlTPQhcwF+WN8qt2ajHiUckjqIjxyYZ5jrS/F/YvZrLkkvla01v+QitMVD1kBtjsrrQozv6yJ3DxcyxffeWCe5S+P9sfaHa8Wo1p2k/e5rdD/W3jHZucWlcfjQdTrqS6WU8nJuiU/AQ3669NQ81gH/EPKQlG2U73FL47gmj/FT1ZfCKr7wnWtdaB56IdTj5Mhlzy9h6o+yl87Ry+ckd+ne+lj7w7UeDLn3ia+J/69pu2Jl58RD4vDSdRVHfamUUvqQeWHc0gPgkkMyuaVxlOcDv8EHrnWh+ZqLKjYc8cd7vYQdHfc15uesD5lb46id147DPfqQKaUcpbfEg3CoacPX5uplJG32JDbiPfzQJOWmrc2cxMHth47wMtpvHfAqJ/mhdaSfCe+L5Dp9LpSQX3GNcQiv93U4Ok6VkVJ/rhnJmerpB7xMer0Mf2LsyqudSH/zNJFr4OMlpczks7nG0+XO6z0hezRGXG4VXyTaTLIuQ73j6+5tU27S66g+2zm+fkr4xBHf29sPXDc25LhSJv3H8XVFj+tyn5/mRHmSz4V0IOftXAZcDqY+IH2PdsLrfC5dRqz0Cx/7lt0TkiV5327TFOtTGf1hn/K+fi7n6wNel+Pf268mOxOfEyX68bYk93PaeLuc9719RXqO+kMp5X6Zb0BlZG9z5fuRgwH8gJnyQmX0Sf+ygX68L8hDS6hcduuAob1Qm6mfCY1bB1Dm4ehcXGscOYeyiU+h+mmce/plZ45Z8oC+zGd7kuYjx0peNrke9UXdlF8hOZdFr8qodxt8nWQHTDJe5vOnvHAb+D7NA+S4kcsykeXet/ug5HLNUk7lsofvtHWom8qTlc2UqRwZyeXcQebBy0i0k01KyGgs2X9CvdqlDeRFjsflprlWucttrTNkGf17O/LICF9HyiVPctv31lX97vlH4mMDteMT3B4fQ5a5HhL5nAvYawsrG3Jse3oTZCabAN1qT53ymuOpncrgqI/ITp9L9VFKuW9+eUqWXaZNWYcDCVYbc6J2vhmjlzI/QKVLcugkD7LHdaQ9oDI+QYeCt1ObqZ/Ex4gukLy3UT+krbm41jiyXjYpD+S9jY9zT7+PByTv/jCtoZjmw+dy68IhGdnm842OFdJFErJR45psAOpVNvk15SqTDdItOyFtmHSB+vNxT2WQ5dMYfL75DpOcl2kc0q92kOu/YmWz2lIPk++pDjSXk50qcz+QrdOaT0i/9ynbff1yPJMdkHKgsqmPSU5lPq6JIz61t66+npq71dgS9a95kr3Ku27ZM5VN/Um3z8/U9hIb4KjeiWnNAJvVHl2AjMaytdbITOsGl/pDKeV+6a5wAdOmrMNBG+zRgxAdyOjQAZXRj5AulxOTjrQHJJfJx6GyqZ/EDxVdELxMB9rRQ/Ja45j0JGozyezpd1JW+JhJmh+Y5mPrIkMSysvuaQ0mtuZRfrbns96Xy/CpMtkwrUHasOpviq+pDLJ80jnN0Z5cJq0T+PpJ38TKZrX1uRHTvKlsa53cdsXdtOYTqR8m24/MNRxpC5eWkXLOjvjU3rp6vdZzNbYEO5GZ1hKmWP+a+J/a7tngSFZJTHonpvUBbFZ7zaGzagc+/6SjvkQ6MuZSyn2wfdKVL5g21yMH6oQOFt+QVUY/QrqmjXvSkfbAJJeozZaM8ANIh5eX6UJ19JC81jim+Uukc9JxZJ50cDOeyUYhXZKFr7nIqF+NTTJbY4VJV87Tls9ShvxKRmWMzWXkA5A2rHRhD2X0J6YyyPJJp/sk9XBUbsLXb0tuZbPaMh8Jslmnsq11cts159OaT6R+mGw/MtdwpC0cLQMfn9cd8am9dT3qHxPYggx2T0yxPpVN/U3rN7XdswHQqTZH9U6s1kf6SdMcr9qpbDXfl/pDKeV+2T7pyhdMm+uRA3VCumgv0JvtpMvlhHTwKabDanUoOGoz9ZP44afDyw8Ycekh+bXjUL23SVS/NZ8r/TnGyUZH8hrX11xkwPsnHVmrSZf8THatfNb9ccuvJacknxBpw0rXNP9qm2uS5ZNOn2++w57clp+63BYrP1Lbad3Uxus0r7Jzst19QmPM+V4h/fIDmOw4MtcwjVtlR+W8zJGtqzE+ZF29XnpXY0tkL2li6nsqm/qb1m9qu2eD+wYc1TuRPiCwWe0ZSzKtq9aStpf4kpP+UEq5X+YdsIxMm+uRA3XC5aa8UBn9JH5Q6RBRnoS94HJuk49D9VM/Exq39GUejh6S1xqH9+fjODrOPf0aIwko9zxgqx+u1KmvaT4mf8l+hI/jKJMu2a15nWzIstXcqG6LtGHqD7biizLaST51Uq6869RYkQeXI2mtJEcSyPrYNAdu38Q0DpB+2eL4nEx5mObN10VjyblZ4WNGt+t3Hz461xq35KYxwDQ/WUb/lAn1iU5Im6a5AR+joF7rqvo9/0gol4yvp9uvevU1lU12T+u3p2+yIfVMczHpnZAudGCzbPX50to4ua45Xvr0vLjUH0op98svd7SyiW/YJDbVqczzJDbgFb6pk7Rpi9TnG7lIG3Tg5AbvB4aSONLPhB+UJD8Ip/78sE2uMQ7wgznrj4xzS3/qdpu1dtjt/XgfKlOabF3ZmHPtaXWY51iwMfVPerWOLosc7V0m/dcT8nA0RiY5obKMD5fPcXjcebnkZJ/j4yNhkyMbs9xJHSTmKcft4xM5nzne1J1jnspShyN92OK6tf6O6kiruUbPtJbOtM5TGXpW/Uzynif5+ue85fp5nfrkcw/68LYkkeWT7FSWYyG/0gdbNmSdz5v8wutJ0jshGbWd+vb20zqBj5F5Tt+71B9KKffNl6dMKeUmyQuOJ10snprpIuNpuhCfGV24Xgoajy6YpZRSytnoQ6aUk+A/ucz0XPBYmewh5U++z4zG+ZIeZ33IlFJKOTt9yJRyAlYPA8qO/DGYx0B/BGSC8tUfeTsb+s3TS3qYQR8ypZRSzk4fMqWcgNVvPp77cr36LdFLgvG8lEeZyL9v8NLWrJRSyn3Q06uUUkoppZRyOvqQKaWUUkoppZyOPmRKKaWUUkopp6MPmVJKKaWUUsrp6EOmlFJKKaWUcjr6kCmllFJKKaWcjj5kSimllFJKKaejD5lSSimllFLK6ehDppRSSimllHI6+pD5hn/4D//hp7/39/5eU1NTU1NTU1NT0ynTP/7H//jbm+390IfMN/ztv/23P7169aqpqampqampqanplInHzL3Rh8w39CHT1NTU1NTU1NR05tSHTCmllFJKKaWcgD5kSimllFJKKaejD5lSSimllFLK6ehDppRSSimllHI6+pAppZRSSimlnI4+ZEoppZRSSimnow+ZUkoppZRSyunoQ6aUUkoppZRyOvqQOcibN2/G/3zo48eP30oc4/37958+fPjwbe75efv27bff/hLyjAs7n4p37959Mae3wq3adQ3wQcaEX5eXx2q/8nRL+9A1YDwP2beIc9/HFfd8Xgvtq6TXr19/W/oyYM4ZV54l5baZ9gggFvB9P//Odk4wBux+abFWZvqQuQAFB+mhmzZtb+UCocuso83tmof4EXQYpj3Pza3a9bVoXN3oXy6+X3k8+6X6IRf/WwVfvnQ8miM+hebn2hdzXQxfWsxpXP2hyDnwMy3P+SzXfeBsa6u7Dam8fLrKF/C1DxkOMNrewkPGx3IL3OqD4VbtKmWP1UPma/exW0QXrksfMpoHf8g8Fi/1IVPOg1/wV7FCLJ39IVPui97OLmB1AVAZyS++HvwuQ/LDTAccydtoEyGhV7q9reqzXOini0psZL6ZKSHnstrIXGY1NvAxeNraAPWwI3l78LlWmeYj+0LW50q2w7XtEqnXH6c5v7kuK1sTtwOd6tNtV71kRM6fp5/+9KfffZdtPp70Bdbd9eV4QHUk2eE6+O7jRl95XHzN3M9W5eBrRHLcR0isKXgbfMXlqFvFg8sJ9xmS+7TvPyTFgceJkkib0QFTfKDP5TU+1+82THGQSJYk3dkux+yxsRqzSNtWuA70q0+NMefDbcj18+T2yTYfD2OmXHl0ub4cz8oO14FOH3c5zpF5Y32YY9C88+nr6nEJHjck98Us1/dc+9QxyaUfTKQPgdvOd9fjvl7OSXeBC/AA0QEAvjHrkFKewKWdy/gmoACTHN9dt9pQpgCkj5SVHm+rYKU/9a+2vmk42ui0SeyNDaRLG45sWW00INukQ/2ShG966FQevW4X4wHl1e9j2SW90iO9WlfaaB2wTfMG0ke5xqO+Eq0xCX30R3tsVJ10ywbKvR3ffe2FxuBlGjsJm2Sfy3k9bNkBlKsNdqhea1IeD/cD9/nVGmj93Y/Jg3Rp3flEj6DO66VLfXi8Sj+4DWoDLi/4rnFQP+lW/7AVEyRkvUzIDo3P25JAc+PzmkhG41V7xQrIxpw32cP3acwgfaB4Vl+JzxF9aux8V510ywbwdqB2bofG4GUZ97JPcj6nsnnLDpA8ifaq1zqVbXzOfa220ByTWHut4+TD6Pc++A7uQ2qnvPxeemWXdMr3QT6FXvmh2ieqJ4n0yclvyzn55SqXXTxIffP0QNWmrLwCbZJxfULBJlQ/BZvq0JNBqf58w3H8YHHUvzaQI2PLNtK96tt1imnj8TL1JVyHNkzlZcdj2aW85kMymnv1q3qRclr/1Ua68jfIjV66yec4XY9smuYCOyhTXz52zXHO6ZYdIHnplPxqzOV6+LpnSibf97V1XROqY/1BvuTrnGXolDx4f26PfC/zwm1zfeihDL0uk3FLcp2yUz476c84SKTb40v2qMz1qn+3GbJepJzmS/nE5zNt1ng1Nukmjz6+a82mdUkZyPmRTpJQXv1u2QGSl85cp7KNr93ROdMca221JpNfo9N9WnHm/apMea3tyl/UD3LkZYf6UT6RPEmoD4198ttyTuZTqYx4kPpGsBWoCsxJxssy6ZBQXgE/oc2GtLXhOKonObmhHBnb3iaUTJvM0TLhduVcPaZdU78p43nvS/1nWtnj/qa5F77mnvDLHOekZ5oL6ZRv+zg0VuTJa0637ADJK88n+dWYy/XwdWe9fD21T4jJH7RWklWepPUUKqcPkF94Pxkn8qHE5UjyPdlIcr0+TvXveMySFAPej/oA2a4xTvrTr5NpPrMs5wNSZjVmXwtPLuNM+5bQWDLRt/qR3klPyoB0ogN8HEL5nNNM0pF5rdNqzOVLfO2OzlnO8bSOYhVnXq4y5bWWK3+Z4sCT6pMpttSHYlZ+u9JRzsP3vbEs8QNNwQBHAnWS8bI8XITqtdk7Clb6yMPEA39iVZ8bypGxSZf6li2qT6ZN5miZmOZO+ce0a+p3aue+onLZc3TjdB2ae6EDxv1QeDu+y2bvd7Ildfq4NNb0jy07QPKq1xocnYPycNwPtF6afy+DyR8kq/gB9wkvVxn1IL9wGXA5719Qhw1TnIGXy1Yfp/oX8j+XUSxN/g3p05N+6ZVMMs1nlnn/Ymo3jXlamy1W8wkay7Qe3g5ks/c72ZI6NS7pAeVzTic7QPKq1zodnYPyyzkkHSHneFpH0NpNceY+pDLl0z/Uj3wq6+X/e0yxJRsVs+rjqM5yuxzz5vIZD1IFAxwJ1CnApwMyWdV7W8jDZLLJmQId8jA5MjZwfaTVeMB1ismelY3gOpgLUP6x7VJe/WqTnQ5U1aHHdantFr7GmntxZBNWW1LaJru8PTKUybcne9M/9uyQvHQesbtcB/cfjwmVkbSu8v3JH7ytUJ3aS5/iS/Xpd77+6dNqg44pvh3pkQ7Jqn+QDPb7XKjNqg/ZIZ/1ttKffp0odnw+M+Zcr5DNk17VYbd0edsttuZztVbC7SSlbbLL22t+5DuTvcrv+YyQvHTuyZfv4+vgseLgK4qRnONpHbX+1LmvSIf7nsqU11qCYkbJ7fO69N8JlxcZs7LbY7Sck2O7YPmMB6lv5kcCNQNc7bVRkARlClbV5aaTga0g9U1dZR6o5CHby061Uf7o2C7dDNSPxuXzoDFMm5HI+XTZx7YL/d6PZDQ/6KBv0Pzl3EkXrGzMMTrSS/K1cr/KNo7G4H1rHNKRPgKaH+9TMpMdkleeT/KrMZfr4f6jtQFfs2n95TeSgYwl+Y9wv/B+3c9BfU/rrzbokH6SfI/vQr7pdSTKJ99zX9b4fB7Qo3YZBz4e7Quue4XaqD+18XZ8kk+9e2N2m9zOnG+RY3V8bmQHn/IZbMo2jsbgfWsc0uHrKZT3Pqcy6VCd8lqn1ZjLjNbL51lQ5/OZczyto8eCr+EUZypTXmuJf6FnC7Vx+1Zt3A7hdoLmYa/fcvv8cpXLJgroTH6gKKWsgtc3ED8YVvJZnpuO1/kGo0AFBa+SozoFsttH8g1IabI12yntbRAuKx0a+zSvSY7ZZR/LLuF9Zz1tfN61WQtvR1rhOkhpA3mvZ22mck/UZT325ngyjy0rP13ZkfOf7akvj0POtZL2nVxf7S3ZTtAu11PrD+4D6Svp/9RnGbj+tC/rSb4furzs8jLaejxpHtxOyH7pI+Mw5yj3ZZF7mOxX3yLH5fVbY0792LnC5UhpA3q9nn6nck/oyHrmL23OOWX+ck5lz8qOnPPM00e5DJ8/Jfevad0yn3KsV8aZviulHuI1fUYpfTrrJ7JP+kv9aYP8rJyT9S2qlINMm5XSc24Qt2rXU5AbtadSSjlKPjqUth5OpVzCPZ/V5evpraZ8NWw002ajn4Q8F7dq12Ojn44n+mlnKaUcgT1jerDwU/g+ZMq1uNezulyH3mrKV8OBNh1qXJr9V9VPza3a9djoV/3+R3+AA4GDoZRSjsCewV7CT8ydXjDLNbnXs7pchz5kylVgw8mUF+nn4Fbtemx0AfHUi0cp5VJ4tORe0r+TUq5N+hjpHs7q8vX0IVNKKaWUUsoTwW+a+lC7Dn3IlFJKKaWU8sjwgMnfPOUf3SyX0YdMKaWUUkopTwR/J6h/3Ps69CFTSimllFLKE8ADhr9nxt8/6z9m8PX0IVNKKaWUUq7GQ3/bkO34zcW1//iV/t+a6e+oTH/0i6R/4CLr8yGifzXUk/rpb2Aehz5kSimllFLKVeDizgX+UvRbCicfA9eABwU6tx4W/q/1TaSd/p96Zp10ZXm5Dn3IlFJKKaWUr8Yv9Jeg33Q8xWVf9pFWv+nR44M0kY8gya4eR9MjrVyHPmRKKaWUUp4Q/ZEpEr9t0B9J0mXXHwSkvCB7exI6sk3K8VjQbyOU9EemJOf9uBz1jl/0SejWb2I8ub60WUx/HAt9Lo/u1K/HD0nj2CPnYNXukoeM68PGFX3IPA59yJRSSimlPCH+6OAizIWaizuXXdXp8aALvC7PuvgL2ugC7Zd78H6oA128/XGCnPSrjfKSV159IAeUU0beHyUOeV3kJaM87fjuZSA7SBqf66dff9zIni2kX48knwNH9pAmNBcgXSvZ8rh01ksppZRSnhC/pPulGMhnuWT9sZDt4MhDZipDp6N6ZGWPHgHqwx8dYvWQ0WWfh4dk/BGhh4PrdDunhwxc8pBB1serdtLtXPKQkdzqUVQelz5kSimllFKekOmSLnTp98eFZHURV57k7fXIIMH0aAFd1HUh974cv9D7I8N/C+F686GR6FFEuvZDZnqQOP74cN3ep/BxT0xrs5Itj0tnvZRSSinlCfnahwz4ZVvlRx8yLkf/aYPqsSF/IyP8USJb86Eh9OCgjWSe8iHjuqZEvXPJQ8Zlt2woj0MfMqWUUkopT8jWQ0YPBF2WXTYv3KrTA+DoQwZU7o8H8DawesgI6vQoyf6FytA9PWSmPtyOr33I0C7r3VZ/mIA/0iaoF26DlyfZR7kO8wqVUkoppZRHYbqkC9Xl40CXZC7EfilGTnV+qfZHAykfMrqs5wXbL/joQD/f/bHkF3bKvc7bottt4juyfF89ZNCB3DRHPh5I3RPqc0Jjy/au18cKtME2x8ed8qorj0NntpRSSinlCfELNCkv4X6JJ/nlmMu8Lv4kfxCA1/l3kl/AdVnPSzl4G388oE8PGZdxNDa3y8fr+vTA8PGiG6Y58rweRJ4S74vk8+zlSsg7k8w0X2KySeMpj0MfMqWUUkoppZTT0YdMKaWUUkop5XT0IVNKKaWUUko5HX3IlFJKKaWUUk5HHzKllFJKKaWU09GHTCmllFJKKeV09CFTSimllFJKOR19yJRSSimllFJORx8ypZRSSimllNPRh8w3/M2/+Te/9z+xNjU1NTU1NTU1NZ0lcZ+9N/qQKaWUUkoppZyOPmRKKaWUUkopp6MPmVJKKaWUUsrp6EOmlFJKKaW8CF6/fv3574t8/Pjxc+I7ZfD+/fvP+bdv334uU/m7d+8+l3/48OG7NsiU26cPmVJKKaWU8iLoQ+a+6EOmlFJKKaW8CPqQuS/6kCmllFLuBC5oXNpKean0IXNf9CHzSCgQCJojKLhod8sQ9A3uUsoR2Cu29jXqlG4JXWo8ccERfM/6TC5/KX7BSrzvN2/efFt6DLXrQ6a8ZIgd/Jx9R3cxxVMfMi+PPmQewHSIAU7/kIeIAov0kPZnYrogkHLD4ID2+qMPwmuzd2FJu7WBKmmj9LJMRzfLa2yq3u/qEuQyE742X3NZuwZuayYdUGJaG+bUyzKljnIcn8dpX6Ncca098BbAjlx37QMZg+QnH0GWdOlDw/ebSa/qNZ/0/5DHTB8y5amRX5P2zg09JLbO/VXsAeW0R490SVZ7jdqrvA+Z89KHzIXoEpeBSBlJB8ylKLge2v4sTBsDc+rzyfdLD+fHZto0tWZZjv3pI1MZoJfyvbW/xpy4ndqoUydlOjw0Pgd5raF05Jiemil2ZFuWr9aBsrzcSS9Jc1IuY1obYK7T9/DP575gY0PGs9BY3MZpXxCK7YeMaaWXOXN9D4nBh9pUXhb4wZQyVhN8ELlLcL20X8UMyKdJq31XsbXSQ7n6lD7JKo4VYyonJignltQGmXL79CFzAQoeBWRCQDz0Urc68F8S09wwXm0kgo3uofP4WKwuFr75Cb4fKROqm/QL6vLidwn0kb4l2wX57IN+demRnQ7z8jV2XYNV7Mhe2Q8q49NJOYe6SX/ZZ7U27ldi8j/h66Z9WHpJymd7tSNtxRfI1pUfADqQEat9QajvS5n0apzpu4x5y2afg2mMPp8k5H1OSbQDtSeB6wZ0lduH9c+YZC239vL0iaPIZy5BfcnvJvZir9wPl++wd4oCayvQCTodMgpe3yxyI5AsTPJ+SJDysMIWlfvGxHcC3PvbOuClQ6gdNumQQ97LU472fJfsUdSHcLu25lrs2aB8bnjIq+5IP6tNU336mDWGvTJH86y5dSj3pLXy9SX5PB6BvnxMfHc/APKaH/Sv/GgFOmknOZL6QJfKGIuj8qku0VqmnPr0Ma3WIeUc6b90fst6bShLX2f+KU/cd/AnteM7PiQfzrXNvGKMNK216iU/IZ91nep/4ojOiUmvxpNziU0ZlyLbyB6NP+dccwq0cVmBDuFt+e515XaZ/JG1y5icWMXpikvlQb63Zc8UI+U+ucy77hgdyLmpT0iWpANkdaAItVnJK6+DAjtkizYKZKWXpCCn3Ntu6ZYsiQNNdv30pz/9rpwyl6Mf2bJ1qE4gS//Cv0u/lzl7NlAOksNuyLmWrMskzE1umtKb5ZrPHFeWOarXGiUak1Df0qe8y+xBX5ozoH2OX74F6E77tsbFvFDHp+ySPvJqQ73rpV52aa3UZiLXU6h/L1/ZS5nPRUJ9rnPZZ7U2lG35WqJ18zYZk4oByaBvqp98FfCvrXqgT5dJG5KUP8qkV3OQc4ndq9hAR/o1OlSWc5T9TmuCjHB7+PS6ci5Y9/SticknViCXSSjeshwUq7lHYCPltJ1ipNwnx7yxfBe8GVgrkENeG4MCT+ShtCcP5CWDPV7Pd7Xlewa42sKebhLfU0blmgPlsUXw/ejmQvs92b1Nc2VDtnEZxsUciNUFwdH8ZPJ+hfT55WUqc1Sfcy6w123OMYDGveojybmnbfq3z+XkN3vjoo9prl3ex6Z6Xwt0TPMsFDuZcn5gZS9lW31Qf9Svyy/JfU1QtuVrybRu+KKvifYC6Z30Tf0KxXj6hpMyaUNyROfEpFdzkHPp8eNoPrJvyiZfp5y0Nad8uj76Vbu0q5wH1nTyoYmtOJ2Y5OkLHxfyI/lQ+h3gl/JbxcJW7JX74bg33jkKxtUhmCDngelBOJHyfE95BS+f+k7yDQGmQ9D17+meNhHI8klO83QEZLfmRDAW7Jo4agN59ZXzIx2rPmCaU7XLtj6XYipzVJ9rKdjo/aDBlpSd5mIFbZF3prY+l3n4wN640s5J3se2ql/NC2AzbXI89E25+9ikH1IuoT7Xv+yztTY536yx+7gzrRvyviaT/3tetuTaC9Vv+YF8SqQNCbIuf5RJr8aX9k9zCSt5ylzebZz69XWZ1kfzRkK2nA/WzeNmC3xH/nKElFcs+54gX5X/ZCyjY/LLrdgr98PlO+ydouA7ulFrc1ewrg4bkfJ8T3nZ4AcTeinztlOAu/493bmJiCyf5HLT2oJD0ceyYkvuqA3kNWa1kU7JU75itWlKl9f5XIqpzEE/9TnngjnwSwT9pS9OczHBeCcZdGqOBH2oX/8u0EOfK9LOaR5ybHxXG40p7XJkw7R+9O91q3XY6kP6c77LPqu1Ya7Tlyb/E9O6sR60EZP/o48yJa+bkNyEbHAb0waHupQ/ykovc+b6NOb0ZzH172UeazD1q3Ezdy4Lnl+tdbl9WLej4DtfI79qjy9qT8hYTj+FyVcn0KOUOsrL4Lg3ls/BRDCsNmo2fB0Qual7kArqFKgpT4BmkEoG6MftQFZBOgU48irb041evss2keWT3GqTSmibNqzYkjtqA3mtDTBHlCmtLgJia9Okvdfp4HedU5lQ3dY403/ki470MCcrmCefB4fy9FFskrz0O8xLtnFoL7+EaR5ybJJR8vYTjAm5adyaJ9VN/QNlq3mhbqW/bLO1NpQrbvnc8v9p3TIm6SN17vlOIh1pi8aR+tIGgewkf5SVXs2D5hO5rT6oQ17zpnHINvrw2CM/9UuZ6xGUab5lWzkXrNvWHp6wT+Y6a+09yUdTfmoPfg5kLFOefi7/3UP2kLZipZyX7joXooDIDZ3g9M1AB4aCWYHulyW+q34l74FH0Ko9nx7E9K062tBWm0BuCnu6U15k+SSHDsr2QE79bcG40g7nqA3k1d/Rvp3VpkmZ6wbNr/vIVAZaK9IW3j/fNW73uWmzd5ijrEePl6FTc8lnjtn7kA18rqC965/mAZ0aB7qmed4COyc76DfnaLUOlKVPSO8kX/ZRbCjl/Mp/SFtr7utAIs+aepnWVYm+skzJ/WGFfMeT+9dKt6cEmyj3eEh8TpTS93w+tnQJnyuNS2uRc+vj9vEiN60R8t6mcXI+WD/W9yjy46OkvHwu+8S/5JeKA8lgY/rfVFbuk+PeWL5DgelJAQhZr81dAaykNiv5PCw98Gnj9X44K8D9gMlNY6U7y2VjlrtuEnJZ5gdhgn1T/XRBWTHZmjZMduc6eF2S7afkc8u4vI58lmXKtZlwOzRv2uyVtFYT1LmsJ18H14ndEz6eaQ2FZEisa847edel/lzG08Qk58nXNNeBfPpLpsknVLc19vL8sD5TbFF2JOYei8mnbh3m8ox2l33Yyy5BZ8lRJnmd89pDdTYIyskrTnX+uQ+SVyr3TT3gBUKw61JYvg+bIilhw53Ky9MyPchu7SKFPZOd5XZY7YGr+H8q/IdOZ6F748uEh8K0r+ohkTHkjwfS3g8EUt59339o6f3gZ95G+6weO0q95xTRh8wLpAG+zWpu2Cj1E6LyPOC7qwvTLT0cerG7bXQRy0sa5c/1kMBnsOmM9Dwppdwqfci8QPqQWaOf9uSlmPK89JSnB7+dfPeW/Hnyn3KbsFaeui8ex39iXkopt0p3qBeGHz49gGb001pPz/VT2vJ90odJ/U1ZKaWUUpLedEsppZRSSimnow+ZUkoppZRSyunoQ6aUUkoppZRyOvqQuQP6l/9LKaWUUspLow+ZB+L/pvnev6X+1GCP/mlYHjHY2IdMKaWUUkp5SfQh8wB4FPA4uNX/R4J/9clt629kSimllFLKS6MPmQvhQXDLjwL9pqgPmVJKKaWU8pLpQ+YC9Me0juL/k7N+i6MHhf/RtPzP9dSPkv8fGls6VecJ/CGj8vx/U1Te/xiylFJKKaWcgT5kDqL/RJHHgh4QpNXfj/FHBfK0lw4eEXos+MMEKPdHhh41PDC2dMoO5CQv9JChHFLG/yga3/XoKaWUUkop5VbpQ+Yg+g2KHhDgj4wJPTwkD7TXIwak1x8lqY8yPW5WOimHfKSA7HTI6/GDbn+Q+UOqlFJKKaWUW6QPmYPowZFQ5g8TJ3/bAlsPGf/uIK/fkuzpXD1k1F4go8ePdJL8QVNKKaWUUsqt0ofMQVYPmXyYOGd5yAB9UkZK2VJKKaWUUm6NPmQOoot+/saCS//qtxiXPmT0CPEHBvBHvdTmMR4ybs9qnKWUUkoppdwSfchcABd+f0TwENj67cWlDxlQH3qI6GGi+j2d/hAh0Z66rYeMP5TA+y+llFJKKeUW6UPmQvTQIG09YlyOpAeGEo8HPUqU9HjItuKITuCTPPL6rpRtkCHpQUXSA6eUUkoppZRbpQ+ZUkoppZRSyunoQ6aUUkoppZRyOvqQKaWUUkoppZyOPmRKKaWUUkopp6MPmVJKKaWUUsrp6EOmlFJKKaWUcjr6kCmllFJKKaWcjj5kSimllFJKKaejD5lSSimllFLK6ehDppRSSimllHI6+pAppZRSSimlnI4+ZEoppZRSSimnow+ZUkoppZTyInj9+vWnV69effr48ePnxHfK4P3795/zb9++/Vym8nfv3n0u//Dhw3dtkCm3Tx8ypZRSSinlRdCHzH3Rh0wppZRSSnkR9CFzX/QhU0oppTwQXXq4IF0LLlO6VF2Da+sr5ZbpQ+a+6EOmHOLNmzef072zt7FpM7xleqkpT83exUBxQ+L7PaP4vFaMXltfKbdOHzL3RR8yXwEX+z1Hv/dA8AsKaYI5Uv30U01tPKTnns+H9P/SfAC/X62lDgCSDohEhwwJ+fKy8T1gigXq3Vf43sdMfyNTXhbaA474oc6Rrd9yspfsnTHokS7J9iHz8uhD5oHoYCCtIGDuORDYGPxCwoaRv9VhfryM+fTNS5uOOPJ4fCyw5dKLAPI55rOizX3l96rXHOUFFcjLJxRDtCsvH9Z+il33GciYv0cUGz4vX8O19ZXzozhTOroPb/0ga4Xrp32eC46fM34XcNhHqF/poVx9Sp9kNW50UKbyPmTOy32fFl8BDi7H98u6c++BoI1LsIH4xqPNwuXy8st338x0IKfup+AhDxLsfykPGSG/T/D19HfktH65/sDc9LC4D1j7XGtdKhLKVpdudMiPkCMpxuSbJN83gHaqW+3ZW9Cn9Po4NAbtSf5o8D5zz5I+yTquw5H8VJfkXGQblbmMsxov+Liyrtw+uaZ7jwvQea10FPnZJaiv9EkH+/dsLvdBHzIPgCBTAPGZwZQB7wHJhuHlOtx0cE1JeJn3qY0CXa7f8UONJHvQozJdBtx+yfHdD3/lpXdrwxHIuhz51dzxqTnRHAnarPqTPaCxqQ/akCch56gdaXUw58ZPko2qUzlIn5L36eWSF9iLPveJtNfbT+Mj6dKCLpfzOQLPu9yKbC8oy3Whb58bfRfIb/WHTvrzsakP2qnM8XnbG0t5OliLXH/Wdloj1o66xH1Z6671xr/UBjnXm3nklXJ/maC9/E42gPul71kk+nNfpZ3w/OSvKuMTfF8ExeDK9pxXvrs+2S2U9/mbxgs+z7JL+XIO0m/kb0eQ7x3lUnmQX8kHJ/BL9/Fyv1zmXeUzBKYCTEGqA8Lxwwoy8Ginetp70OpgkV7XpU0HGcmRkJE8eR0uktHmxUHkdmQe3B7plz7ldaDRVrIrkFN7wXjQ4fgGJrsTnwsH/bINGXRJH/2ojeRE5mkrPZpPbNF3dEmn9GosKheScZDx+SKv+VfffKrdZJ/G4r4w5UWOXfo8T3+0ky0r0h7QPGuOBP362Gjr0B/t5JuO7PLxSh9JbZCRXo1fdiAvPdl3eVp8HQVrQnmytV5aUyfl+e4y9JH1U78r6NPbe0ynD08xSHu1mWKFOp+b9GP69v6lw8vEpD/15XwANiADq/GiO+eNukvmstwe+OrkSxPIyU/2QC6TkL9lOciHPYYAP6Nc8VK/K3DMG8sXZNCR90NIEGRezncdCMB3z4vpkEKX571eB6kfXAp0UL3IjUiHHP0K7wu8PyA/2Z5oLEpb8wG+gaXdIufV0dh8LCkvvZLxuYKp3+yPNpNtlPuYMo99ufmqPz6Bem+T67PlC0Bbt5d20g2aI6G8+88W2R60bqkDOzTetBtyLRLqttYO0CsZ9Ks/WNlVnh5fJ5HrJViz9BXhPiVSnu+UiexbfnQUyU92pU8qXt3n3Gb5JO0E9VPMSwd15DPlfMI0Ntc39Q8+Dn0n+Xi9PFM5J6zp5EcrMrb2mOTzjJJ/K4YmHyV+5Ivy52nvKPdHd58LIbDyICMgp8DOw1MoSEl+eAnaTeUwHTAq0yYAtF/pVnvHNwnIMXp/kPkjqF8dzsxN2ugbmMaVrOYVsCnbpHzOV86VNknV85n9reY3y/fygv40n2mvX0KcyRcg5y3XKedomrMtJnmtW9rIOBgPpI9BrkVCnbeZ5H2+JtvI0648L+nXkL4KK18S7lMCefeT9IPshxhMHUdAh5JIn5ziNW0m7/sA8j43qQPZjJ0V05y6Ps1vxkSOA8grATIPmbdym/j6TufSxLTHbpHy8kX3M/mkYiB9FB3pd9M+UO6T495YPkPgEGBTyoMGWT+cFJwKPjaO3DyQRybRISN93t90AKVu2Y3MtBH5RoE+1wXeH2T+CBq/DmfvU/gmN214QJk2uGQaW65Dzlf2k2uAvGwW09pBlu/lBf1pPtNe2ScbZP/kC4IyzVHW5RxNc7bFSt77FIxVdvp3ga70AQedbn+uHeR8uR2Sz/UrT0+uk8j10ZqtQEf6DPLuJ5OP0oYypUtIu72/9MmMV0ibkZUdpNwTUgftp31jms+p/yyb+vRYXI1Xejz+YLKjnAfFhvbNLabY2iLlV+3xR/mk4kP2UJ4+Rj73gQn0KNVPXyaX7eZ3DkG1CgQCKoOKvMuTJ4iFBy7oQPQDCBTUXk5euvIgBdeNDd7PtJH4xuE2Cu8PMn8Ut1N9ut3o9HnkuzYzWB2kYhpbrsNqvihT8rppzX1+nSzPPLpSP98p0/qmvRoznykL5HMtaI8e5FwWco6mOdtiJU+fOVfIaf349LUF5ibbODm2ae1yvmSfkvtPeT5ynQTr5X7B9601Q0f6UfpJ+ih+lnFwCfTpcew2pk/SD3nvL2122yZSh+I+Y2E1T/TlfdA/eZLapT7VwdZ4Kc/5d9lyTnz9t8jYAvmrJ8VDyk/tAR+SH8nf3efwSSdjaoXsIaWO8jLY3k3LFxAIfoFypoPBA1MHiQcS+Qxcbw/Ia5NQUCsvWfXttnnffHrAk0c+kdy0maVtmT8CY8mNhLzsBPTq8AaNTSC71S91OTbG5P3mfFE3jRmQmfrDDrdbZDm6Nfeygb59PXIO0l6tN597viBUPtmYczTN2RYrefkwfQNy2T9jk62ycQvqJQ+5duDzRb3PXXl+tGaeEtZMdatYBPzJ9cjnlNDjukjIZJmS+pLeVd+0l7+SyINiQelHP/rRF3n0pc2Az3qZErbmfMmmaaxbpCyfik3IfrxuNV4xjamcG3zSfWDFav9fkfLyO/m18LNBvi4Z/I96Zyor90l3oAP4hk7yixXkYUYCPygg5XS4kFYHmwLVDw6+r+Sx1ev4nvZ7v75xyV4nD88f/OAHX+TzgHPSxty4hI9t2kh93nLuHR8XKW2nn1wD+pvWj0Q5KW3K+RVTuc899giVkXwOvRx73YdI5Fe+wHeH8pyvnKNcT7dxwmVJuaY+3rRHePsVuXbYPa2d5+kvy7yu3C8ZByL9Yms/uyZH7SnlKcAfj/qe9uGjTPL0RZnOm7x7aP/X+aJ9fXVWlvumHlDuHjbL6QLPprl3sS+3BeuVjyugbCovLx8uQasHij8okFs9MK4Jfax88Sn6L0UPCaX0Oz0k/Ad14G1Ie3tqyvtjyW3wfvKHUbKNvrycmE77yn3Sh0y5a9iwVz+J6qXifKwONg5HUrk/iGMuPrn+lOsixh6w2geujS5wCeX9wUkppVxGHzLlrtFPefInS+T7kDkX+ili/vR967Fa7oP8aS7pOeMbH017+tAupZTL6UOm3D35q2zS6o+ilNsn17J//KCUUkp5mfQhU0oppZRSSjkdfciUUkoppZRSTkcfMqWUUkoppZTT0YdMKaWUUkop5XT0IXNn8Jef+69xlVJKKaWUs9OHzAOY/pWrfBxkfaaHPib0fxAoXfL/Dnxt36WUUkoppdwKfchciB4S+YCgLP+ZV/3fBSnrj5FLyP/JVvovAfk+ZEoppZRSytnpQ+YC9J+YTb8FoYw6/4/3Vg8ZUN0l/1Efjxj//03U56R/BfJ9yJRSSimllLPTh8xBpodKooeO/ofmrYcM6DczR/9H59TPg2TvUeJ/DE72eBvpVELe26gMaEdevxWSPvKMsQ+kUkoppZTyVPQhc5DpEZDooi+ZvYfMEZ2J/7G0vXZ6kKh/PVrUTvYKHiR6qKktNjr6jRA69aDh+xF7SimllFJKuRZ9yBxEl/6ty3o+TB7jIaNHA2nvj6Xx0Ejd3h+feowAj5StPH2rrewQPHwuGUcppZRSSilfQx8yBzny6HjshwyPBT0s9BuT1WNGDw3knFV/lJP84aI+pIN2PhZk1a6UUkoppZSnpDfQg+hhsPVbEP3RLV389x4y+mNi+dhYwcMBnSIfGs7Rhwx5EuRvYAAb9cfJprGjSzqOPshKKaWUUkr5WvqQuYC9hwd1ftnfesiobnocrEDeHzKQjxsH+XxceJk/UmB6yMhOPl0XY/I835ErpZRSSinlKejN80L0x6n8caLffqweAfmQ0YMo5fdQO6HfyKxY/YaIpEeLP6TITzapzTRm133peEoppZRSSnkofcg8AH8QKFHmZH2m/K2OHiV7jwE9ZpT2cHk9bPSblByH6kn+aEHeHzxAvcqnNqWUUkoppTwmfcjcGDwu8pHz3GCP/zGyUkoppZRSnps+ZG6M/M3HLcBvavrbllJKKaWUckv0IVNKKaWUUko5HX3IlFJKKaWUUk5HHzKllFJKKaWU09GHTCmllFJKKeV09CFTSimllFJKOR19yJRSSimllFJORx8ypZRSSimllNPRh0wppZRSSinldPQhU0oppZRSSjkdfciUUkoppZRSTkcfMqWUUkoppZTT0YdMKaWUUkop5XT0IVNKKaWUUko5HX3IlFJKKaWUUk5HHzKPwOvXrz+9ffv229zL4aWO6155//79p1evXn36+PHjtyWllEthT2RvvCZv3rz5nK7FtfWV8lA4c5Q+fPjwbekMZxNynFUrHiP+yrnoQ+ZCOAwUhLrU93K/DxsWc/bu3btvS75El2qlPHS9/tbmG3vcdpI/Dhhz1md6CJMe0pGHic9nHzLlsVGMrHxNvki6d3TGXOvhcW195WWR59Pe4wLkU0pHzxCXRcfWAwQ56V89ZLSvHHnIMK7GwMukp8YFZODpMtiHzDZ+0V89ZJjX1WaoeRaswy3MuTba3Bxlb46VMabdeuBtzc0Esjlfl27UsnM176VcA/n3ytco10UlY/1eIY4vieU9rq2vvAyINz93dFZvPWaQme5BezwktnXGan+YSHtWoId0C3eHcl16YlzAFFDkGxjHYP6my/reHLJJ+bzr8v/cF3BsWF0OGGf6y/SQEdQhv3WAOJMcutM/t0D2FuaxvHxWvkacZAwRC9M+cU9c++FxbX3lZTCdF8TpVvzlOabHxt45ojPxEqR761zDFmxaIR3aaxoLL48+ZC6AYJgCcQpqBZ7nFcgkXUSVz0BUOyXygiDUpVX1vvEosKXDg1bypLSBpLHosSC5HBeQp1+Na2uzAckn2EodyccJsiPLabPqT/aAdGt+V3MGakfyNZ04Mmbq1S/wfaVX4/yaDRb9OU8J/WuMmgtvozqSbPd5IQlsJa8xSTef6JZ/lTL5GuBjUxyu4oD26EGf+6V8TXmPO1A7pUuR/Yoxt5kyj2tsJ3mfXg/SR5rGKh2O4mvSN+Gykz7slkzO19Z4tVcplZcFa876r5AfKubwDfePCfcXJYFfTuXg8e7Id2mLPem/DjLoISkGsHdrjOVcdBe6AJxfwTYdJH5wESSeJ9AU7ASTghcyWHVQCG0coAAmyQbaqb1kkaMP+lQgU84naCzKS95BH7b4OGSj8uqD9qpbgbzmQKBbNsh2n1uNLaE/lxMaFwkZ6SePrWojOZF52kqPNmwHXdTJ9gnpkMzKZiH5h4CNuX4JfbuMxjfZJx/Ummp+crySR86/IzvNW7lP5BPpP+5jImNR0JZyEr6KHODTikeQnPRmXvpJW/EoaE9/+k479a2YlR7ZQbna5NgzrzYk2agxCb6rz7RhwnWpP9fn8wcaB2yNF12qA3R6vpwbrfcerDty7ht7IJe60eMxKL2KDdkjXwb3XZ1TR3wQXR4D5eWw77HlCxQ4SnkQZuAp78E+BbTLoNMDNy+VBG32S5mClDrktRkAut2GtAvdadMk73aRv2Rj8P5WZD+TXTDNgaAP2vj4U156JZMb6qpfgb7sI8lNectmkM6HgF5fm0Q+5PbmHNC/rw91np/mUI8Vvrsv0E51paSvCcrSbxW/E7RPv5zkXUZ9O+Sz3xXqU+DX3n/GBXFAmVB7xQOyHitTbFIvGcpdH2QfTuoH1zfNh2xgXFvjRYfGAdLlZeW8sM5H4kI+QkpfW4Hu9Cvy7vfSq3hSXjahI/0e2VUsOOg6ams5F1/uZuUw2sBJHhwZeJmHDGggr8OCoCSfyev94AQP5imwsXHS6XrIu91u8zQO8rLpCEflkZFd9Ee7ZJoDQftsk/LSy7iA+fF1nDZZR/O5qoeU2bIZqE+7j7LXjjlJn8g5ECon+XrlvPpY0KE2Po+lwMrXKKPOmeJXyM+8zSRPXr479U0suG/vodjMfiDjOveStBlZj0XV+2PAdcj+KU1MY3N92b/wcfB96sP79pRrWM4Hfuh+vAI/lf/onHR/X5FxOsUtuK9m7FCeNq78OUHXETvL+Zh3wjIyBTllBJoOoQy8zMMUwOR1+BCUWweDHzjCg3kKbAI4D7eEdgr0lJ3G4TYf4ag8fWh8qwdF2uLQB/VOzhltXW/2g2zqcNTH1jpR7+swrZu45EBIaLvXDnvTJ3IOlJeNfM/1ogw52kxjwQ5kSIqJUtLXBD6ZPoZfrfyZ9vJBMcU7edfr/SjWXMcR1M+k22MB293+tFl5xYf0+ty4Dtpl7G4xzanrw9ZJX45jGq/bXV4WR30MOY8dxROf+u5Jfi1/EpkX7qsZO5TnubPy5wRd0lteFuubWvkeU9DloZSBl3mYApi8DospWNGj+jxwwNtMgU3ZFMSuxzck9SWmcbjNRzgqj4z3s9o4sWmC9tQ7OWfoSx3MD2VKK/2g+VhtoNKf43AbHOqQlx9dAjq9n4lpvF6m8Xj/5HO96AtbKXdZdHmeuZz8rdwnk/8BfpR+Iv+akJ+6v0/xnr6r/pVW+ifo0+Wzv4zr9P3JZuTdnox710EdMjl3q70k+wcvk/3ZJ2XYuDXeaW3Q42Mr54N1PYr8xKH9ng9k3CC/0iUfy9jR+eNMZRPoyrgoL4Mvd/+y5J9/E0z/u2+SAvEvfvazTz//rd/6XP67//a//bkMPv7Tf/rpv/umjPJf/P7vfxeI/7f//r//Tv5//Ft/a9RDOXAw/Mo3+T/6j/6j7/QQ2JQj/3/9N//Nz+X/37//9z/LE+TI/y//6X/6ufz/8h//x98Ftuv/L75J2iAod/3if//v/rvf6ffyHBcwhv/Tf/PffKf/57/zO5/LVyCfh2DCWHKz0YYnqN/SQ53LA/PhB7906nJAnTbLo+iCkfaq/7QxbQDpIF3av6DtEZDzDR+71fdPfvKTL2yQXTkGlefBkWvEOHOs5X7JeHPc7/hM33LyYgNTvJOX7+KzX3OBUZ/ogbQx45q+vL+0GbsyrpLUwfecF6936MfHr/5J0sEneYGs6rbGK92qA8ZOm3JOWNtcv601xe/cd3Qm7IGPpZx0qS/5l5AvKnbUl8cbeaUt0LWKmXJu9r2vfObPv7mk/8N//9///J2A+fE36b/9Jv3Xf+WvfPqTX/3Vz+UEmcr/q2/Sx1/5le8CjPJ//Df+xqf/4Zv0T78tI/2//pP/5Dt5yhWgWa5D6ee//duf/s//1r/1Wc//89/4N77T87/8Z//Zp5//7u9++gf/3r/3hX7kKf/F7/3ep//fv/PvfFeOPf/TX/2rn8tlP/zPf/2vf9bv5Tmu//c3D53U86//2T/79L9+s0n8+Q9/+LmNow1MSYciaONS8g3KcR2aiwnauz5thEpsZGkP48sypa2+hDZjT85Kt9K0uUqnNvAV1K/mLMm50FzpEPFx8F2XnbSPfM4LduiQIfkal/tGfqSUvuN+ueU37l/Sk/GeMtSn3yupL7VZ9U17+vL4UMwoT/KYIfF9sjn3PCXFceoQ3j9pC/pxHbQlOd6P122NF9L+vT2q3C6+jp7ki4od90O4xBfBZUnub67L+5liB9L/sDXtm2As3m95OfQhc5B//cd//OlPf+3XPv3sBz/49Iuf/OSLy78/Fp6inKAleJ+6X7Eq/4s/+7NPf/rrv/7pF3/wB9+WnAc2Rz+shS5Cz4UOlFuCA4VDppSzoEuQgw97OXvAU/g1fUz9NK5KeTz6kHm59CFzAf/bH/3Rp5/95m9+749d+R/feopyPWSeul+xKod/9Yd/+Olf/oN/8G3uHGxtcNMF6KnIi9at0MOgnAn8dfphBGX+24Sn8uvVT49XP0wppXw9fci8XPqQKaWUUkoppZyOPmRKKaWUUkopp6MPmVJKKaWUUsrp6EOmlFJKKaWUcjr6kCmllFJKKaWcjj5kSimllFJKKaejD5lSSimllFLK6ehDppRSSimllHI6+pAppZRSSimlnI4+ZEoppZRSSimnow+ZUkoppZRyet6/f//p1atXn96+ffs5zyd5yuH169ef8z/+8Y+/KOf7mzdvPn9Xm48fP37Ol9umD5lSSimllHJ6+pC5P/qQKaWUUkopp6cPmfujD5kb5d27d58D6akgYD2o7xXmgbnfgnnak3lu2JC1KZdS7pOnPkdKeW76kLk/usMdBKfOVL4P8/Lhw4dvc79kb97YQFQ/tX8qOPgv3byw9yU9ABkP67B6rGmTJ03j1kFC0mFSinyCND2y9cMUEpeNW8J9Xsn3CT0YttKl+HxkOoLbVMq9oPNHZ49iV2dVHzIvj+5wF6AAqXPP6DGSDxHfLDSHDu206ejwfq7HjOy4BNpofGdHGzhpeshQ75dQX1vI9fW1LfeLP0wU4+5HGff43i08ZiZbQX6eMYLN6e/6wcAkv8UUN/R7STzpMVPKcyI/JGUsTeDjW/GvuJzOXcWm4oRPl+1D5uXRHe4CFCB17u/DRsUmwPz4I0TlDhuJDnQd8g6byJHN7tpgi+w6iuyfNtQzw5hyLnR4uP8j4wcO330uND+NmfsFH8j1x2887ol5XTzELcQVNqz2Io3BbcT/cxxCFyjm4wiTHLYcbQ85z6UI/ELp6Hmr/TzPhi2QVUyo/VZcI4uMnyuOzqGVHsqoU5/SJ1nFYR8yL4fucBegADni3AoEJW8jPaD6DFoCyjcX9ElGbXLzIa86En1q41BS0OqAI0GOTe34lN7VuClHxtsIbM5Nj7xsZ1w5DulZgU7aSY6kPnwO0l6VT3WAjr3xe7nmzJPa+/ySkBc+126vk+21btqESZo39KQc3zUnoDlT3143McmQlw8K9e1zozkQtJFdyZZf+xxke9qpbm8s5fZgPd2XVmtMmvA4dF/A9zwe5EtC/j/VJfK/le8C9T4Ovu/ZvNfvFrTfA/2yS2MQskFJtiKbZT6PtPM831fjLLeP+6zWdc8vPc4u2XPlh5dAX25jIpu3YrPcD/u7YvkOHYIE0RYEoW8K2gA4DHSwKAm+q40OIuXVXocN6EDiEzLwqaMMFPS5majeD3dk/bDDhr1xq9+0CcjnZuOHK/plh5j0CM0Bn5of6SOvNtS7Xuo1fh+vdIDk1b/qJf/Tn/70u3L1M22o9ONrIfuQ8b6RkR7yaZ/mGxtcX+YBPbJB+qUPWfK0Y4x8qm6Ftxdq6/j4ZXdC/7nGQBnysg80924jcj7ezCOvtPLRcluwhlpf+ZBiQeQ6C/kIiXr5Pd89NiQnvVNcSY90OKrf8in6chny2L1C8g8BG7d0AzZLRvOq/pTXWJn/tJ32DrKaP+q3ZMs5YD21jkK+cATk8mzY4lJ5WMW+SF8u983DdtQ7haDxjX9CAabNX1CmjX/aNPJQQdYPCgI725BXIFPv8lN7z4NvLjk2XQL2NiDqNVa18bG7jcLHj006eMWkx8lDdJL38ave1w0dPjZk3E61yfFnX1pvb5t5oD9tzJpr6QCfB9ULny+QDT6etJN6L/P+j5DtYfIhH3/aLeg311hQnm2y7xw/+rL+krGV58fXSz7k8QD4xmpdFQMeZymfsZn+O8WRg66tekCfy9Bm5esgnQ+BvnKOnCn+PHZynjX+VR58LNjudbkXlPOC73jsbIGP+P67Qr7nSe3ka1kuptiXf5P0XbFd7puH7ah3ioJn62BbyXhg+uEi8hDhkPCDYgps5HMD0GFF8vbSL7uw021Mu9OeCeq8/6kN+dxsfPzYmAf/Xt/Mg7eZ5H3+VvWug+8+H1MbyHLNt8a4audjnnzE7XUYK7JqKyj3uU8/QN7Lcs72yPZA+7TRx69xJVt9U069k33z3fWmvlW/5TZh7dz35UMZM5NviCnOUj5jc1Wf/Qp8nXq3NUmZ9M2EeuQvBf2ruRD0m/GZsSOQpZzk43f76dPjcNWmnB/WNvf7Faz/UVlIecWuYkZ5+R3w3f0993jFnWK73Dc9/S9AwTQdbJRRv5LxwJwOFwWzDggC1Q+lDGxAXhsE/ZGXTLYH6iSfG1HanfZMYBMyU1Lf3qegner9u5AtK9BJOzHZmuPnu9portwu1wer8We5dGEzrNrRF+Uw+Ujayxgl420FZVpr9LkuQN7Hl3O2R7YH71NovPTv3x3KND8JNqXO7JvvlIn0D+YtdZTbhLWcfGHyEY/ZZIqz9CX80PUqrzbyq/RXofqV7wL13iff92z2OD8KNuzFL/WpO2MHGY1pmkPKJU9brwO1IT1kHOU2uWT/ZO3xjaOk/BTX8kvFInm3iTqPw4ztct98eTsqm2iTnw4+Ao9ybfQZ6B68ebiAHyCAvB8UGdjg/VCXm4W3B/WLnbkB5NimQ26PqQ19ph1uq9o4jDXbOLTXXMLUb45fMkrZPudj0glZnhuq8q4ffEw51+D25vi1bo736+suqPPynLM9sj2oT7cbGfdLvvtcar68jYNN3h6yb75T5tCGMqVy+6x8FfCD9E/W1X3JmeIzfcljRCAjn8n2idqnfwr0pn5kcxxCPrvV5wr2g712U5x4mewV0xwCZbTzPQh8XKu25Xywrqv9eUL+cZSUn9qnP3ksq85tnGJ7Qv6vdMk4y3noDeACdBDk5p0HhA5LyWUgKri2gtsvtuCBLbwN3/2gIZ8HkYJ/Opg1Btkom3OsW6zaUKYNh8/sHztlu2zc2nBo72Od+vX5Q9c0ZuG6xGosUzl51oEyxqf11Zg1JrXJuQa3l0+3lzzyieTUjyObRM7ZHtleoEN2go8LNDaB7KRHoC/XJvvWfAp0ep/l9sEv0v/wf5VljLDm7mcJcul76UvSqfhA55YvTqiftEU+mfqmOJMOt+USGEfGyITG67bSTn3/8Ic//PyJHGgMPoeA/ZRPY1OZ+pKuck5Yz0t9cvINfI5yJY+BlJ/aZzx7LKvOfU3+t2c7/SCnVH99mfQhcxAPhinlQafDQMlRcHmQeWD74cP33CQUxEr0lQHr/Tvo8k0Gsu2PfvSjL/JHN7rcjITbq80p8TFvbTaSITEWbPMy8jl/2c4T5NpNOrfKNdeuJ+dUY8py5irt1Twq+Vr63MoeZ/INz+dYk7RP8+egQ/W51uA6+L7C9ZAm29N+ZLJMSetRbov0KU8e6+73W346xWH6UsYQNmQ7Jfxpj9RPcrbGSJrGI517fovurThyVnuHmOpIrl9x6GsDyPs4G2/nhvU76ldO+sseKc+ZkueKYlPga5KRP7q/TWXlfvlyNy5Pgg6D8nRMGy+b4ZFLTLktVofo1uW3FC75q4f3VP5U3OIe1Fh62fAASL87eh7mw2SPlNdj2/vi0eIy1PljR49+Pa6RJX+pLeVl0tv0M6AgLE8Dm+LqotJN8FywjqvDtmtZtsifAgsudbogPTX486357S3aVK6H7h9TUhywx5L333hku1U8iakfncN8ern3o0eLkqA/lU32lfult+lnQAFengY2wGnT3duIy+2h2NGBKCjvoVZW6OKEnziUrx7Gjw0Xtlv8zQc2PdfDrpRSLqW36SdGP0lQ6oHxNORPeTr354UHS65lXlBLSYj39JtbfEg8B/oBASl/SFBKKbdMHzKllFJKKaWU09GHTCmllFJKKeV09CFTSimllFJKOR19yJRSSimllFJORx8yZRP9Bdn+i1CllFJKKeWW6EPmIPoXXaaU/4yv/wswSr/xG7/xvTJPX/NPAeuxMf0zotO/1kU68jDxf+WnD5lSSimllHJL9CFzAfpnX/2f7fXLvpcDj5N8XCCX/1Ss/3Oylz4Y/NGUffHPaE76kD2KxteHTCmllFJKuSX6kLmA6SEDq/9s7ehDRlA36T/C1Nf0/wEwhuk3Nyv6kCmllFJKKbdIHzIX8NgPGem/5KEhpr4mkNl7lMgOkr57m/zjasyHt1EZ0B95/cdz+g0S+dVvjEoppZRSStmjD5kL0GU9HzI8IlbllzxkgHraXcrRhwz6t9AYhR4tenDQh9tHnfpV2/xNkOop14NGj78+ZEoppZRSykPoQ+YCdFHPpMt5cmsPGezfk6F/f1zwOPMy2vt4+b6V99+68N3HRrn3VUoppZRSylH6kLkALt1c6le/kfnaP1oG1D/WQ4YHRv62xNFvSXx8+ZARKif5wyXnaBo/6SFjLKWUUkopRfQhcwGrhwzoMeN1lz5kpH/vQTJx5CGD7i2OPGSU10MkfwMD1GmMWQfYiQ7XW0oppZRSyiX0IXMBWw8ZLuxZd+lDRpf7Sf8eew8ZbN976OSjBbLMHykwPWSoVxvX5X/MDLBHD6JSSimllFIuoQ+ZC+ASPj009BuG6TcTRx4y0kva+qNfW+w9ZLDtiO58kOlRIrv59H7I57j1+CE5+Rsf9GXbUkoppZRSjtCHzEF0MV8lv9z75V9p73/2nx4helT4bzESfwQpJTwcLvnNB7LShV18yoYcm+pJDuU5Jv1GxvWXUkoppZTyEHqTPAHTI+fW4cGy9QArpZRSSinla+hD5sbhtxj8FuRs9I+MlVJKKaWUx6QPmVJKKaWUUsrp6EOmlFJKKaWUcjr6kCmllFJKKaWcjj5kSimllFJKKaejD5lSSimllFLK6ehDppRSSimllHI6+pAppZRSSimlnI4+ZEoppZRSSimnow+ZUkoppZRSyunoQ6aUUkoppZRyOvqQKaWUUkoppZyOPmRKKaWUUkopp6MPmVJKKaWUUsrp6EOmlFJKKaWUcjr6kCmllFJKKaWcjj5kSimllFJKKaejD5lSSimllFLK6ehDppRSSimlnI43b958evXq1acPHz58zvOdBJTxHRnJwfv37z9/5xMkU85JHzKllFJKKeV09CFT+pAppZRSSimnow+Z0odMKaWU8hW8ffv20+vXr7/NXQddvq7FtfWVcgvg0zxE+pC5X/qQeSQUKB8/fvy25Dqg8927d9/mvs9jHKiXwph9k7gntHFqU70209w+55rTN/aQ+L6HDhTx2PN1Kffsu4+JfIS0ujC4zL2jS9e1LlfX1lfKrSDf1hnie4jOF2QkB7qfaZ+XTDknPTEegILDE3CR4yKkICFd+yGzhS6Vz/mQ0UWQtHcZlBxpepy5rtWYKJfMU871hPvFY1zML5nbpwB/07rJ57fGrYNEB8Zjz9el3Nr8vhQ8djXHeWnwOZcv3TvM0TUvV9fWV8oKP5eP7KXIbf2AlrrVnoBPU6czRP2Czhj5vsq1x8g2yZRz0tPiQjJoBGUkXaYVKE99ueZy+ZwPGdBlZWsDo15ornxOpUNlbGQ5LvLa/LRhPfV8J7Ij/eNaHJnbp+IhduhAEY89X5dyS/P7EmBdMybzUkI+LxEe2/dKxsrXcm195WVDjCpd4jfErvZz/XB1C/WxinftFys92Ead+nRZnS/yfZXrzqF9XjLlnGx7WPkCBeXqsuwBrEB56ov1GR4y05xgs8szDpLjOvnMcbIRZZunRhun/ODa7M3tU/FQO3SgiMeer0u5lfl9yWTs8j0vMdPjRvga+SVHPqR87g9qp3Qp9Ce96HKbKfO9R37ufebeJH2kaazS4aBjpW/CZSd92C2ZnK+t8SpulcrLwn1BPjz5aCK/oM0l0Cb3AEdxXspEPeMgR4KZjV+HqQ4BD2jpUMqDiM2DgFXQktAjtEmoD6HDCNvQmQcS5dJHSry/tMnHoX6E6/VNSON02/dIm6f22Cb7NFYH+dTjyE6NyfvQ2EiJykm+nhPTGu2tu9tD8rmEtFefAttdJ3ND8n63+kT2EtCltkqyx/V6uZBtYuXTrsPlvZzxue9q7X3c0uvrmza5zfqeMuV64D/u49N8a10TX1vWVHrkV2ojOenNvPtNxsYE7dO/1Ld8S3pkB+VqI7+i7ZRXG5Js1JgE39Vn2jDhutSf6/P5A40DtsaLLtUBOj1fzg17pvxSsPbyjS3Sr4/i/jVxtP9yn9QzDqIA3Qo2JwNah4EuVsrrYOG7kvpQ8NKGpHrpAD+MJJOHjB/U5JGRXblB0Fb9/OhHP/ruO+00JsmRB/WrvMam/B7SKXKuBOPQ2HzcIufcoZxEO82H9JHUBhnX63npJ2ndEs2FbM+xKK/2KY9N5IX6FFo/zS22k9eYVK9xQc5L5tWGJL17aBwuL71CeZ9P+tLYIccPqZe8xgK013hhsoU+NT7XL5syLzQXrqtcF19LmOab9fN1cbTe7leTvMvkOgP5o+usPgX+4/0zJvdJ/MjHqfbyO2SnOJDPAvWSoTznLftwUj+4vmk+ZAPj2hovOjQOkC4vKy8L1njla4J6/MCT/Bl/nMoFZR5PgJ9Rjl7q+F7KRD3jIAqkowefNncP5DxYpFMHAN8zmCnTAamDRvLI5uaCrMok75uGDijpxCZ9hzzglPdxozfHQp8qUx97c0W/yCnJTrXXOIWPTZubk3OeUDeN1eXRK5lp/qZ+HbWR7ejaWvfsI23iu88j5VnmNgP9aZ5AbVY2pQ1HWNmRc0M/yAnyU9+ybfJpzYn6mmSod72ygzY+N4CsylwvTOMq14N5Tz+b5lsxMjGt0SRP3v2AvPc9+esWyKMj+wHqMgbdH9NmZN2HVa84ANch+6c0MY3N9WX/wsfB96kP79tTrmF5OeATR2JlijPaeiyQR8Z9nbzrR15+qNgglTJRzzgIQUYgHd2sM6D9gBB5uPF96/DJS58HuyCvA0o2J67Tv4P6kN3TxiS9mdRvjmsP6ZMdau8bHfjY+My5mmx1qPM2k7yvU843YGPOuZNtXJ9YzQ+6KZdN0uX2TW2zj1zTbOPzCKr3ce6ROie7gDzl1EPalvOV9QIZrV3aSx+MSf2QJKvyTPRxdH7LdWBNpnmdYpl1m/wApjWiPWUOedfr/WjtL11n9TPpviQGlZcPS6/7ouugncfsHtOcur7cA0SOYxqv213ug6O+h5+6H6efC8o8Pty/pMORH5YyUc84iA4+3+S3yIDOAwIU5Drc+L51+MgGbQqUp04/oFbBP+mUnbT3NjkOQK/aT+S4jkC/rnNq7+P17wK7tjZcdPr8TmPLdfJ+NK5cIyfX6Mi604fauE25NpBtYbKZJLKN8rJRfuL97LHS6XaBjwfStpyvrBfI+LwjozHz6f2TpI+6nH9xdH7L18N8ruKG8lxzfHolP62RfNgh7zqQp0xppX+CPl0++7s0BgF5t0c+K1zH5Kuw8u3sH7xM9meflGHj1nintUGPj628HPCx9LsVijHJZ16gEz8SyMinqEvfdf/bAp3IkVJHebnse0b5DgJjCkrBZq5gzABWWycPJ77nAeGHhuR1+ORmAF4mG/KAcZ0g25R8fNNGpLKEvgFZ6rPfLbBH7YHvngfXyWeOnXFkG4f2Pu5pbOh0HZpzpS39kGu0t+7Y4+Nwm6Z5nMrSZvokiakN8pQpyd6jTDrJe7+Q40vbcr5kF/qF+nIbpZcy2SDdPhfZv0BmGsNUVr4O5tLXBJhnL/M553NaMzGtEetMmUOecsBP0jcvIX0wbeS7jyf9PG3GLtm2InXwPefF6x368fGrf5J08EleIKu6rfFKt8ej4qm8LPAJ+axwX1JyPyEvX8i8wF/cl5GRr1KXfk0dMnvIp0mr2Cgvj33PKF+gIPFNHAg0D5wMYAW/y/A9D3OSyOClT/LqW/lJh9rRB99zYxG0zY3KWW1EbBg+Fuplh8a6pdeRvPehMo015xewQZuf5mIL6iUP09jQ6ePwzfYIuUYax2rd+XS7lZdNuX7yCZLG4jYDbbw/2aD1oJ3Pw0NInaD5dN0pk7blfAF5n3fG5m1A/buc+ve5gCyjL9mIXuq35rc8HJ/PTJpz0HqStmJO/qKEfsWMUspQ7/o9qS+1WfVNe/qSv5Bkv/Ik6tGhPN8nm+WrmeSnqUN4/6QtfO7RQVuS4/143dZ4Ie33GC8vA9YUH7gE+YV8Rb6fevAr35NdRn7rTGWliHrGA1BQefJAzXqCGQhuL/c2oDKXEauDI8vZHPzgAz+Msm4aC4ny1TiEH4LSOx3aSdqcNgnXlQewcD0rct6Zo2lsnld/XuZpYrVGW+s+2abvau/zrHrVqZyEzbkm03qknUo6WDQ3yiduo5IOrtTtPpO2pazGBF6+sgMd6V+pR7i+9CW3K+e3vBzSVwD/9HLW3X32saCPqR9seYr+S9mCOMh9lz1+tRcL2rF/6jwA7anyaz5ThrziUGei79O+R3u7UqAPmRvCg/mpYOOZNgY2n24Y8+WHednb0G+Zo5eoM4+xFIdL0bSfUeaP1nzkPhZczCZW+3EpTwXngB4NmbZ80x8bJPdxPWaUBPq8XGeOHjtezmcpE/WMG4JAfcqHDJvI6uB+6gfVLcLmOV344czzc/QS9VSXulIeG/bWyZ8VC7o4reL9mqiv3EMo7w8PSinlMvqQuSGe+iGjXwP7TySBfB8yf3nJmS79q4fAGThyiaIOmVJeEsQtfu3pucifRJP6g4NSSrmc3lZugNWvV58CXWyfq/9bh8tFzo//1uKM9BJVSimllJdAHzKllFJKKaWU09GHTCmllFJKKeV09CFTSimllFJKOR19yFwAf1m0f3/kNuHvePTveZRSSiml3A99yBxE/+LNtR8y+ZeulfwvlOdfyL/1fzUL2/f+1TPm0ce09Rfo+VfUtsasv5Dfh0wppZRSyv3Qh8wFXPs3Mlz28wLPoyUv5OQpPwuMa+shQ53/k896iEyPGcqo23u8oaMPmVJKKaWU+6EPmQu49kNmepyg3y/508PmltHDY+shk/9vjdpkOTDnjL8PmVJKKaWU4vQhcwF6yHBJ5+LtF3bqVKbHji7opKO/UUGP/2aCy/klOuhbl3610wXf7c5HA+1Ut/UIEW4XCZuxz8tIR8c9yWIHdvqYVugh43OudRDoUh1Jc+DlskHj837JY5PmkXbeH9+zz1JKKaWU8jj0IXMBeqzoou8XWqBejwZB3dHLPHLZXm3VV9Y7eozITqC92snufBhkHnklf1SJSd4v8OTV1xGw0fUBZdKZ/U0wPmQkp8eJ7FdeKC87NU+ab/B+qSNpHilHB5/qg+9b61NKKaWUUq5HHzIXwEXVL+zAxVWX19Vl+CjIcjnewi/fE+hAxsk2fHcZxpX1lK2gD7+w+xzAno0J+nzOwPVRv2UPIO8y+k2J9OYYgTaah9XauU7q3S6g3ttkfSmllFJKeRz6kLkALq1cbp287LoMl+lLLvS6VG/BQ2frsjxd+tGbDxXvK8eVv71YoccCyW3K/rbgEZCy2KLfcsA0poT+3QbZxlj8u6NxUn/0ITPZSnm2LaWUUkopj0sfMheQF37Iy64/Arj0Hr3cInfkp/l7ctOlPy/gfJeNkA8X9G89HPQwkEw+IrK/FeiZxkL7VcrHiEgbnuohA2pLmsZTSimllFKuTx8yF8ClNh8yXFzzcqsL7yWXWvSuLukOMluPhIc8ZIA2uoxnXYKs68tHRPa3Iu1cMY0pSRvy8cL3XA9slF7JX/qQcX+YHkOllFJKKeVx6EPmArjUclEV04MAuNxOl94tJj0JF+S9C/1DHjJc8C+5fNPWL/Dk/ZFA/9TzOFjNwTTefGiIaUwJbb19PmT02xe3x+slr3o9SkjqO9sDdSqTDj5LKaWUUsrjsn97Ll/AZVkX3NXF+9ILLZdpfxgIv0xv9SfcNpLsUKIPkpchk2VKuuQnXNxdztt7/fT4SJs85SNBoH/rIUOddPA950169ZhRysebj4u5VL/TPAq+e7vVnJVSSimllOvSh8wjsffouCVWD4gzjaGUUkoppdwXfcg8Avykf/U4uDWw1X/D4JxlDKWUUkop5f7oQ+YR4DcZR/9Y2XOjPxY1/TGr/jGpUkoppZRyq/QhU0oppZRSSjkdfciUUkoppZRSTkcfMqWUUkoppZTT0YdMKaWUUkop5XT0IVNKKaWUUko5HX3IlFJKKaWUUk5HHzKllFJKKaWU09GHTCmllFJKKeV09CFTSimllFJKOR19yJRSSimllFJORx8ypZRSSimllNPRh0wppZRSSinldPQhU0oppZRSSjkdfciUUkoppZRSTkcfMqWUUkoppZTT0YdMKaWUUkop5XT0IVNKKaWUUl4E79+///Tq1atPb9++/Zznkzzl8Pr168/5H//4x1+U8/3Nmzefv6vNx48fP+fL7dKHTCmllFJKeRH0IXNf9CFTSimllFJeBH3I3Bd9yJwQBSmJgHz37t3n74IApPypyX4/fPjw2S4+y/mR33VjL+WXPMZ+y2VKF6prcG19pdwyfcjcF33IPABd0D1RRjA89qWdPhRoBBh985ARCr7neMg4PkdH50QPsmzjulaHsepJz4nWZJXSfm2oSuS1hqv00LWddJGObNQ6GI7KlyLSn6f9wOvvHfYI5mG1113KtfWVcuvovGLvAe1BerD0IfOy6KlxIToU5PhC5Ucv7Q+FfhScK6h/7ocM6AFyZE6QmzYN6VA5Y8sDmXqthzaw5yZ/SwYay6o854kyf6SCxkdKH9wCPdPc5lxuob67sZejZBxkPIP78q3E73NDXF4Sm3tcW18pl+I/qDzii3v3GPYQ3zsc7SO6K/Hpsn3IvCx6YlyAAjEvnIIAmILqmhCACs4VexvAU7G6oCe+eSSU+2Vem5d0UpdtGbu3eQ7kK4k2WPeT1TxRthoHdaSjm+y0BvjJJf4q27uxl6MQmxmf7uu3Gr/PzTRvX8O19ZWXwyUXdp1VStO5MkE8694iHVtnj2xa3WN0D1jp0VmlPqVPsugl34fMy6APmQtwJ58gQDOokKcdyQ9ngkRBqnrpRk5l0qfA9KQgpZ3bJd2+6Xi9dBGgCmjh9no5SDaTbKReNoH639rs6E/zkGizyva00VzSNi895H28jnRis8+z+lA+bfK5XNnrSHeiudecwWqeKMuxCenx+b4UxrG3SaOffmQzn95GdSTNi7fxueI7ZRqTfI08ac+Wcj4UB/J3Pt1n8Yn0cfLXjl+1U7oU+T560eU2U+ZjwnaS95lxKn2kaazS4Xhcpb4Jl530KR5JOV9b4/W9kFTOi68j67yF1l1yq3NrAj/KON8Dv02/dBRf+Gq5b7oLHUQb+yXBSBAqyBT05HUgUc+n13PYqI8pkMn7IYa82gnpV5l0U65xqF55ID/p1sbldSCdoLG4zN5G53PCp5LkVZ8bLHZpbGrvMH+UJ9r4SNireZY+tckNMsfBGKVn5Q8rG9TOSf1iSz9Qn/5xFPrSHK5gnC4j27Ue7osag+ZMc+TQTuPh07+73vKy8HiRvwj3GSF/SB4av5mXflLaM0F7xZl0qW/KXY/soFxt6Jcy2k55tSHJRo1J8F19pg0Trkv9uT6fP9A4YGu86FIdoNPz5XykP65grTNeyLtfrXAfOgq6t3xLvik/L/fL90+LMkIQroJRdUoE33RRpFxlBCmyTuqXXgcduZmg0/uaNgDXpY3LNwBdRH0z00aR/QH9ZR9pm3TyOSGbXA96ZcdkE/h4qc+NbJo3oTHtzbPL8Ok2SsdqXCCdmaa5XM0TZW5nQn2uwVGwY+sAmOZefqMy+nb70t7M811t+e5zwXfvq7ws8AVS+itljx2/8luH/Jb/O+pTEBveP2NyX869Ue0V38hq/4Ip1nyPozznLftwUj+4vmk+ZAPj2hovOjQOkC4vK+dCa+j+N4G/ud/D5EsO8tR7kg75XJYL/Dh9XP2R9J3Pct+sPbB8gYImg80h6HSgTQFMUmBOQUq965cOx/sQfkjB1gbAZuXfxdQXpG6QbG58aZs2qtUhh560U4codWqf/bhN1OdGthoLSL+3meTJUw6r+uzXWdlAWbZdzRNlsmGC+py/o9B2C/rd8iFH5Wlv+uHkG6T05/JyULz5d/cJ8hlHq9iBh8Tv5LfY4L66B/LoyH6AOvfh3DPT5owL1Xv8uw6Pr0wT09hcX/YvfBx8n/rwvj3lGpbzMMXHBD7hfg1H2yLjPplnu/IeR+mn6ktgC/n6Xpl3wvI9dNhMB4Dwg4CgzaB3psME/R7sfPfABe9D+CEFk27fcKbNZ+oLUrc2nGnzSNsk6we0Q59pJ9CGOs15tqeN5sm/C2xYzb10uv3T2GWD8Daav9W4YNIpKPe61TxRlmMTsiF94Qj0s5ofQb9bPuR52ZD2+vqRprHQBzKut7wc8LPJJxRLTxW/3o/izXUcQf1Muj0Osd3tT5s9LkB63f9dB+0yFreY5tT1YeukL8cxjdftLi8D/Cv9b0L+4HGDv1C2h/sQ4IvuayBdsiP9NPvOuCr3y74Hlu9QoOUhIfwg0OaQqD6DFFK3Ng4nDxvwQwom3eiSzLRxqSw3BfS4Tchk/yJt04VhdfCt6r0Mm71/bV6q93GJtNmZNj9kKXPIuw7JKOU8JZNOgX1etzUPq3FQR/I1PAprtGe//GHyEcpyHYB82ivfpE/XhZzn03fKy2CKRY9pPp8ifuW7Siv9E/Tp8tlf+q58Xkw2I+/2ZOy7Du0PHi+wipfsH7xM9k/7DTZujXdaG/T42Mq5UGykf02k35LS1yaQc7/JPMjP5Zf0hb/BFANTXE3If5WOjLOci/mmVZYQtATDFLx5oJF3OQJI9R6kAr0e3ApAJ/sA+vB+qKedNoTcIFYbl8amcskJ6tNmZKQ3bct+J1In7X0s0iGbqM/xU6/NjM+00UGPy8M0z+S1Fshmn3tMOkFzfGSe3AaBLZRP8keh7RGQ87mU7aSf/OQnnz81jxrDyl5fU0AudWfbcn7wc9Zf8av4Ux7cj/i8dvzim+l/l6A+FW9pI989nunL+0ubsWvP11MH33NevN6hHx+/+idJB5/kBbKq2xqvdPvew9hpU86J1vTSNUw/wR/JK3lMkHefzzygh3Lpo738TnVuo/pXXK2gH+SU6qsvj2M3mvIFCqpMHrhCBwZJQZkBr4BUQg/Jy/TvnXvSAaO89EMGr8hybRrCbdvS5ynnAx3aHJW2Nhvvk++J65rm2OfPbU7STsaU85wy1K/We7I113JK9Ct8/Ujk06ZM0xxoDvc2deqn9hOTX/KpgyDXTWPJeaE87WIOfF6nuSwvg/Rn+Y947PhdxaT6UptV37SnL/d3jUF5kscAie+Tzb6feVJcpg7h/ZO2oB/XQduMMe/H67bGC2n/3p5Tbhutp6/xEWgjn90DWXxK4Hvu2yA7BLolg23pa1NZuU/6kCllBzbMabOk7NY20aMHy1Oiy2Qpz4VfogSPDC8nlil7bOhj6gdbnqL/Uhz8ngfB0T1a8pecNch7rOHnqYNHi8v4Qwb0sJadyJJP3eX+6EOmlB3yJ0didSF5LrDlFjf0/ElwKU8J/jdd0vIHFE/lp6v9BFv64C9PCb6ox0A+CHhIUKYYWf2Gbgt/bCjpzNRjRilj0euE25v2lfulD5lSNmDD1qbpUH5LF3RsuSV7BAdZD5rynBC/U2zoQaEL1VP8UEJ95Q8cKM89ppRSyj59yJRyAC4fnlY/VS1f/qTtFn9DVO6P/Mkz6bnQD0c83eIPIUop5Qz0IVNKKaWUUko5HX3IlFJKKaWUUk5HHzKllFJKKaWU09GHTCmllFJKKeV09CFTSimllFJKOR19yJRSSimllFJORx8ypZRSSimllNPRh0wppZRSSinldPQhU0oppZRSSjkdfciUUkoppZRSTkcfMqWUUkoppZTT0YdMKaWUUkop5XT0IVNKKaWUUko5HX3IlFJKKaWUF8H79+8/vXr16tPbt28/5/kkTzm8fv36c/7HP/7xF+V8f/PmzefvavPx48fP+XK79CFTSimllFJeBH3I3Bd9yJRSSimllBdBHzL3RR8yj8CHDx8+BwCftwC2vHv37ttcKTNs2L6pl1L24cLDxeiacJnSheoaXFtfKbdMHzL3RR8yB8Ght5IOMj1iSP6Q4ftzXBBly5keMtqEMuVBrI1G6VbGONnva68Hw1Z6qK9Muo/g7Z7DT8vLZu9SIN8j3Tvsc8zDtR4e19ZXyq2jM7gPmfugp8YFKDgmx/ZDYvqNDEHxXBdEbDnTQ0abj5Pzxxpc+6eg10AbpKNHQl4kWJOUBel4yPi+xs9k53P5aXmZ4FNK097pPscn+XuHveKaD49r6yvlUnTekY74ImfZ1hm4dV5pH9Fdgk+X1Rnbh8zLoCfGBSg49hw7HzLKTwH3FND3WR4yzO3qsuN8zYX9sWADTDuFfEAbK6weMqA6l9+DeXvI40fQnj5vbV7L+Vntnfh5Xmrw4bPsV48Fc3LksneUa+srL4eHXtj1GDhy5hDPOsuO3Idk00q3zqqVHu036lP6JCvbLx1zuU36kLmA1WGsYBH+kFEbT7SnDcGkgPRDxmXz8KENbdUHSYc+sipzGyWjYCZl8HsdydtrDKD63GCyPfY5blv2vQe6fB40Z6TVRudInn6ZB7WVjStd3g9pC60H87BCc6C5lS0rsMfl99ha3xVaW7XJtr5uJGxx3yNpHjUezaP0kaed/LTcH/KF9GV8I/2CvMe7Q3v0oE/+RrpmLE9s+TJlHvfYTvI+c1+QPtI0VulwPL639hnhspM+7JZMztfWeDP+y3nxdWSdjyDfmPx2BX6Ucb4Hfpt+6Si+sKfcN92FLkAB7AHP9wxobfQ6XDPgdCARpLT1gzsDU3LAp7cDHebk1R/1ftBR73rVv+R10Amvl34lwfe0Qbh9wHflNRepbwvs8TmR3aA58XrH+0NWm6lskg25Rpn3efC5Fapf2QGa19S54ohOR/OCPO0Y7xaSE5oP9Ye9roM6jZ2+JttUz/ypreZSc1/uD/kavuBMPrSKC/kR6TFjOaH9ypcpdz2yg3K1ybFnXm1IslFjEnxXn2nDhOtSf67P5w80DtgaL7pUB+j0fDkf6Y9bSFa+dRT3oaPk+ZPINy+1pbw81reo8j0UxJn8gABd8nSxnAKOIKXMNw8CPQM3Nw7qvb/sC6h3GepzE0EPNsg2bw+USQdtyTsqo33anRsQcjn2nLMtsu9Ec+Rz6WiMPgfTmFxGOh3yPg5H67mqB/UpmckGJ+UvRWu8InVrnlSW65R+lessX9B3Hxv+pbpyf+BT+EPG6OTfW3HxFLGc7PlyxhkxknFBe+2xGVeUU+9z47FGueuD7MNJ/eD6pvmQDYxra7zo0DhAurysnAutofvfhPzCfX8PZGnjSe3lc1ku8nwB2UrSdz7LffPlblY2mQKe73loKEC1uWsD8ICbgtQPG4e2CnLa+KGZfUHq8fZCMtOYwO3TZuRM/QJlJB8bee+f7zn2Fdjn412hsUxM8z+Nye2c5gWbfRyO9K1sgJSZbHCO6NyCtVnNs9bPxzfNE6ic5H6VPoC9OV9qV+6bKZ6AsvS3rbiYfHSSJ085TH1vxfLEli9T53uU9laRNufer3rfS12H7J/SxDQ215f9Cx8H36c+vG9PuYblPEzxMYFvaK217pMfTSDrPpnnj/IeR+mn6lfgz+Tre2XeCcvIKuA9+CAveHmQQQYp+GHj0FabgB82kH1B6vH2QjJbY5J9tEXGyX75LpkcG+09z/dpnBPoOrJRbclN8z+NibzPE3Yqr/Gu+lC9r03CmJHRXE82OPTv8pdCO593R/a67pwn5aVDPuOQ15inNdUYST635b7Ap9LfwGNM4E+TL0H6KExxlP52SSyvUD+Tbo/7jJNVXGnvlF6fG9dBu1UcT0xz6vqwddKX45jG63aXl8EqNhP8w31Efuy+vsJ9CGjjvgbk3Y70U+o8ZtX/pXFcXh7rW1T5HnsBr4DWQakNfwq4DFLIQAa1la48bLIv8EMLqM+DDT3Yo/bTwad+dKA5mgvITWkaG7JKWbdF9rsCG1brMs3/NCbyPg8ao1LOUcK4kJvskA0+T5MNQnUufyms7ar9NCdZxnh8zOlXoDni02XR5fmtsZaXj/wkYwO/SJ9Kv3Mmv518i7zrUP9KK/0Te76MvR5nGSeTzci7Pb5/g+vQHp1zt4rt7B+8TPZnn5Rh49Z4p7VBj4+tnAvFRvpXMq29fGOvLTLeNvMgP5df4t/0CVMM8J2yPd+TjUp7tpbz0ZvFBWwFPAGngMqABPIEFGXIeZA6yHk5cn4oUecH2NRXHmSTzsy7DunUOLURrDYidKWNrp/vD9k8NE97IOO2JdOGpzE5PibmwMd0FHSkXs1n6ptsAOZrkr8EjXkL9COT60zSd59/8pNNauNrrP7lU8y9+0S5L1j/9BFBuWJzz0/kV08Ry2LPl/nucUJf3l/ajF2ybUXq4HvOi9c79OPjV/8k6eCTvEBWdVvjlW7VAWOnTTknWtO9NcQH0m+9Lf7Id6U8O7xt5gGfoly+RXv5nercRvkpNmxBP8gp1VdfHts3nfIdHgirBApsJQUZQUleB5TLJF6Xm4ESOqa+dECRtAmAl7tOIfuUHG0EviH4JpR2uK5pg1Pyw3CCdpNM2qo5ntAGqITd2T5lqNcmmcnndEVunCQfx0q3p9xsNcfMyUTqPGInpF/wqfnMcfi8OcilXdijcrXJMZX7wH2MhF847rtbfvtYsaw2q763fFl5EvU+Vr5PNud+qYStkDqE90/agn5cB21JjvfjdVvjhbR/a/8tt4/W09d4Av90fwTaZtkE+vEpQZtJF3LC+8O29LWprNwn27thKd+gQ/Gh+Abm5MF6a0x2czFZjecpoO+9A+epee45KWWPI7HMhYiyx4Y+pn6w5Sn6L8XRA2LvXNHDwWPm6EMi2+HnlOnxDjxaXCYfTnpYy05kyafucn/0IXOQf/5NsPzFn/zJt7lPn/7iZz/79PPf+q3P5b/4/d//tvRllrNJ/Mo3+Yfq+R//1t/6tvTL8v/Hf/gfflt6e7BpThs7Zc/5E6BbfPxx4OwdgqU8F0dj+aliK38SLbClcVSeEnxRj4F8ELCvU+Yxgn+6/N5Z6I8NJT3W9ZhRylj0OuH2TvaV+6QPmYP8+e/8zqc//zt/59vcp08//+3f/vTz3/3dT7/4vd/79Ce/+qvflr7McjajH3+zYTxEz//wN/7Gp3/6TVsd0Cr/P/7n//mn/89/8B98+vMf/vBz+a3BBjldbFaXkMeGzRqbbu2igz23+LgqRezFsi5UT/HbEPWVP0Gm3H86XUop5Rh9yBzkX//xH3/601/7tU8/+8EPPv3iJz958KMAzlT+P/3Vv/rpv/rm4OUxoov0pXr+57/+1z/9t9+0dT1czP/iz/7s05/++q9/+sUf/MG3krdF/rSKVP4Szc1zPexKuYRbiuX8qTapPwwopZSH0ZvZBfxvf/RHn372m7/5oD9e1fLvl8O/+sM//PQv/8E/+DZXSimllFLKMfqQKaWUUkoppZyOPmRKKaWUUkopp6MPmVJKKaWUUsrp6EOmlFJKKaWUcjr6kCmllFJKKaWcjj5kSimllFJKKaejD5lSSimllFLK6ehDppRSSimllHI6+pAppZRSSimlnI4+ZEoppZRSSimnow+ZUkoppZRyel6/fv3p1atXnz5+/Pg58Z0yeP/+/ef827dvP5ep/N27d5/LP3z48F0bZMo56EOmlFJKKaWcnj5k7o8+ZEoppZRSyunpQ+b+6EOmfAGBrIC+Zxg/m94KbXZbMrcAG3U35FLuk8Z/uTfwec7mPmTuhz5kDoJjbyUCofwl2ixIftHXBkHSBpJoEyIh/1w8ZBPDB57T5mujdVw91t68efPdWk0PXx0OpMZHAXwBv5nwfePWLhGySynH4PvWlB66n3yNLtnUC1m5J+T3nMW6c+i+oT2GmKBM5Yq1PmTOSR8yF6AgyMuqX+juHW0iebHV5qByNg5tIoK8LrzITXP9VDxkE8P+57L32rhPTw8Z6jVHubaQ6+trW+4Pf6RMDxnVC/ev50QXnIwBxYfHu/as3PsYB+Upv8c0fvpN/VsQd7cwj+W+kf9P8ZHoPJnOHYFP+/niUK5Yky7Jap9Re5UrzrFNbRo356E37wtQEEyHkeqmQ/pe8I0hYVPIjYH50mbFZ7Z9rssMtsiuo2gjnHzjrGhDz7nQhc1hndz3qfcDCx3Zptwf+Mi0RxL77mfyseeMJ/nsai/AZvdp2ex+L1S32h+TSQdzcbS9QL4XsjKh/f2of0je0xGQUxwT+1s+7H2s4g57qV/poVx9Sp9kFdPooEzlfcicm94sLkBBoKBMCFIFA+jwUvLAUCB54CopgBWwJEEbyl13/qRb5aQMYCXZqD4yoIWPGRmvc6RnBXUal6ANCZg7fRfIy65E84aMbCZpXMpn+5zvCbdjNX4v19iVvM+sQ174XEt32pvtc3wk2es+wXefI/C89ErfRLYXtM3LqPoGzU2y1R/6SOqTpHH5HGR7xRwp7Sy3h9bZke94bACxsFpTfEKxovWXXt8Psv0l/qKYXCE/1/6rcax8XH78UD+lnWJihccPdjEGb+OxRMJW2e1loHnUPGu85OlH4y7nw2Nkz6cEcpf6rnzmElbnjoMt8stSLvOwO0dBmQeuUD2bRAajNg7KdZgQiBys1PE5BbDaAfLeDrweqNPGpANK+jIvJC9d0qfxkOhP+UR20142ktSP6nVACt+M+KS9o/5o70gfydthI4lyyPnMvI9XcwD6rv5JPn4vl20qc1vRo3UC8sgwD943Y6Ddyj6BnOvLPNAW/dIlfZ73seSaOGmPoL3PF8i3NDZsS6jXWjnoo442aif7ZCvwnSQ87+Mjldsk1xC01gm+kH4GiiPq1U7+h275GHLuh5f4i+rTVsf79DyfE6qfxnQE+lnpBtksGe0f6m9rP5FtGetqi27NpfqZYrmci1WMJb7+l5A+dwT5V/qik7Fd7pvLPOzO0YFLoE2onuBVMOpQ0UGhPIGYuqYA3jp8QHqlh3o/YKjzPG1946LdVn8ak8skkqFv2aHxYZ/GpbEL34zSbpBe6XSk09uk7eAy0ueQ97Hx3e1UG5cBlcu2zK/GTJnWT/b6+Hwe+NT8QG7e6tNRW5ANsl15X/8tsr1IHwL5IZ9pt6De7XPQ6W2mvnP8U73HRrk9WJ9co8mPgbVe+Srl2Sb9i+8uc4m/yJ+3/Ek+KhmPgQnVr8a0BX1NMeVgR+r2Ocy4pHwrT5+aT41VKM7LuXH/2AIZ1p+U58EKyXsS+OpUDtPeD9hKufzcfbXcN196UNlEBy6BNqH63OB9E9AhNwXiFMB5GOfGszo8ZQvJ7VG5SFuzv70xQ+oUlGGrxpU2+hzwmbZs9X1kroC89E76st+8uKxsyPK9vPAxT/bm+grkSGorKKMvoC99B/JZ7/k9VvLThcn9kHGlnUC9z7WDTp/7qW+fO0h9q37L7ZDrDKwxa5msYgHSF2DyB9d7ib/I/9JWJ2VWe7FQ/WpMW2Cr2z6B7ozV1RwiS/Lxp/30xxgFsmpXXgYr/0jkE4rVVdwk+FD6C/HifZJHRr427f30J/+Xnx61obx8uiNdgILYN3dHAamgJ1gVkHlIUJeBOAVwbgS58aRe2SgZvucB6H1kXfa3N2aQTOK2ep/CN7Tc3ABbVpvVkbkC8j5G9CmvuXMdacNq/Fm+lxfo15gme3N9qZeMtxWUMXfg44Sco8zvsZL3PoXGm9+FdMlPE/S5zqnvHD/j9Tzf065yW+Q6g+KQNXdy/Z0pFpD3GMj4utRfqPf2ifxcfeZenGAz9asxbYGdK71i0s0Y6FcgQ4JpDulH8tPcaE5JPtflnKR/HOVou4zBKda110tf7v0ZtzD5brlf1rt0+R46uPLABdVp81de5CG3CkQPYMiNIDcQ16sNQH0A+Txw1DdyLgvZ39aYRW48gj5URp9uN3gbPnM+/FBNpj7TdiDv40eeMqWsy/mQfI4/yzOPntQPPqbJXl/fHD/fc47UD5/ZV87RNGdbrOTVp4NtfvGRTULzs4K23n7qexo/MkpZV26PXGfB2vlay8cUT8nKFzwGpviSr5D2/EXtM64E43D9HouJ6h7io8zBkXbI+H4BXoa9Xj/NoeKUTx83NuzNbTkfk88cAX8+4pPpJyu/8X0h9/70W5h8dwI9Sg8ZZzkH3YkuQJt8Hq460DywFLCSVV6H3CoQPeAU0EqQG48fnvquDUB5+nZUro3DyY1mNeYEm7wdenx8Ggt9A/XZP/KyVTaukD6NFdJ2IO86pzGLaaNbjT/LZS+f9Ee55kRjlozaTPb6+vLd7SXvcypUrn5EzlHm99iSxy7ZKTmNCxib28r3rX7R52Od+qa/1Ol9ltsn11mwzqy3QEZxO5G+ALT3NhlfD/EXxXD6Lrood32+BzjS4bZcAuPYmguh8cpW2UNiPrHZ5558ziGojY9N8aix0cfUtpwL1lD7+CXgD1p/97P0nYzBzAvfF+Rr8mPK08Yp/idkD+kh4yzn4GE76x3iATGlPLzA6/0wy+ToQCcRqB74KicR3C5LIk+5y6BD3x3pdtLGH/7wh1/kpzE63n7aZPJgnVA9aUVunIwjbU8Z6rVBZsJW6pBxNPdKGv+qXHPt85p2iSxP26b19TY6KID+cr6n8XvebZxI+Wm9NF6S2yNchw6lCdfD92l96d/LIMuUtB7ldsg1JaXPeFxt+Weue8YOfpf+i8xD/SX1k9DvuA9PKf3fde6B7pyrFT5uxktb2XrJfkJbh/qMw6M2ldvF/eMSiJkj7RTTQj6Y8YAdinnFhmToh3pnKiv3y/4uWsoLYrogsSlP5eW2Wa1ZXsJKgVv0F/aevNQ9N90P74eHPGT00DgCfpSyegzrIazHjciHDP5I3u0kr1RKvaDcDWyg008RKbu1y0TZhvVaXbZ6CSvJrfoLl7NpT3pObtGmcl30eJgeBHpI6Dceyisd/U2ItyH5Dwz0mCG5Pj1alBSbaW9/I1OcPmTK3cAGOP30tRvi+eAgYz3zwkU5h2Epzq35iy6Ht/YDFOya9shSSrlV+pApdwWPFi4Qnso54ad1uZa3djEst0P9ZY32xf5Qp5RyNnqLK6WUUkoppZyOPmRKKaWUUkopp6MPmVJKKaWUUsrp6EPmztG/BpJ/CbaUUkoppZRbpg+Zg/hfEM2Uf0Fy+kulP/rRj75Xlukhj4lJD+mILv8nDfuQKaWUUkopZ6IPmQuYfnvB99VjgAcO/7ynwz9tmf+8petI+S14MGWf/FOil/zzmf2NTCmllFJKOSN9yFzA6tKv/8RJ/3mTOPqQEZSjh36OMP3/B/R3tD30IVNKKaWUUs5IHzIX8NgPGfSi52v+LX/a7j1KsIl+SDkm2aAkW/XI8jJQmR5PyjMnl/x2qZRSSimllEvoQ+YCVg8ZHg+r8kseMqAHw95jZOLIHyvDnukhov74rgeZxqvf/NAuH1nU6RFD/ZZsKaWUUkop16IPmQvQxT7T6vHw1A8Z+tKjYoJHRurOxxnfpYOyrTz4+LDd67bGWUoppZRSytfQh8wF5KVf6DcyX/tHy+BrHjK02wL78rckqzEhSzkpHyduv49v1aaUUkoppZRr04fMBawu/aDHjNdd+pChLTrysXGEI3+s7MhDRo8RPmWPP0r8tzqU54NFbUgPGUcppZRSSilH6EPmArYeMjwisu7Sh4x05OPgCPSz126y38vyj57xOdmjceU4fKyrtqWUUkoppVyDPmQuYHoIABd4yvNif/Qho0s/id+EPATaHgE5/02JHk8k/aed+gv7Gm8+RvRbm2lsXua6SimllFJKuSZ9yByES/lW8gu8Lvqe9v5n/+mPYemBtPe44aGRj4oV/mgiqQ89zrAj6/TdoSwfKcjo8UN66KOslFJKKaWUPfqQOQFHHylPSf5WqZRSSimllKekD5kbh9+U3NpD5hZtKqWUUkop90UfMjcMj4Xpj5w9N9jVv/tSSimllFKekz5kyiH8777kX/4vpZRSSinlqelDppRSSimllHI6+pAppZRSSimlnI4+ZEoppZRSSimnow+ZUkoppZRSyunoQ6aUUkoppZRyOvqQKaWUUkoppZyOPmRKKaWUUkopp6MPmVJKKaWUUsrp6EOmlFJKKaWUcjr6kCmllFJKKafn9evXn169evXp48ePnxPfKYP3799/zr99+/ZzmcrfvXv3ufzDhw/ftUGmnIM+ZEoppZRSyunpQ+b+6EOmlFJKKaWcnj5k7o8+ZB4JAoHgODMK7nuHeWBzW6HNcUvmudHmjK2llOuhS9E1efPmzed0La6tr5RbpQ+Z+6O31IPI0bdSHf+XaMNQykPU66d502ZCuvYl4VIesq4vyRe0DqTVZchlJmineg6Lcl8QD6w9cT0h3yDdO4qVaz08rq2vlFumD5n7o6fGQXB0kuBQ8IOBAOhB8UvYIFaXFm0mgnnzTUMbiS68zLs2nKcGG7D3ErD/uey9Nj4OrUv6OWWao1xb8PXNtS0vH9ZbadoTKN/yn3uEmLnmeXJtfaVcgu8Be3u/zoitc1cPkQnKaY8e6ZKs9pc+ZF4WPTEO4o8YmA6GOv5fwmaxNRdsHr5JsXlo4wHaZnvqtza2xwI7ZNdR8AttkGdGm7qjDV+Qzzhg7IoXra3DnPZSdV/oAjH505b/3CvMyTVj5Nr6yvl56IVd7Y6eiy6LD26djdJNWp332Ev9Sg/l6lP6JKt9CB2UqVznWh8y56QPmQeydTDo8sanIE8QKQiznoCiToGmg5w+JE/ShqBgQ15BSHKdskNJgek2kIQ2AMnlGClHRn2vxi89JNkrZFOW00YbF/X6LuhbdiWaM3T6fIHPQbZXO9JqLN5mNX6Vg4+d5O29TvICXSTpzraQuiHXWPPmPgE+R5mX3iPQzm3ne146yfvc5NzK5hXUocPXR+PyOUhUTtI4y22Q/if2/CdRfKAPOa03PgXKu4+C2ildiuxHL7rcZso8Vo/Esvv2NFbpcNCx0jfhspM+j6Wcr63x5p5TzofHzhFfcuQ3+MUe8qNLUNzQdgU2p8+W+6W70AOZDgbwTZ7vfph5cOpQol4bA/p06LDRZLAiQ5nrpF6HjNuUm4E2LsqnvEA/oId66ZO99Cf7VOegTzrVRjphtbGh18emi4mgzudCSJ9s8wsN9slGycm2zCMnPZozdOn7avxeLiZbyWudgDztQH1TpnaTfSTQHElf5gV2gHRJn+fRqfwR0On90E5zJKiXPs2RoxjJNQbKScyD2mk+SZoPZNIO5XN85fnRmmj9BGVb/uPIz0n4gtZbsaE2kpPezEs/KX1zgvaKS+lS35S7Htkhf4Uce+bVhiQbNSbBd/WZNky4LvXn+nz+QOOArfGiS3WATs+Xc8HaHYkBgSxrjk/If7fAb+RXR5HPyX8ndCaUApd5WPkOgtkPBicvalNg5gFBUGZgatMQ3me2B75Lh+plw3R5TJv4TjuRY8Qe2rjMHrJD/fBJPtGGmnaLrY1LOr1N2p7jz7lVvY8NGWc1/rQt89OY1Z/WD1u8Tc4D9W6P5kvw3ccD7huyQbYrz+cl5BpMOuiXcki7Idcioc7bpO3g45/Wjnoff3lepjUEyrb8J1Fc+NpO8i6jvh3y2e8K9SnwN+8/Y3EvljNWJ/+lXjKUZ9xlH07qB9c3zYdsYFxb40WHxgHS5WXlPKTvbsEaI6s1d3+dQCaTwI+mcpD/ZXxiK+W0xY6V/5f740sPKofxgyHRoaDNfSswtYlsbShqryD2Mtc5HeiAXrX3A4dyH4MfzpBjfOjmgV6NTZtgovFrXHkwbvU9baxpe65J6pv69fawsiHL9/KCMuog7Z3WFzQOktqCyjUHtPP5yDma5mwP+kt5dKSN7oeMye2EXIuEOvfFyVafu0nf1G95Plb+RtmW/yS0zzaTPHn50Mp/3Mf2QB4d2Q+4L8JeLCNLG6H69F/pkP1TmpjG5vqyf+Hj4PvUh/ftKdewnANf8z3kM1M8rZhiEz/MeHF9GS9A3/Jp7feyp5R5Jyy7+MGQ5MVqCkzwTWTaUNROAet9Tjpz00CfZNImUBm6SGlfjhF9D9k80KuxeZ+O7MzvAjtyfgSyqTNtz/Fr/pTX3EkH5WnDavxZvpcXlGlMaa/skw2yXzLeVlCmzV6fIudomrMt0JfzAd6nwC7Z6d+F+l5BneucbM3x04fymru0qzwfK3/b859Ea+u+SHvKnFx/70exNPnzFupn0p2+6Panzcqv9h5wHbSjj6NMc+r6sHXSl+OYxut2l/OTa74CGfnnKpYn5ENCsedtFQ+yQ3nFCzrSX1c+XO6TPmQeiB8MiYJVG34GpvCyaUOhzA8k73PS6ZuGNhuRNgn16/2IHONDNw90u53o8HxubvSTc5FjdTRWtYe0fRo/fVCmlHXJavxZnnmtS849ZRpT2pvr698B/Wmj+qFtzlXOUea3QHbyD6Dc7QZsk7zm3cHubOMg7/1Ntub41Y9Szk15Xlb+tuc/Ce3Rgz6BLGUO+cmHlFb6J+jT5bO/9MW9WAbk3Z7cG1yHfDvnbuXj2T94mexf7Udb453WBj0+tnIe0ncnWFtfX75P/jiRsZJ54f6Z8UJ52kge2/dAj9LeOMt5+b5HlUN44CU6eHRQKDA98DIQpw0lg4/8KtjBNwl912ajfB5eKuczyTEe3Twc7Mt50kYoqPf+NTbZSl3qcKaNNW3PNUHnNGYxbXqr8Wc5ejU+6aHex4yMt0l7fX31XfYqnzaqfLIx52iaswnkpn68DD3IAZ/ZP+OSvGzc6pd6X5vJVvpwndOYy+2w5W97/uPIfyQPHm+CvHyImPfYuhT1qb0jbXRfhK1YBuxy/55IHXzPefF6h358/OqfJB18khfIqm5rvNKtOmDstCnng3V1353Az+Q/mWiLL2S5/AG/Ii8yL9zfM14oTxvJyye3kD2kvXGW8/J9jyqbaCP3pICDrCevwFQQkzwIVUbyw8nlSQSi55WQyzr1qeT1yAvJ+cEE2Cd5vudmtiLHv9o8fGxuj/DN0eckyTmiXdo+rUmWKWGv6p3V+Kdyn3ufV7fLx5T25sGQ64uM+uW7Q3nOec6R6yLl2ots54kxCh9v2iN8jN7WcT0k7JzW1/OaRy/zVJ4fX3sSa+oc8R/YiwtSylCffqWkvtRm1Tft6ctjXT6sPIl6HyvfJ5u39h5IHcL7J23hcYMO2ipWhPfjdVvjhbQ/98pyHvAB+d1RtP7uEyvkh0Jt02ewA1lAr8tgn8cBTGXlfulJ/wRkYJbnhwsGKWEzncrLbaND0CHuLj2ky8tk8g/i3MvZn58i9rv3lFvhqR8yoAey2kufyPsSMUHe7SSvVEq94AnoQ+b2WP00hzU6skGX24EDbnUBnC6w5b7g4jTFNGW+J+dvLB6L7j3lucHX/DHgDwLdV7b8lPo9X3XdJI8v/22f96NHi5L277S3v5EpTh8yT4A2Bj80y/OhzTIvuZT3J/jngwNtOtR60BUg1qdHivxD+8HqMXxNuveUUsp16UPmkdHBpdSfEN8Gelx6eqqfyJbr4z/hU+pPt4vg0ZL+8Vx07ymllOvRh0wppZRSSinldPQhU0oppZRSSjkdfciUUkoppZRSTkcfMqWUUkoppZTT0YdM2aT/4loppZRSSrlF+pA5SP4rM57yn3nlXyZLmd/4jd/4Xpmnr/mnYvXY2PrnO9F/aR/+r+v0IVNKKaWUUm6JPmQuYPqPoPyy7+XAwyEfF8jlP8Hs/9nTpQ8GfzRNDxn/558f8ljS+PqQKaWUUkopt0QfMhcwPWRg9Z+cHX3ICOom/UeY+nKo60OmlFJKKaW8FPqQuYDHfshI/9aDZMU1HzKyg6Tv/pDJ/3yQ+fA2KgP6Ja//8E2/QSLPvLneUkoppZRSjtKHzAXosp4PGR4Iq/JLHjJA/dEHh3Oth4zGKPRo0YMj9VCnftWWB4qjesr1oNHjrw+ZUkoppZTyEPqQuQBd1DPpcp6c8SFD//644HHmZejx8fJ9K++/deG720C591VKKaWUUspR+pC5AC7dXOpXv5H52j9aBtQfeXAkU1/OkYeMfkvi48uHjFA5yR8uOUfT+EkPGWMppZRSSimiD5kLWD1kgIt51k2PC2RWDxnp33qQrHiqh4zy0pW/gQHqNMasA2xBh+stpZRSSinlEvqQuYCthwwX9qy79CGjy/2kf49rPGTy0QJZ5o8UmB4y1KuN6/I/ZgZHbCqllFJKKWWiD5kL4BI+PTT0G4bpNxNHHjLSS+Ky/xCu8ZCBfJDpUSK7+fR+yOe49fghOfkbH/Rl21JKKaWUUo7Qh8xBdDFfJb/c++Vfae9/9p8eIXpU+G8xEn8EKTn+qFDaeyzx4JEsdvEpG3Jsqic5lOeY9BsZ119KKaWUUspD6E3yBEyPnFuHB8vWA6yUUkoppZSvoQ+ZG4ffYvBbkLPRPzJWSimllFIekz5kSimllFJKKaejD5lSSimllFLK6ehDppRSSimllHI6+pAppZRSSimlnI4+ZEoppZRSSimnow+ZUkoppZRSyunoQ6aUUkoppZRyOvqQKaWUUkoppZyOPmRKKaWUUkopp6MPmVJKKaWU8iJ4//79p1evXn16+/bt5zyf5CmH169ff87/+Mc//qKc72/evPn8XW0+fvz4OV9ulz5kSimllFLKi6APmfuiD5lSSimllPIi6EPmvuhD5oVDEHqgllJKeV4+fPjweV/mU3C50sVrj3fv3n1uvwUXMl3KSrkn+pC5L/qQOQgOvZU4WG4NPWJIZ37IsOlM9mszIk2bjTaiWxi/2zolx+1W0oa7lbrhlpeGLvxKupg4GVtH42DS9VxoDEds0iOGtILLGPV9yJR7hPPe40lnqu4Birc+ZF4GfchcgIIjHVuHBunWwFbseu6L/EPJDUiwEenxqMuOrwvt/BC/hTmYfgoLlK3K84HMmPJyojUmaeMu5aUhH5/imNi55IdJxAx7yC2BPUfjV4+ZLaa9opTnwh/gR/ySWNiK0a27DWXUKZ74dNk+ZF4WfchcgIJjcmzV3drBsRXstw42M59pP99zg0NOm5bG7OvEJvrcF5fVQ0b2yn5B2ZGHjJjmqpSXgnx/iqFLHzLoee79IMGe3ANW9CFTrsVDL+y0u8RfJatzcOuckk2rGNWZudJDGXXqU/oki17yfci8DPqQuQAFx8qx85DVwaR2OmgVyEp+ACtAaaPDipQHt/rK9qD+SPrOp/C2JB8PefSpb7VznV4OGg+fCn5SzpM2j2y/AnmfD4H92qAE9dr0sF3fhfSkTUJr5WujefX52hpTrlHi8+TIthwTZbm22EKakJ4ceykvAfk9Pk5yiKkpViTr8h6zpIw74XuBy/Hp5UJ6V3Ie99pfHe1BQvGs5HGv9i6TcT/tFWqX+sp9Il8g5dm2he4D7q9b4JsZn3ugO33ake8fuUuUl00fMheg4F0FvOoJWB1qHBYEJJ+U63CUDuWRyUNJgZ8HEnUKXrVXXjYI2nl9bg7UaTPiO0m2qp/UqbyPh+R28V16gXod5Gqv/AQ2MB/TZoVuzY2QTuQ1386kR6CPOj7VDv2UkZedOSbP5zxMSCbHTR9TOWU5TmRzbI50Md5SXhLye8Wyxxmx47GCrMdqxgV1qziF3C+0H6h95oX6VL2gL9mvOq8H30+Aeo0p90zp0Bhkr/oAvnse3anf8+U+8bPzCMjhd+mvW6BfvnwUdMu/J+Tz05le7os+ZC5gL+BVr4BVsDscLBn85KVXwelBz3fp4SDzwwmoU1kGdgY7fXl7vnse2Ul/bkLIIAvYlP16P5TnmJHPMoG8dE2b1WQP9cghn2OESY/jcwgaky4OQL1kpC/rV2MC6cyktU2om+bd7Uyoox32lfKScL9XvCveiC3FiuLMY0DxKnk+V3EHGd/SqTyQ9/2E7+rT92zI/qinvUO97x+uX/YoP7XXnMiG3CtSnr6yrNwf6Td74FPIpr9OyE89ZZxmuZhiVLaS9F0xUe6X7mIXsBfwqldAToHu9cIPyTywQJuBf89EX9Lj9k36QOWkPOzcvlV7nwu3X/gmpAMzk/cr0OdzNvWP3pxDt4f2qXs1DpFrNY0JndI76Zv6dSadQBvKvX+gLMfpNkxIF/aV8pJIvydeFCPElGKFT8oTjx3aan/aQ/2QPHYz3jNWhdp6f5ONuQcJyZK030ztc3/x8apuSt0r7hs/O/fA7+SDK3+dQL/Hh/xRfSrv+vjuMSM7Bb5N3s/gcp98f7cvS/YCXoGlg2QKdOo9oEFBzCe6Mzj90OK7H55Obg6Q+pTXBuGHHVDn9k32gM+F2y98E+J7zsMKjXVKbnPqo53q/buY5sZB3nVOY8q5Qj7nbmuck06Bnqwj72sBaYOTa1vKS2Lye8UNcaJY4ZOyxGOHON2LE2TQw143xa7KiDtS7pHUyY7sb7Ix9yDJ8KnYVh9T+7TRx6u6UhI/y7eg3v0z/XUL9OOzAr/MtuTdDvIeM9R5jGVMlPulO9sFbAW86nRwwBTolHlwgtrCFJx+aLmsQz9T2yyj79xQ3GZkvR4ocxlARuPIAxR8E3JZJ+dmYhoT31Ofb4xqw6dY2SCoc3umMeVcqR+lnKNk0inoO+vI51qkDQ7ltPG5KuWlsPJ7fN5jBf+f4oAYl4zvTxPSIVaxq31jilPfT7I/5F0/+B6k/rSH5T44tafO+/C9Qu3TfvT4PlnuD/n6nh9k/Lm/7oF+j5HMQ8aYx0zGA2RMrFCsKNXfXx7fvxGXJauAJ8Ap90MEpkBXQHo5cgrqKTgViAJ531RoI32yRTZ6EOu7903edUnO0bi9nLxszA0IfBMC6r1fZLOfiWk+wOdM/Tv0leNy+5Jcq2lM6EudlzDpBK2LzxdQlnOUNoDmaJIv5aWQfi/k/+77yFKmfVB7mFDMgce9UH3uo6vY9b4h92jyHt/ev/A9SPaqP+W1D6q98tM+mXsFurPP1ZyW+0G+JV+f0Nm1SrRVzCl5XJH3GMk85PlIe8WM6tzGyecnFCtKW+Ms5+Sym9gd44EwJQWf8Lo8LHJTUCBmOQGow0dJQUiAq8wPSPA6tVcfGdSp38sdbXZKGm+Wk88NTXjZ0QN0a7NyfRNuR66P43poM41pmm8v8zRtlCtZJZ+PaU32/md/2VTKSyPjYdoLKMuLkcd/xof2FdJqb1A9yW3wfqQndeQe4u1/8IMffFHntpC0F/ie4e35DtmH7zve1seeczntVeW+kB9d6gv4lXxxD/R73NDW/RJkh0C3ZBQjyIiprNwnfciU8kDy4iT8UVJKKaXcKs/xkNEPbb09+lzGHzKgH0zITmTJp+5yf/QhU8oDYONc/SSom2oppZRbh4eCHgP5IOAhQdnqnDvykPHHhpJ+e6nHjJL3479NJQm3d8++cj/0IVPKA9BGm1B+6U+2SimllFLK5fQhU8oD0U+EPK3+vH0ppZRSSrkufciUUkoppZRSTkcfMqWUUkoppZTT0YdMKaWUUkop5XT0IVNKKaWUUko5HX3IlFJKKaWUUk5HHzKllFJKKaWU09GHTCmllFJKKeV09CFTSimllFJKOR19yJRSSimllFJORx8ypZRSSimllNPRh0wppZRSSinldPQhU0oppZRSTsnr168/vXr16tPHjx8/J75TBu/fv/+cf/v27ed8eXn0IVNKKaWUUk5JHzL3TR8ypZRSSinllPQhc9/0IVO+GjaMbhIvDx0AHAyllBn2Pl2arsWbN28+p2txbX2l3BKXPGQ+fPjw6d27d5+/C2RI5Zz0IXMQDgGCwZO450u8NpCvmQPa+rxOF2eXmTYcbVakW1uPLd8BNtWsz/RQUvfRufH57EOmfC2K35UvyddI9472i2s9PK6tr5Rb4+hDhu98KgFnpPL5wCnnoKfGBShA/CJNmQLmXmH82hQuhY3D51OHrl940O2HcK6BNiqB7EPtuSb85EcbqKPHhY8BpnmUDtJDNlmfl0vRvPpalHIp8t+VL1GuWMhYvlfYw6758Li2vlL28LjnHNtiulslnI2ruxbltEePdElWewrt9V150HlM6kPmnPTEuIAp2DgcVsF1L0wX8KPkxpVzrDyfgs3G55zvrkeXf2/z1Mju1bxQTr1v8FvzSF3K78E8fc3GrE3/OeexvAxWvoR/5gUbX7/3C8W1Hx7X1lfOyd65tELtjp4FLovf+XmdSDcp7wNC5+VKj85HdEmfZLX3aMycobm/ILPqu9w+fchcgAJEDq/gUVKg8F2XyC35xOsyqNgMvN6hXwWt6vPQyvbaZHTpn5LQOJTyMk3fuTF6f5deSrwP2mpsQuvAp+zXeARtVhuTxgNaE/VBG/KktFub6VSXSDbnSmgMvk7TPAqNM9d1C9lKOoqPUXPhc6s6kuZM86kk5AMak3Tzie7V3JSXx+RLgA9lLJFf+bniBn3ud/Il5eWbQu2ULkX2oxddbnPGLbaTvE+vB+kjTWOVDkfxM+mbcNlJH3ZLJudra7zai5TKOfB4OeI/jnwFX9hDvnMJihXarsDm9NNSoLvQBUzBlsFFPYlDg42DOuT9IJEeHQ7K6zDWhqNNg3a+8ZBXPeV810YDOmikb7JR+pDx8WgTclu8rWzzNtS7fRozyBaX3wJ57w+9mjfh6yB7k7RJyH4SMuiSPp9nyQnK3S7pIGmdHGS9/YTai5XN4ohOofUD+Qtj2iLnWvZpfG5frqvmK+dC8sj5d2TdxvKy0Zqnf7gPiYw9oTgl4YvyZ3xWPg6Sk97MSz9pK94E7elP32mnvhWT0iM7KFebHHvm1YYkGzUmwXf1mTZMuC715/p8/kDjgK3xokt1gE7Pl9uH9Tri9wJZ1hk/kM9uga/Il44iP5PPTmBHfa1MXOZtd84UbFNwIeOHBpD3zcM3E20UQv1w0dOF0TcQ1Xt78g552Zn6+Z72gfT6Aed6BLb7mH0s2Ju6qZ/6m0CPX3DTdvB1IOXYwW1KtNH6nKa89EqGep8XvlO2graTXQ7tXWbLZkj5S5Af+dw6k5/tzQF1nk/7aa/++O7rSLuVLeXlkb4kKKPOwTcon6B9+t0k7zLq2yGf/a5QnwK/9f7T7/FzyoTay9+R9ViYYo96yVDu+iD7cFI/uL5pPmQD49oaLzo0DpAuLyu3TfrrFqwrslpn99EJZDIJfGcqB/lcxiS2Uk5b7Fj5fLlvvvSmsskUbFNwIeMHnaMDg6TNREE6gR5kE9qQ4KgNsp+ktg46vFy25iGVNtFO9qsu05ENiH7SZvSmrb4O2mATtymZ5jTlc+Ne1a9AfqseUmbLZjiicwt05/wKytHv5BwIlZNcX86rj2XP98rLZuVLlFHnTPEpPPbFJE9evjn1ja+77+6h2Mt+IOMW/3YfT5uR9VhTve+zrkP2T2liGpvry/6Fj4PvUx/et6dcw3K7+DrvIT+ZYmjFFI/4XsaI68sYAfqWH+suIntKceadsIxMwTYdCsjkQaJA1GHim0kGuTNtCkAb6dqzQXZLxtsKdGQ/stkPWEibfCzUpe4jYOPUDn05NtlFG//uULY6XKc59TFAbtzKC2xNuxzNZ86d0Jr4mNMGR+N8yNwKxk2amOZ5NQeyke+pjzLkaDONBfuRIa3mprw80pcEPpc+hN+s/Fxxgz5Be8oc8q7X+1EsuY4jqJ9Jt/s6trv9abPy8n/p9blxHbTL2NximlPXh62TvhzHNF63u5yTXOcVyMgnV/E7Ib8RijdvqxiQHcorRtCRPrry21K+3P3LJhlsMAUXMnmQZDvfTFYBig5tIN4WkFcfeza4LPihBuojD6jcbAR5b+9jka4kdSTT+EE28CkYi8vz3edn2jgd2qeNPgbQOFwHMpQpbSEbfJ4c2eBznjY46jvX6BLQvWo/jdfLSNk/efcroA9spdxl0eX59MHyspn8C/CT9AP5z4T8EH1CseSkb6p/pZX+Cfp0+ewv4zZ9e7IZebcn49J1UIdMzt1qr8j+wctkf/ZJGTZujXdaG/T42Mptk/46wXr6mvJ98sGJjI/MC/fJjBHK00by2L4HepT2xlleBt/3rrJkOpA8SBU05H2zVzuVKS/5zAN96KAhqKlHDrSpiCnAvb/UTT43ELcXJK/xacyS90MwN0by0g+08foEfYm3p63ns/+cD2RzPI7G5OQYpFNzjs48+PeQjhw7eco1pyJtAPpEdpK/BMacuhP6cD9izOr7Jz/5yRc2yK6cZ5W7HtBcCGzZs6e8HLT+iifH/YrP9B1H+4/kYYpn8vJNfNL3j0vJPS9tzLilL+8vbcaujJskdfA958XrHfrx8at/knTwSV4gq7qt8Uq36oCx06acA9Zyb+/Ft+QzmWirfd6TfABfIi8yL9zHM0YoTxvJyw+3kD2kvXGWl8H3vauMTIENfkj89Kc//aLeg4jvKicYpU+BmRtDBqD378Gcdrk9JPRoI/EyfUeX13m5yPZ+aHk5tgjX67qctNUTfTo+Tj9EhduYbR0fOyltoJ8cL/1lOyVtvFvkHOd8ZH+ZfF6F5mPVf+rcmhMx+Q6fWm9fA75rXGkf+ewPO93HVz5RXh7p/+kb7ndbfpF7JHoyLqd9dLXPqC+1WfVNe/py/1dMKE/ymCDxfbJZj4FM2AqpQ3j/pC3ox3XQluR4P163NV5I+4/sgeV2YN3la0fRmrsfrJDvCbVNP8EOZAG9LoN97vswlZUCfciUcgBtuEleDp6aSw+kp4C54gJXyq0wxS8+6uVcop7Cb+lj6qdxU56Cp37IgB7Fai99Ih8yxAF5t5O8UilOPaKUHdhUVxv/dEF6KrDrOftf8dyPu1Ic/HG6gFGmixM8ld+ufqqMLUcuiqU8BD0epgeBHhJbvkn9nn+6bpLHlB4zJO9HjxYlnWlpb38jU1b0IVPKDvoJU/60lHK/CD0lHApPdfG6BObjFh9X5X4hdqdY0aVIF6mM78dAfWWMUH6Lv10tpZRbpw+ZUg4w/TSrF/a/RD/NI/UyVm4RHi0eu6TnwuNF6RZ/KFFKKWegD5lSSimllFLK6ehDppRSSimllHI6+pAppZRSSimlnI4+ZEoppZRSSimnow+ZUkoppZRSyunoQ6aUUkoppZRyOvqQKaWUUkoppZyOPmRKKaWUUkopp6MPmVJKKaWUUsrp6EOmlFJKKaWUcjr6kCmllPLVvHrV46SU8vS8fv368/7z8ePHz4nvlMH79+8/59++ffs5X14ePXlKKaV8NX3IlFKegz5k7puePKWUUr6aPmRKKc9BHzL3TU+eE/DmzZvP6WtQMBPk8O7du1487oRr+E8pe3Q/OQ95HpRyZi55yHz48OHz/cdBhlTOSU+egxAIW0lB87UQZI8dUHrEkK4NF+aVXm0w15yva6HNzpOvA+uS9ZmQeShb8+Ywb5f4h/T2IVMeG/mv4nz1E1Dff/JCcWvogqSU+xZj9PpMX7PPac/ZmyP2g0v68b2uD5nyElCc7j1k+M6nEhBfyt/6flRm+pC5AAXEtPlf66JIMNHPY6PLxLXQ5qGUqF6Xffr/mkP+mmgTdGRvrivrM9mtcV/qB3vz5tA3Mpf6Bzb1IVMeG3xT+woJf00y7vl+i5cH7fVpm2Iwf2gxyUoH6dKYVT+TXkf7x6V7qWyjfSmPgfyXtPdDPvnxVpyszl6gXP6cMSFfp73HpPYn4ktlt7gXlX36kLmAx9789RO4rWC+Fgrea7PSy6ahjUM81Vi34IK/mgeth9vN99VmSh3yD9kM99aDeZKtl85ZHzLlKXD/JUYy3gEZv9RoT70lFPerOFYc+jmwJU9dyh9lSy8wz9iz2pNWaN4f6ywrt4ku+VNsJpJVOtJGuG/t+af3szrbdLau9FCuPqVPsvJ12U98Z0whs+q73D63dYLcOKvNPwMcmSnpANdBqQTS7Un98N0DjwClT9ejeh2y3h6Q900AeclIPjcJr5PsHtKbUJYbBTbl3AmNjU9k3Aa3Ky/oPic5nkSyKxsgLy05j4n6vpTVvAn61LiPbLiyA3sZg8+T+lJCn8+pysD9Enx+YWvuyn0hnwD8NX1DvpRQhl9NyHfdP6WXT5Vle8Ut6Ui8OGqrmE+mfYO89uBE435IrGzppRzd6N3b68DnSzb5GFVHkr7cK4TmSGOSbj7RvVrP8nz4WmrdtnCfmnx+hXzrEo6cbfR9xM/L/XGZt9050+bPdzZ1x4NdAarDCB0ejLRVfgpm8t4eWfJ8ql9tUOR1gFAvO/hUG6E22bd0auMS0rGH9DrSnYfbamNS3yTqNR989/mSnPRmXjaTNH+ObN3bPF1mZbOQvGw4yjRvgjEzh5N/TLgMn+S1rsqjC3w+pT/nijEJ6gXfva7cN+4b+FT6Bn41xc7kc4BvUkcbtXN/lo/zXf4NnpdPKx1Bfa6QTpchP41B7OlcsdLL/qL55XNPNzI+R+glaR+gvfRpH9X80r/LCskj59+RvXT/K0+Hr/UKrb1DmyM+LH+5BMXU1K842n+5Py7ztjtHm3QmPyASAi8PWd/kfeNfBTNlfpilTh08rpd6l8lNYNpsZAt2IO92qI+0LZn0alxuH2xtTFN/KZ/zRd9TffYr0Jd9JBqPZLZsBulc9blimjegX/W98g+H/n3dwX2Btt5P9jvZgU5BHXYAn15X7hv3G2IkfSPjU9COugn8divmgX5cZqrPmFgh/VsxDimzNQY4onNipdfHk+NPtJcqbkH7gMpo7/1kv9T7etJeexzf3R7aXbr/lacj1/IorOteHOE3mQRtp3KY4hqwlXLa7vl5uV++9KaySW7+wPdVcBN4GbDkp4TuVTBTtnWo6KDywwOb3K7cBNBHG8f1aAPJ5HZMTHo1rjzctjamaUwpn/M19e31ieRX9ZAyWzYD9cjnWPdYzRv6xMo/HGxDl5O+IHyNRfbBp48FPWqDbCnC/Qjfct8F/HKKHdqlz4r03SkGMiZT36rfFbTfk0+ZrTHAEZ0Tk17G67GX40+m8TN/6M4YVnn2y3fKxLQvkaZ9ptwW+ELG5hFYW4+7FekrQFvvkzwy8r8prrFTPqj7wENiqLx8vvS2sslq8582BcnmhXYqE1MwA2V+qORGpCDPC6cfKsj7JjBtNq4H2SObVjLpBcpSX25uzjSmHMM0X57nM3U46mNlA+SGmzYkyJIuZZo3lU1pZQPl7iuQvoAMOhjT1C9jlLy3E5pX0tbclfvC/QgfS9+Q3ziK4VWMpu9OMZ8xiU97nu+TH69Alj4U88m0b5DPuBMa90NiZdJL2Sr5vIicD5BNGmPayPepX+RoM41F80ZarWd5fqbY3IM1PxpD+A0+IBQvHk98p0x2KC//nXwW2SwrBb48VcomufknCnQFZR4EQCBmOYGuA8KDWaSu3Ii0UfjhgS2+8eQmkJsN0K9kaJubHfZNY3ImvYCu1DeNVUxjyjFM86X+lVb6BfqQm9ZU+t3utMGhDvm9OZpYzZuz8g8n1x28DBu9fupXc08/PnbwPPXITXNX7g/3I2IkfQeQ8ZiWD61If55igH4yJpFRWsXrCtk02Q+UU+9+T34V97LjIXGypVdM43emOPUyzamvy9Sv+qE819DzuWbltljF5haXrGeeKZkX7ifyQcU15Wnjnp8L9ChdOs5yTtYnSPke04EgCDAFId8z8Alm2kmHb/wEm3RSp4NC+lQmciNCNnX6JgG5CWhzUR+5kUin8iC7tpDeRPrVHrmcI2caU44hbebzIRsXOtJm9Z82pg1COh7SP6zmzcnxTlCHDPpAbUjyS7ef/NQvMpTnelOm/jVHpYD7Av4zxQJ+6f7H9y1/xj89BqcYyJjkO3Jfg+JRcSQUL1NcpKxicZI/yqQ3We1JDnpcRuMg/eQnP/n8mXGd/ao8+9I4BfY8dB8sjw/rd8n6IJv+K1/wpJhT7IjMC4/tjGvK00bye34OsodUP7wPegs5iAfHKgGBM9WRFOh+wJEUvKD2BLKCWyl1IzPpItiV5ztyLiOybR7+uVntHaguS/JxgevTBjYxjSnHMNk2ba6krb6ENltP6BMr3Z4SjWOv/9ST8yZys1/hY9H6y4Ych/uUj5c+pkMD+VWbct/gD/J5T4n7z5Yv5z6Wvouf574AWaYkX5XeI76bOjKWc0/ORH1ypP/cj6ZYFPSxVQ+rs0R7vs8Z32Vjjpc8tjmsoa/Nni3leWF9Jr+cYK33zptEviu0J6Qe7JAv5dk2+fQRPy/3yfdPmVJOCpvhtOlSNpU/FWzWujCcBew9etiVAn55eU7yoi2mR8hzcsb4Ym6PPADL7XL0IcNaZyyx9qv4EtTnXqCHss5BzmOXyYeMHsZuJ3mlUpx6RHkxrH5aw6b4nIdvXqDOQC8s5VJu4YLBRWh10fLy5/7hxnP3/1DOuJeVvwR/88eAx6seEjpDeUCkrNIWKev+oscMyc9qPVqUFKdpLzb1NzJlog+Z8iLQRpw/aaL8uQ5fbcT6KdSZ6IFRLgVff250AcuYo1wPc3w794mn5Ln7fyjsZ6tHYimlPBd9yJQXBZcYT72QH8d/YlbKpdyK33DZlh8rnfG3H7eAfkBEOuPjq5Ty8umNpZRSSimllHI6+pAppZRSSimlnI4+ZEoppZRSSimnow+ZUkoppZRSyunoQ6aUUkoppZRyOvqQKaWUUkoppZyOPmRKKaWUUkopp6MPmVJKKaWUUsrp6EOmlFJKKaWUcjr6kCmllFJKKaWcjj5kSimllFLKTfHmzZtPr1795TX1/fv3n7/zCXynvpQ+ZEoppZRSytXgoaH07t27b0s/ffrw4cMXdeQFcl7Xh0w5Qh8ypZRSSinlaugxQupDpjwmfciUm+Ljx49fbFb3zNu3b7/9NvP69etdmeeGg6aHTSml3Bec40p9yJTHpA+ZgyiwVqkX7+clN0ClvOh73YQ2TpJvsE8N/nRp/8jXD0t5ethn+MHCNbn2DwGura+ULfys7UOmPCZ9yFyAAonfGjgEogdqeXqm30ywyfkm6Zug1tJBXnr0myFv/5Q85DcttNH4Srk18M9p/xTUKd07usBd66J2bX2l7OHx3IdMeUx6YlyAAml1EJfnYXpssEb+E1I2yNz0qNcGq83V4eL1HBsltl/6kJH9fciUWwTfVJr2T/dd7bP3DnvPNfefa+srZQuP+Yc+ZEo5Qj3lAqaHjAeoyGDMi7aX+4VV+pVcN3K6mKteh5L35xdZ6mnneiedjMf1geRJbr8OQ7Uh5aUbnd4ecvOSnW475Bx7XnqPQDu3yx8tgrzGjKyPH2TzCnTSzsemPtClMvcX8PnxuRXYrnLNs8ajNl6uOfKU86dEXshuPqWb5PZme43Px6B5k00k9eNtQHMmvbkm5eWiNXf/Ao9DMcXrvcGc5Lx8DdfWV8oWOgtyn9e5o6SzDpDzulKOUE+5gOkg5sB1CEQvU2DqYsdBosDlu2T9Ugm6WPp3ZFUmeXRok0BO+iRLohxkP5+uUzr41GVUY5T95KlXG/WTc4IMCaRL9mVepH3S53l0Kn8E5H2DpB3tHY0NkJcdItfE0fxq/kD6vG/qXa/npV96hOo1X9Kp8f/0pz/9rlxjkqyPMedLeezMvtVusk9jodz1YZPbDchKl/RrvZElr7nmM32hvFzkf/iqg1+kH5DHPybc15GTn8lPlU/f9HgiXYrsRy+63GbKFDeA7STv0+tB+kjTWKXDUQxO+iZcdtKnmCTlfG2N1/cPUimlPBfdgS7ADx6l3PwpQ85BRnIcJF6vg0UHAwcGqC/ldYA55P1w0aEu6DMPO8rUp3SqD0CH69RBrDLa+phVr0sE9d5n2sB39S+8vxy38jmnW9DWbYRJh89X2g1aE40t8bmESZ56yeRcQfaLzDT/aZvKNabMA/a5LqA/5ED2ehtfH9WjG5DzfNZD9ke9l2FTrk25D9J/BGXug+Cx6cjPSe7fijO1kZz0Zl76SRlbE7SX30qX+qbc9cgO9/Uce+bVhiQbNSbBd/WZNky4LvXn+nz+QOOArfGiS3WATs+XUspT8v2ToizJwwf8YNDFzi+qwAGgA0LfSTpkEnRKRn1xSOZhQb0fRN4PIJ+HtOuZdHrfnvyQ9jHrkMuxaC68LUyXY5/PnONpzvdgHnxeAB1po88XY8q5Wq2nyPmd5H2+prmivc8nNnn7qQ1k+V5ekKec+sle7EmfAGxEVm0Fsj7X07x7Wc5ZuR/c9xzK0k89NhP5dvpdyruM+nbIZ78r1KcgZrb8mnjxOFJ7xVrGvWLR54Z6yVCecZl9OKkfXN80H7KBcW2NFx0aB0iXl5VSylPx5U5WNtGG7YeNH2Y6CHJDR8YPBR0SJD+IOCDUPvuaLpjUe//ZD/J5aXQ9k05scJ2JH4agsehCoDmQzGQDZeoj+8pxT3O+B33nGnifArtkp38X6ntFjm1af3S63uwHedfh3yHnV2T5Xl5oTNRP9tK/+wS2SsbbCuZU8tR7HSDv855zVu6HyX+AsvRTfIbyicm3J3ny8r2p72lP2AJ5dGQ/kH6dcZ82Z5ypfrV3yP4pTUxjc33Zv/Bx8H3qw/v2lGtYSqI4Jf2Tf/JPPv2Lf/EvPv21v/bXPuc9Xkq5hHkXLCPTYejoMMqLGnk/QIQfbgS4HyzZ13TwUO+HlTYJ4YeSwA6VTTopmzYUtaHO630M4N9hskF20tZlIced+T2QyzEBfea4kNP86VLvrOZC5Nimh8FqvpSyztcTJJ/zlOWTXOoH9Gt+JnsZj+pdFqa18H7TdqDOy3POyv0w+Q/gE+k7W7E3+TrtKXMm31Nevu86jqB+Jt3u16u4V3/KK/ak1+fGddDOY3GPaU5dn8e5k+OYxut2l3IUxZz7Er6mstwXSjlKHzIXsDqIHW38qwOLg8QPCtUpoIXy6ot8HjzU+2GlvgXyriPtn3TKXtdLO43HD0OQPPXZVnkfL6h8OkjTxszvQd9uu4MejYPP7N/XRjZu9Ut7H5s2aj/kc76oX4Hd2Z/skN1iKiePDvqnnKQy4W0me90n+E69UD5tZHy0SRsh+885K/eD/DH9B//wGAH8xP3GmXwfWfdVSN9T/0or/RP06fLZX/p1xv1ks+JJyeMQXIdiNeduFUvZP3iZ7M8+KcPGrfFOa4MeH1spDr95wW/wIT7J/6N/9I8+50npT6VcwvpWVb5AAaeUh4SjTV/JDx8OHj9QFcA66JTykPM0yaY8MjpctYGoHLDf5Z1JP7gevutwVWIsbgcy6ofvDuXSK3Leckx56E7Qj8aY+LjSHkG5ZFZ6QDIkxpKXJPKuS/15mSf6Sp+a5nerXPPletIuzeFkr9ZKafIDfUdeSJez1ZaUYy0vH/nJFFeUy6f4XMUnyLfcB7V3OOQ9Zr7G59Snx4/byHffz+jL+0ubsUu2rUgdfM958XqHfnz8Ho/SwSd5gazqtsYr3aoDxk6bUib+7t/9u9/5n2JA/keq75SvoQ+Zg/zzb4LtL/7kT77Nffr0Fz/72aef/9ZvfS7/xe///relt1XORvF/+C//yyfvFx6j/Oe/8zvflp6X1eVldSEp5SXglxZSxsF00Z7g8px68pGcMrpke5mS+lKbVd+0py/iVG11+VKepMeG8nyfbNZjIJMeQ6lDeP+kLejHddA29xnvx+u2xgtpvy6npUz0NzLlMelD5iB//s0l+s//zt/5Nvfp089/+7c//fx3f/fTL37v9z79ya/+6relt1XOhvF///Vff/J+4drl//qf/bNP/+s3h+qf//CH39acD11gJrqRl/K4TDHGI8PLiU/KHhv6mPrBlqfov5SnBr/Oh4v/EMIfyqVcQh8yB/nXf/zHn/70137t089+8INPv/jJT57lMn9p+X/9V/7Kp4+/8ivflj5dv49V/hd/9mef/vSbh9kv/uAPvi05F/rpZkJ5N/FSHo9VjFHmP1zw30o8JvyQaQJbuheUlwoPGD1c+q+WlWvRh8wF/G9/9Eeffvabv/kkf4zqa8v/u2/KKP8vvknaIJ6i38csh3/1h3/46V/+/b//be585B+DIfUnsKU8LquLkh4U+mnxU8Si+srfEFGuP1pWSinlGH3IlFJKefHoz+h7ei74rUva0p9Il1LK5fQhU0oppZRSSjkdfciU8v9v7+15LEu688r6B0JDrrwyJENmG7TolikakhqgDBGSVZAxcoQ26Q1Q8gaaF2hHkFmgMzTmB9AoQ25DnowCxhiMjGlKEEkMjRmx5l3Fevp9enecc+/Nunnznsy1gECeEx87dsTZO3bszP4QERERkcNhIiMiIiIiIofDREaeJfzz5v4z5yIiIiLPFxOZB8AFeetfFO1/iXPrP7HZ/9LpU/6nNlf/wmmXmQis/otbv//7v/+rui4PTSb4z5C2nPlf+Nkj38dERkREROT5YiJzAfPiP0l7/hOeXL5nMsN7LuX5z3A+ZTID+W+7N9FttU7qOrHIuuf/7DFyKdmTc8jcPWYlfw+SGBMZERERkeeLicwDWF38gb9YzP8PQF/A+TkTGy7bT/3/DthaT/4qMhMI6s5JZKCTv3NZ6cM+9ZynMJERERERed6YyDyArYv/6jLfyc0qaVklNw0ymS9JRc/R/4ha08nDbFuxtZ7MOddEXScVe4kMRH6P2SN/kcleIX9vjwJjMm4mMr1/lOjSe9jzpS5/Fer3+Q1FRERE5PaYyDyA1cU/l9/+x6GAS28u4fycl/lcsBk/yeWZcbk8Rx4lY+gTudEjSUV0pWxdwFfrgYybUNfrmHNO0n7JX0g68cj+7dHzZ2zmS2KUb8M+8B6QP3VDRvrT1s/n6CMiIiIij4uJzANYXfxzWb9mIgO0dQKy6o/c9El7wzv1W3Sy02Ur8aHtsRMZoH902dofQM8pm/fUJZGJjLmHae9v12tHTq9tziUiIiIit8dE5gHcOpHpMav+q0Rmts95m9V6gDpKX+KBupaXtc9+Ie2XJADonL3kmfFbe7RaXycyDXXImvJ6D6lvedkfytYaRUREROS2mMg8gL2L/7zocnHOBbmfA7K4RG+BzL5UbyUqLbcv9vlrw94FfGs9QP1s4711SqKyNUfk95g96DeTkLnGptcbGN8yeEYH9mO1h6kDZM2ENGuk7H0vEREREbkNJjIPIBfzCRftedmmXy74/JyX4FVy0zC+L+mrS/i85KdPyrzkT7bWA8iebVPmXiLTCcC5sJaZyDDfrAvUz7auY2zv+2oPIeuasnpv99YqIiIiIrfDROYBbF38c8nNb/NXl2Iu1NRD/lqyRy7X4VQig8w55ym21oMc6meiNXXautxHLmUmDXtkjS2PNW4lD+kfnaIPJXvDc8j71Cn1vTZgH3oP6DP/YiMiIiIit8VE5kK4xHaZl+skJ5SthKLHb9GXcQoX6U4MKD0XhfnmuJT+i0TY6tulL/W56Hc59X/2n0kBpG0mEk2Sk5StJCb03rBW9iL7v9rLPLfc9Jt60b/1Wa1JRERERG6LicwzZHXRJum5pws4ycI9JgRbyaeIiIiI3BcmMs+M/FVmQt2pv2rcEpKYe/vHs+4t2RMRERGRbUxknhn8o0+rvyqs/tGyp+Je//GsrSRQRERERO4PExkRERERETkcJjIiIiIiInI4TGRERERERORwmMiIiIiIiMjhMJEREREREZHDYSIjIiIiIiKHw0RGREREREQOh4mMiIiIiIgcDhMZERERERE5HCYyIiIiIiJyOExkRERERORqvHv37tOrV69+Ls2bN29+rue56TFv3779xfuHDx++9Hq4fHl+mMiIiIiIyNUwkZFbYSIjIiIiIlfDREZuhYnMI/L+/fvPjvTx48cvNV8HToy8duZrzyG3gwPWQ1ZEzoFL3evXr7+8idw3JjJyK0xkvgIcBEdbkQSDco0kI0kMpZ15xZZOT0l0p5yi10o5td6nYOqYcu5FIweth6zI+XB5WflMX2p4vje+9rzIhc5ERo6CiYzcChOZB9KBaYtb/EVmwlz3FuzQmb2A7MkWrK0Pnhxk98YqWeRgveQSxTo9ZEXOI+ff9Bl8rs88ni/xw1twjfMCGSYychSwbfw1pcGHUz/9uceYyMg53N8N8SDgYHGkrWD0FIkMTntPwY69mQfJ3kVj7hXv19zDa7H6BqzrEj3ZFw9ZkfPIpWT6zDwTT/2y5Cm4xnlhIiNH4qGJRo8xkZFzMJF5AASfBBR+bgWXVSKDI8bBKBNkpW0Gv4zt+g5uPZZCG0SPlE4i5pgUxkAfCJReC+/IyoGSMQ3yez7g/dzDhbVmHVsgi4Ju0TNj+iCc+7m315fSNrFH5kOv6B22vlPrmXX1WqN7v5/aM5EjgT1j11s+M2m/mETGpecFY9K2Ousu4dzzIr7P3OjWY9Av+lCyBs8LEXlJmMg8AC6YCWS5xK+CZoIsQSTvHYgITv3OcwJKB6n0SV3mom+3A3X9vjUmzABGW+qmrG7jmcIa2AP6rYI7fWZ99uwU6Iz8PXK5YP7omn2nLXPz3LLom7VkjyLnIbAmyh7Ijz6tI5z6TujV+gMy0p+2fn7oOkTuDew8voVttx/k7JngOyt/ZCxtjMm49sX455yn3zspoDyEc84L9EufnA/ROTpEX/rxnlhDv9YfPC9E5DliIvMAZvDiPZfiJgEywaWDB6SdugSmbqd/y6Vt9qG9g9B8z5joMHVqZkBDFnWB535HTr+voE+CbUjQ3QM96EM5FWSn3tnLnrf35Zy9vhRkr/Y0zL0E3lN36jttffuAnF7vnEvkqLQtt88AZ8nqfMBXthIFxl9yXsCq/Wt87NR5sVpX6xSdcx7M88HzQkReCiYyF8LhPwMkAYKgMaEv9QlYPK8K/baCaQeYreDUAW++N8jKnDOIJrlYBdfoRml9eN+6LAT69Jogc51DdN6bhz6t19ZezkvA3l5fAt/j1FjmnmuYegfq0I/S3wMZ6AnUt7zs6VyXyJGZ/jF9BrtfnXf4wdaZMWWcOi9gytua9xzOOS9oj6+HqVOgPr7fscHzQu6Nn3766dM333zz2e6+++67z3XY38p+Rc7FROZCCA5xullm4IyD5jLK856jEnQ6wNG/gxljp4wZ3OY7IDPjpk4QuTOgJcBHHnKmfnPNE8bOPnOdp1jJaKZe51xMpg70p+4hoNtD9mHqzTN6bH2n1AGy2g4g66b0WkWOSNvzqrSfNBk3/SNMvzvnvMDf+p3nlnEJ55wXyJ7n0eoMi945w3vNnhdybyTGkcyQ1Pz4448/JzYPjb8iJjIXQGDYcjYCwQwGCSQEDKB9BrAEY5iBewbKVbBaBbd+nwF46gS8r9Y19UWf1olxpwIy7XMdq33Yg/HZoxVTr3MuJqf2+hKQ2/u5YuoIXXfOdwLqVnva32+1fpHnwMqPsPWtC/yKKeOc8wLokzLbLuGc82I1f9fNNa5iA1DneSH3wA8//PDZzig8w7fffvv5PYmNyEMwkbkAHG4rACWw9AU9dRmT95mIpJ22PVbBagY85o8c2igtN++ZkwA3AyZ6Zi76B947IPLe692CfgmS/Jzz7XFO/4dcTGi/BuzTvCSsQJfer+hIQa9T3ymkfu47Osxv1XYi8hyYvg74Qvs2z+37kynjnPOC5+mLD+Hc82Lr/E3JOR+d8j593vNC7gGSFGyMEr9KTKS0LYpcynVuc8+cBJWUGRQSRGaffk+QaOeldPDEwbsthWC1Gkcw6jpIUKYwZ79TEtgoW/NRGDvX0GNn/R6tQ18OIOuKjDnHKdm9Bp5X32q1T3t7DfN9C/Trb7hH7yfzo1cuNXvfqeWn39QremQMc4k8N9pnmi1/mTz0vJh1KTnXIzfvW1xyXrQ/UxjLPGG25bl93/NC7gX/IiOPhYnMmfzfv3W2v/nzP//y9unT3/zFX3z6y3/+zz/X//W///dfar+u/n/7x//4S+0v6//nf/gPv9Q+zrzXqv/Lf/WvvtTeP1uBuy9JBP97DPCri5yIPB7nnBdAgnBveF7IvZBfCPjvyMg1MZE5k7/67SX9r/7Nv/ny9unTX/6Lf/HpL//1v/701//u333687/3977UPrz+f/9H/+jT//l3/+6X2l/2/z/+zt/5Unv9ea9V/z/+83/+9N9/e0j91ffff2m5X7iUbP1WtC8sPJ/6DeutQZ97TK5EniucFVs+1/X02zpXngrPC7knSF6SuPhfLZNrYSJzJv/jv/yXT//17//9T3/xz/7Zp7/+zW+unhTwm4r/5beOvKr/v/7JP/lq+fDY9X/z3/7bp//6D/7Bp7/+D//hS819kt8KTajPP4JB+z1eAFpHEXl88o9trf7xrFy8+Ee+7vWvMZ4XIvKcMZG5gP/vP/2nT3/xT//po/1jWv/Tv/yXn/7X39ZR/4e/LfkNxbXkP3Y9/L//8T9++n/+7b/98na/5HLS5V5/G0RCde86ijxn2gdT7u2vL8HzQkReEiYyIiIiIiJyOExkRERERETkcJjIiIiIiIjI4TCRERERERGRw2EiIyIiIiIih8NERkREREREDoeJjIiIiIiIHA4TGRERERERORwmMiIiIiIicjhMZERERETkarx79+7Tq1evfi7Nmzdvfq7nuekxb9++/cX7hw8fvvR6uHx5fpjIiIiIiMjVMJGRW2EiIyIiIiJXw0RGboWJzCPw+vXrzw4YeKbuHpm6yvPk48ePnw/19+/ff6kRkWvwGOc7l69rXsCuLU/kFCYycitMZC6kHSQJwF4iEEe810TmWmSdXJj3YP84gCa9r31YPQVc9qPLVkFf9Jz133///a/qZnloMjHnO9emksR8zdwiX8Op8yH2SXnp5Czk5zW4tjyRczCRkVth1LgAHKIvj7nw7iUyQPtzTmRyYFD2EpkcPDORYV+zh7l0P2Uyw3ftbzq/Hzr2++r7Zq0T+lH/EHtgnx66L9lXExm5Ndhdyup8aLvMmfrSwdeveQG7tjyRU5jIyK0wYlwATjEvgvPSu2J10X1u5AKylchwAOVw6USGeuoa9uspDx/W0utYfb/+5qv2rUQG0tYyTpH9eygmMvKUbJ0P+MK0a3ypz4iXCHtyzTPw2vJETpE4l9Jgi6mfdtljiJH9biIjK0xkLmDlMNAX0tWFsS+6Ww6WOsblcs/PdmRkRz5lOmjLTn9onSIP2StdeeeAyMVjtm+R/plzkvVHfkCfuY6sfwtkMS79WmbvwdSFcWlj7Ln091uxas8hu0V02dqvSa/rXN3nN8zP0PtBga3gkPlZK/Az78i8ZD/l5bF1PmCDfR4A7/NMCH1mta3G/vI+/THjUi4l+iMXWa0zdfELQHdKz9ntEHmU1Vojo4nPreSt6L4ree3/c7/21tvnLkVE5CnxFLqADpyrQNKBi0AQ6NuBgoAyAwfBgTEdJOgTOTz3uPRLAJ9z0EZd68T4BKg/+ZM/+bk+c+QdOVnflLtF5DLfBBnRkz4dFNEpc4W5tgZdomMCc74L7xnTa4B+j/zIOcWpPVi1R6ct0p69P0XW1WvdI98j0L/n4z0yYiP5LpljfsvsHzL6mb6rbyUSYifTptomw5bv9FmGv8VeY8sZk36RO98jnxI73oPx8e/IytzUt5zoQX3GzLXP94yhRMesKfCcOacOK1pW5mt5vX+QdcDeepGVNkBmv4uI3Jrtm5Ys6UswZQbCHPwJIkCfPuy3+oTMcYkM2mfgy3v6nqPr7EcbdadIP2Q2rKUDJn36HR2nXln/1uWYfei1rvqv1j/b57xb0G8vWK/aWSNzbpH23vtLYGzv42TKnt96rh/9994Zl/3jufcfPba+lQhgM9jfPB9WPrDnO7Hjtv1V/+6TuRve57xbZM6Arff801fwjT4P5vlD3/Yf6mnvvaE9faif58uco5nyoeWt9iM6sK699SIj64DI6joRkVvyy9NMziYHOKWDRoJAB0kCyyoQ9bgOhAkqHRymjNU8kPrW61Tfrue9g3TWSd89tvr1GmHKp73XDqv1N+zDqf3q/V2tk/FTty3m3k9W7ayRObdI+/wm58K4Lf2zH/0tVnsA6UvpPZ36d1tkUc7dQ3nZbJ0P1E2b3POdlR2v+vNOPazmxl/Tfg70R8acB+Z51GcPTJ3neZH2rfMr+q/KitXaWt7qvIJeB8+rOXruLvMbiqz46aefPn3zzTefbea77777XNf23T4gci7rk1CWdLAK1LUDrgLtKnD0ZZO+3T9t7dRTxpwn7+nTgWulE6zqee8gSBt19N1j1S91WwVYV/QMGbdFB1xY7VevH+Y89G8Ze8y9n6zaV5erhv60n9rXLVjr3LeQ/WjZ81unT2TMPYX0Z+xqrxhLH0rvvchkdT4Adjcv3djalm1PO4aVr/Hecnue2H7LOIfMs5Ld/oHurf/UOe/xmcjtvWkZjGOOc1ntactbnVcw17Fab+stcinYIDZEMkNS8+OPP/6c2KxijMg5mMhcAM42mUFpFWhPBY4EmJBA2wFjypjz0NbBqwPXSidY1fPecmijjr57nNtvys9am9WeNDPgrvar1w9Za8qe/MnW9wur9lwCVqSt13Ap7HfvY7P6rrNuts89hayLeXpvGbe31yITbAabm+cDtjVtJza3YmXb8aeG95aR+VO25K9gzu4/55u+M/1hpTP9W5/2J2gZOd/m3m2dH3N+6LroP+ekDh331rv6NsjptYms+OGHHz7bEYVn+Pbbbz+/J7EReQjrm5YsiRM2ueyFraDVfUICxAxICVwdaE7NM+XwnsC10glW9bx3oKKNOvrucW6/KR/QM7pHpz058+Kw2q8O3ED7Q5l7P1m1d/Bv6Ed963YprHNPH0B+72P0oeR/2pnvkD3vPYXs65wr3zowbo4VafbOB+pzBvFzz7Zjq+kPK1/jPfaNHX+Nv2XOnC9TR57b/ufZM3VGr+i2xZTB89yXbm+Yp9ef+SmRwU/eA33TtrfeyE4bsHbGiGxBkjJtMLZEMX7I1/Dw290LJM4W52unhFz8UggOBJuum1DXQaGdm8L7lLGah9J16NrvKQluU8b8P9IzfspsPZsExZTMsWKrvWXsBcX0obAvq/1qWfk+U8eUvbnmHlFa91X7Of9n/zln1rB1MZnzbPWb9JpjD8wFbR/0i41lvwL183sho3WaY0Sa6XvTnnJxPmVL0w+QM8+52Yf2lt8lc2XM1tyMZ674CCU+nHcK7b1Wnlc6zzMrBV1hygg9P2UP5mkZjKU0PU+37a0Xpv45U0T28C8y8liYyDwxM7jI40BgXnFP+4+OfWG4B9CJy5jIkVn5P3bd9UnQHxvmWM2jr8lzJ8mx/46MXBMTmSeES6vO+/hwQdj6reHqgvNU3GNSa6ItRwcbXv2CgLo+F25l6/1XlgZd7u0XGSLXhOQliYv/1TK5FiYyTwhJjI77+OS3QJOtC86tyUF+b5cY9LqnRE/kIeBbqyQlCQVn8K0uUZlr+hX1/lJLRORyTGRuTP/2gWe5DVwSsu8pJpG/hmQq++PFSp4L/e+DpDwV7WMpt/prkIjIc8NERkREREREDoeJjIiIiIiIHA4TGRERERERORwmMiIiIiIicjhMZERERERE5HCYyIiIiIiIyOEwkRERERERkcNhIiMiIiIiIofDREZERERERA6HiYyIiIiIiBwOExkRERERuRrv3r379OrVq59L8+bNm5/reW56zNu3b3/x/uHDhy+9Hi5fnh8mMiIiIiJyNUxk5FaYyIiIiIjI1TCRkVthInNQ2olxVBz+9evXX1r/1pF1YFkxbUVE7h/9Vo6EiYzcChOZM2mHWZX3799/6fn44MA4OODYc/448WM4cOb9WqI3hfXMui5PGbznQboq6I+OXcf7qbEPWdfHjx+XsijnEJ28EMmRiN1vnT99qcl5ck987dmm38rRaJ+kNHuJRo+ZMdRERlaYyFwAyQKOQVBtcK5bBk+C2an5cN5rOzDrvkYgzSEzk7/VJYV13nJvJ+jUerL+1pO2vOey0octUDfXEFta7cMeqz1qHc6Bvl6I5CjgO/GVlZ3T3vZ8zvl4a7b0vkRP/VaORPstpdlLNHoMNt/vJjKywkTmAnL5nInMrUGHUwEQ5722AyPvawNpDpgVMwEA5nvK/Z77jD7zUpL3SxKZQBvl3DWu9og9XdVv4YVIjsjK92D6XM7pe2Lln5eebfqtHAkTGbkVJjIXsEpkVhfUdrB2oh7fjjZJPaXHT8elZP4Z5BlHyZyUbo8s4GcCZPentPyub1ldv3ehzpznBm/67QVu2pGHzr030SHvUwbtW22noH+vvYncuQfUZR8n2e8tmefA+FPk+2ETzNXr7v1oXdpG2w5Th+4Q2bx/zTpE9lj5XvxnQt30w5CzMecHJXL5mbo5vv0htv9QTp1t4SF+mzFd12vNuvo9/UREjoaJzAUkaBIUwgxGBIQOCvTnPWMpjOlg0pdc3jtIpn8zxyRw9bwJuqnL/IzrSz/9aItO1EU3xvIeeG9dEhyzH5Hb+9PQhoy+EPQ6JtF1RQdmdEo/ZEc+pF/2dGuNlD1dAnNlTydTdjglm/be10tgXVv6hN6f6Jj55v7Qj/d8Q/Zy6oaM9GfufmasyGOw8j3sdeU72OHK53I2MCbjsF/qaIst5xwJ/d5nD+UhoNtKvwb90udSv6Vf6w/0zdlEWz9HrojI0fDWcQEJeF1mAKCu6ctdxieAAEEkwZlgNOVlTAIW8D6DIOM6yCN3BjLaIz+Br3VJsEwwzNx57/GAjNYjwXXqBpHN+MwZHXptDX0z94rVfJHZdB9+9hoio/dhD8b2PjdZ45Q1dZzQ3jpdQl9IVsz1Qn/Huf65hrT3N+r189xrmzYnci1Wvreyb9jzOWy0x2zZePdZtX+NrSObebf4Wr+d79B7h+69Hv1WRI6KicwFcPATHDoAdQBI8FgVxmyNj4x+bhjTQXm+AwFuBqopizGMnc8rGEs7JfrO4N59urQeIXvTawfkrdZM/1V9gyxkdkBerYv37NdWe8vYY+5zs7o8QM+/gvbe13Nh/afGsYdT3/kdA/XoMteAjP4WLS82fWqNIl/LyvewuZUt79njtOfVOTJ9ZMrbmvcczjnbaJ9rnToF6uOD7be9X6xx6p8x5559Il/LTz/99Ombb775bHfffffd57qOITN2ipyDicwFxOH6Mt7BASekfYvV+A6q/dwwpueZ79BBC1ayErzmc8MY6lnL1HcGUvpOPbbI3vTaYaUnIPeUbGQhswPxal28t6wekzWee4DOfW6yxilrzt9k/i2ZezD21Dj2dvaZ35H37MlqDaljv+lDmdCeIvIYrHwv/tPkXJh+GOaZszpHpo/gv/3O8+rcOgdkbZ0H4Rp+23vDfHM/sm5KyxV5LLBr7I1khqTmxx9//DmxmfYuci7eOi4ggYEAsGIrgBJEaFuN76CawNTtK5m8z0BIIOqDoOUG2tOH8chpqOuANvVl7Aykcw5oPZqV3oyfdcA8vQ8rsjfoGVbrmvOmT0qPP8Xc52Z1mYA5fxMdTq11BXs355rMbwZdl28cttaQda9sqtlbq8jXsOV7016nTU+w4bbj1Tmy8hv6pMy2S2DsKX9fzd915/otdfjjnt+u1i9ybX744YfPdkbhGb799tvP70lsRB7C9mkvvyLBYy8IESDo0ySIrMbPoEp7BzDkzSBEn3lZZEwHJ8b0XHPuXOabqXveV2Noo5731oV5tgJixk+dJgTjueYVmb/nW62rdaRv79OlzH1uTl0mmqx91f8cWPu86KyITq1z5qXMb5L3qVPq59p572+FTlvfX+Rr2PI9bLN94ZQNYq9ts6tzhHmmzPjI14BfnXO2XctvGZ/+DTpM2XOsyLUgScHGKPGrjoErvxY5l1/fImVJHC5lLxgleKQQbBJoUggaOHTeO2h2v3bwKYOSgJfSerUeLX+lHySgp3Q/Dp1uT9BbjdljrmEFMk5dhue6kTvXNfvQPutSTl0utvY+9Lek8D71mWW1V+hB26n1ow/lHDpgZN49e8vzlE9drxnmnq7WJPI1TPulTNpu93yn/ZTneR5g8/HBFJh1KfGHyJ3+MUHPU74druG3OZ9zxofosRoj8hj4Fxl5LExk5EVBQF9dJKg794JxC7ho3Bunkj2R58rWRX/6hH4rsk1+IeC/IyPXxERGXhT9G82G36Se+m3qrUCPe/sNKQmggUZeIvyCY8sfu/7efhkC93iWyMuF5CWJi//VMrkWJjLyYsg/ZjEv5NTfy28t0eMef4PKnhlk5CWC7XNurP7xrPgEvyC5x0Sfs2TqLSLynDCRkRdHfvuTsvVXmpdO/6bs3n7TLHJL+KtGnxn37BOtq798EJHnjomMiIiIiIgcDhMZERERERE5HCYyIiIiIiJyOExkRERERETkcJjIiIiIiIjI4TCRERERERGRw2EiIyIiIiIih8NERkREREREDoeJjIiIiIiIHA4TGRERERERORwmMiIiIiJyNd69e/fp1atXP5fmzZs3P9fz3PSYt2/f/uL9w4cPX3o9XL48P0xkRERERORqmMjIrTCREREREZGrYSIjt8JE5pH4+PHjZyd6//79l5rf8fr165+dbNX+2DA/B4Q8P7ApDngRuQ2cpZyp14TL1zUvYNeWJ3IKExm5FSYyZ9IOM8slF0cCXpwxTnp0WEMfMKEPE8pM2rp9Nf6pQJfWmzK/8Wyf5SHJxDyYU85NOtP/IXOLPBZty1uXiu7z0sm5eK0L2LXliZzDjGdNbHJllz3GREbOwahxAVzEcQz+2hLiaOdcNnNB7vFHJwfGTER43ztAaMue5a9XU8ZTkPXMb0Td/K3ryh4gMiiXsLIhZF2yL8xpIiP3QvtM/HyeC9TllxzxqZcOezT36Wu4tjyRU5jIyK0wYlzA1sWVYD0dacXW+KPCQZIDY162qd+6gFM/94sD66kPnByaq++zuoTtfc+0nbum1V4h99J/ZIU5TWTkHsCmp2/k8hFyhjTY/Eu3YfbkmufhteWJnCK+ntJgi6mfdtljTGTkHE7fvuVnti6u1J36bX2SnS60Ubquna5ltGNCkgFK/yaffrxnLKUvBZmP9pA+PabbV0Sn6NEHTOu2OkRWSUvGbEHblo69t5PUU9B5i+zLSt+QQzVrjS5bcpHV/S8F+f1tV/ReR5/+3tE5hf5Za0r2MeMp0LLhlC4ip8DG+qxcJS28b/lhbBc59It9xsfyPs/jafOXEt9ALrJaZ+raN9Cd0nNO32lfW601Mpr25XN8sfuu5KF3+sz92ltvnwsUEZGnxFPoAnK4c7CHBAPaQgep7rsaz3uCRNoJFC2DOTpQd1BqmR2YEujSzk/6pJ13yDtjM4afvO+R9gS16Af9HPldh+4zEK/khMhY6UjJftKnA26/937OgA5p7/ET2lYy+3s258jcAz1X+xGyZ5mfPen5om9gr7L22MLUrb9Lj+V5fjORS8GG2uawq5xFYdpt6PMLW44cbJqSMekXufM98inn2DTjmS/PjMvc1Lec6EF9xsxzYr5nDCU6Zk2B58w5dVjRsjJfy+v9g6wD9taLrLQBMvtdROTW/DpayCYJCF22gkn6JljBqo536iFBI+/pP5OADkgzASCozOBMXcbMOYD3HpN5t2DNmW/Ov4L+LQ9dpo6n5Gzp2HvZa4+82b71vaLjVjtkzvRZ6dDM/peAzFMXhNV6ej5+tgz2pt9pp3/Te9xr4+f8ZiKXMm0aG8NPmpVdBuywbRxW/btP/LDhfc67ReYMnC09P2tq35iX+4zP2Ubf1RkeXwPa+8ye+zbnaKZ8aHmr/YgOrGtvvcjIOiCyuk5E5Jb88jSTXXJoJ+DwPANGmH1hVRcSjCn0g1X/DkiQAJRAMoMq8J6glyCVOYD3Dsx7enZQgzn/FsyfPug/dTwl5xwde+0reat5Q+T1HJPZZ2+f4ByZWzBmb1y+49yvrfmop/TlZ9oCP+d+ZdzWGkXOBd+bdtT2F7Bf6ldMm4VVf97jB/HDnhs/2POvCf2RMeeBPndgntFTZ/qu/HD6XmRE/1VZsVpby5vzh14Hz6s5eu4u8xuKrPjpp58+ffPNN59t5rvvvvtc1/Y945nIOaxPQlkyAyJOx/sqIM6+sKpLEObnDHir/h2QIDrkAOhgFDpwzTkg84fVvAFZtK1K6zWhLToiY/bNnFvQdkrHuXbmyHvWvfpWkPa9NWTtWcfePgGyuv8l9H6tiL6zD3W9Rt4pgP6xg9DfYrX2rJHSeytyCdgktjTBHqdPtk1OYvcti/Gx8cB7y+158Jkp4xwyz0p2+wa6t/5T5+m7kdvnSMtg3PTbPVZ72vJW5wDMdazW23qLXAo2iA2RzJDU/Pjjjz8nNsYXeSgmMhdAQMHhOuDksJ+H+6rvrEtAzTs/eU/AW8nogASRkflnMAL6p27OAbx34FvNu8Wcf4sOnBnToF+va3KOjnPtmSfl1EGZQ3ZrLbS1jnv7lLa9NW2BvNVFY4L83hPouv7uwPOUmz1C37k//X6JTYg02M6000D99BFsdKs/9hd7DfSlrmk/gNhvypb8FczZ/ed889xhPb2mlc70b33mmdMy4qPT96a/hjk/dF30n3NSh4576119G+T02kRW/PDDD5/tiMIzfPvtt5/fk9iIPAQTmQtIMJwBhQBBfR/mq76zLu8JKHmPnJWMGaQS5CKDQLOaI+/87DmA9w5Oq3m3mPOvQN+eD6hLII5Oe/Odo2NfKKjn/VLm/kH0m/K29in28JD5gXXOy8KKXIam/VBoY/62Fd5XOlHXcgJ1+W75ziKXgP3MCzf+0nVtZ/zc85v4YvoDvjJtk/f4ELbbfnApmbP9rHXkudfDXD3f1Pkc/54yeJ770u0N8/T6Mz8lMvjJe6Bv2vbWG9l9VrB2xohsQZIybTC2RJlnhMgleDM5kzhcygwi3faHf/iHv3jn0E/gSIkzdz3OnOff+73f+/mZMmXw3AcBJQEHOd03QQYZ3f/777//xTvjCGhd1wFrRWR2P/bmHBkrHScdhClbOvZ7vk3XdTnF3FcKdc1sn2WuOTqy5lPQ59yLQe917CcXmLmOtq+WH7uZ0L/HbH1HkRXTT7u0/bWP7/nH9HPkt31SZh/a5xmSkrlO+Sbjmat9LfrnnUI7MvLO80rn1flCQVeYMsI8V/fovUcGYylNz9Nte+uFqf88G0VW+BcZeSxMZJ4ZBKcExJcOwXhCQH7K/SHo31tC8NR7IvLYrM4C/LDrb+WbzLGaB13u7WwQuSZJjv13ZOSamMg8M0xk/hb2YOtSsLrU3Ir5W9F7wAuUPGfwuf6LQqCu/5pwK9/sv7I06LLSU+S5QPKSxMX/aplcCxOZZ4aJzN/CPqwuDFuXiMeGA/peD+qn2hORW4DfrZKU2P0tfTNzzV+mUO+5LSJyOSYyzwgCZMo9/ub/1rAHvScUf+P5t/TeiDx3SFr6HHhKu+cMmrp4XouIPAxvMSIiIiIicjhMZERERERE5HCYyIiIiIiIyOEwkRERERERkcNhIiMiIiIiIofDREZERERERA6HiYyIiIiIiBwOExkRERERETkcJjIiIiIiInI4TGRERERERORwmMiIiIiIyNV49+7dp1evXv1cmjdv3vxcz3PTY96+ffuL9w8fPnzp9XD58vwwkRERERGRq2EiI7fCREZEREREroaJjNwKExm5CTl05Pnz/v37z9/648ePX2pEni9ctl6/fv3l7Tpw+brmBeza8kROYSIjt8Kb5Zm0w7RzTGe6xGlw0pdA79FD4QDrfUbmpPtsfYeW8dS0LrPMi1EfzCnT9lblIazkUM5JTJLEnNtfnj97l5HQ7S+d+PolsWSPa8sTOYeHJho9xkRGzsGocQFbv2mOQ11ycaPvtX+Ld89kjx4Ce9WHUb4DMkOSmHwDDsDVAclYiIynZmVTPFO3VZ81BOxoJsWd1PU+nYK+PScg65JgsFqTvEym308/Bd7vzS+fGvztmhewa8sTOUV8P6XBFlM/7bLHmMjIORgxLmB1QcOZHuIojDGROY95cQf2r/edZ+YIufTn4Ft9J/a/xzwFW5f+XPhWa5r7sUpkAm29D6dY9UP26htssbUmeXlMP4W2x3v1y6dmtW9fw7XliZwCH8bXUxpsMfXTLnuMiYycg4nMBcwL2jkBtx0qfXO5TOlLaLfxPGnHng6ay29K69aX4D4A+mCY47f06pILbuSn9FjInE32k7Ja6x7IzxyZu9cC7E/vee8H8L51yJ3ar7xPvec+nGLaVMi3aJ1bpwYd5n6HyPmawxz5U78J8zNP9ONnj0kbJXvW+0oJ8ZmsKbL5iez5neV+yTeOzfKzbfVe/XISm44vtM7U9ZrQndJzdjtEHmW11sho4gcreSu670oeeqfP3K+99eZMSREReUo8hS4gh3sCKAf8HgQBxkAO/7wTXGbw4H0GyA4UBKIEsATJ9I/86JR3+ndA7Tk6uKVP9JtrnIEzsiFjc5nIewfOyAu8dzt69fsp6J/55tpDr4/2rC1MnUL0p6z2K2PSL3Lne+RT5v4F+tI+dc+37/opP9B3Sz5E1kNgb099F+buPszVurd++VZzj+b6059+/UzffHc5Bny/2ES+ZWhbCPfglw3jmS/PjMvc8a3IiR7UZ0zslrGr94yhRMesKfCcOacOK1pW5mt5vX+QdcDeepGVNkBmv4uI3JqH3W5eKAkIXbZYXQA58FNH4OsAENlNLn0EkTwn+AGyOoDOoMx7xqyCH88zYOWSmPny3szgxTxzrcju8XkPjO+1pL3rtkBmrzW6zrHoFL1oT2APU6dma79m/+6z+oa8z3mblU1R5n5CdJry2Mv57RvaGfcQkLun/2rvs6bUMX/vI239PvVnfOyG594LxqVNjgPfnMK3bqib9rXys3Arv2wyZ8D+ev5pv9hrrzPjY7f0bZte+RDt6UP93Lc5RzPlQ8tb7Ud0YF1760VG1gGR1XUiIrfkl6eZ7JJDm4M+B3/eJwmusyT4EGw6EM33QB1tq+DT0NbBFaIjPxOcOnhHxwnzUZ+xTcb0mqNjM+frudK2KucExBmks875HTp4095rh631w7n7xTv1kG809ybtK1ZjgHEtG1Y6wWr/m8h6CKfGoR/ym601pZ7S6+K55+m1ZM2U+d3l/sn36+e2F96nPU97aFY+sOrPe2xsZY/o0DZ4ivjQnAdoa5vtcwemzvTtPUh7n30to/1mlhWrtbW8OX/odfC8mqPn7jK/ociKn3766dM333zz2Wa+++67z3Vt3+fEf5HJ+iSUJTMgJgCtHJBA0sFsMoPJqeCSubegbQavXPD5OYMp0L9lMk/69NiQupYBHQDDnK/nSlv28RLY0zku8lpXQK/sST8HdN76RlN/mPsFvLfcnmdrvxra6LPaC2R120onWO1/iA57trgFY0+NY63M38w15T068jy/RdbFmNVa0IM+lPmd5X7hu/W3njZ8r365IvOsZLfNonvrP3XOe+w4cqkPLYNx08f2WO1py0PXlby5jtV6W2+RS8EGsSGSGZKaH3/88efEZnXui5zD9s1YfgUBBYfrgAPUzQM+fSdx1hlMEjRmkKAOWQm+sz0BBlkzOLUOpy4AU9/VfLyvDpscTk3GZ696LuC5dYGscwvm3mpHh+wFrC4LCeSB/eoxzan9Cry3jOxjypb8kP7TpiD7mraVTjAvIA1tjNnb1y2QOeearPTvuujc8/M+9yX+QH33RVa/syfzO8r9svKx9lV+3qNfNszZ/ed80/+mja50pn/rM/2zZdBGH+Q0Wz4/54eui/5zTurQcW+9q2+DnF6byIoffvjhsx1ReIZvv/3283sSG5GH8MvTX3ZJMJwBJYGG0oc8h34HFMYl+HRwSB39Uwf0oS4gq9shY6NDB7cOOqtg2jrkOWvLe4Idc7cugCzaI7vXynPr0nPBnA96/ARZM1jynrqsP/Lo3/MD7enPz7me5tR+Bd6pB3TYW8MK5LfeAd2pb3krnYB1zLVmP1b9z4Wx50C/lZ1SfvOb3/xCh+iVPQupX9kY9WH1XeV+iR3HvmPDbe+8xz74eQ9+2WRO5MDUcfofc+35LXpN+59MGTzPfen2hnl6/ZmfEhn85D3QN217643stAFrZ4zIFiQp0wZjSxTPdPkazrupyM8Ol5IgkgvYLCEBgxIHhg4uHRS6/ypQdTulmbokcM56glYuGCmtD2W2b5XoPsd3oF7NBfTp+t6Hhn3ofim9n3DqYGwd59jmnP2afWife5CyNdeqb5dew2oP5v7NsrKfyIltbEH7ag9XbNlOvnPrznNseOrHe9sNoEfv9d53k/tk+k7sIjy1X2bM1tyMZ66246wh75S2bQrPK537nOoSf5syQs9P2aPPBmQwltL0PN22t16Y+p86S0TAv8jIY2EiI3JFuABMuMys6p+SXJruCfaIvRK5Nuf4ZZLmx4Y5VvNo//LcSXLsvyMj18RERuRKcEj3by4Ddff0W8t5gbsX5m+MRa7BuX55K/vrv7I06LLSU+S5QPKSxMX/aplcCxMZkSvBQby6DG1dXJ4C9LvHhIFgdo/JlRyfU37J5elWl6jMNW2den8jLSJyOSYyIlek/7nzFFnDb5+zR17i5DG5J79su0+5x18uiIgcAW9ZIiIiIiJyOExkRERERETkcJjIiIiIiIjI4TCRERERERGRw2EiIyIiIiIih8NERkREREREDoeJjIiIiIiIHA4TGRERERERORwmMiIiIiIicjhMZERERETkarx79+7Tq1evfi7Nmzdvfq7nuekxb9++/cX7hw8fvvR6uHx5fpjIiIiIiMjVMJGRW2EiIyIiIiJXw0RGboWJzJX5+PHjZ+d5//79l5rnDQfN69evv7zJS4IAYZCQl85jnIHX9i19VW6NiYzcChOZM2mHWRUSlyQxeX/u5JD5miDOwZQ9o3A4TbrP1qHUMu4J7KB1o7RttM1sla+xpRzoWyQYdIA4h8g1SMgp9i4jodtfOtf2LX1VngITGbkVRo0LyKWUy2eDc+UC7l9kzoe96kMm+9vJTJKY7DnzrQ6+7Hdk3APsy9Ql9jHXkEN5EhmX7nHmSVkR2ZRLExlgDQYJ2WPa9fRn4P0e/fcpubZv6atyax6aaPQYExk5ByPGBSTIdhCe5AKZwPzc+ZpEZrVHHDp98PDciU32NwcabfOgQp8e8xSgE3quyGWOvQs5lFekrfufy55ciC4dIM5lfiuRycpG2t7u1X+fmmv71rXliZwisSelwRZTP+2yx5jIyDls33DkV6wSmRlwO5HJJTHv0I7ZtOPNC2vmTekEoC+iLbt1nONb5/6tfJfM0WugzPUy50xker5LkxzkZf0zaQnsVfRYXXp43zq8+vvQL3pmjrxPvXsfTq0pfed3bPK9852iyxbM2f3P5ZTc6Dr3eAv6Ulgba+h93rKzVV3vJ2vKd8n73t7JcYj95TzhZ3/bW/lv2xflUmLbyEVW60xdryl+0XNOe25fWa01MhpkbMlb0X1X8nKmUOZ+7a23fZciIvKUeApdQA53DvYwA0CCF31X75AAHJCRQJEgkf6ZM+Sd/h1QkJExPCfQpU8CfYJhmAGRtjk26817j+G59wC9OmDSNgPoHvSPrnP+0EGZ9t5bmPsb8i0ozJM9j7yMmd8sekSv7CElMprMP/VqIiN9tnQO58hccUruXNsePT8/ec932NqjwHPbDaBbvi3fo58jV45P+8u0AeqmTW/Z7EP9d75HPmXqs4LxzJdnxmVu6ltO9KA+Y+IrjF29ZwwlOmZNgefMOXVY0bIyX8vr/YOsA/bWi6y0ATL7XUTk1mzfcORXJCB0mYd4Dv4EkfkOBAXqIDIbZCZw9HMgeGRMLpAtn6CaoJV29IDMl/dmBiXeZ6Dnvcfz3mN4btlZ62q+Cbr2fFP3gF5ZH+29duj9nSCLtt7TVf/uw89eY2Tk0j7JHk29msyZPisdmtn/XE7JzR5vrSWwpux56O8wv9W0s/kO/a3Z39ZhziXHhm9PaT8C6qZN79nsQ/w3ttfwfq4vZc6Anfb8rKltGdvdOy+mL03fgfYt6ue+zTmaU7662o/owLr21ouMrAMiq+tERG7JL08z2SWH9gw4TYJAguR8hw68PG8FpNVYaD0SgDqQEMhWMtGVvhnbRKeu5z0BLMz5eq7ouyrnBLq5l5lr6kq/9KV97k/v7yQ6bn2PwHvWvtU+5w3pv9UOs89qjuYcmStOyZ3fcwu+MbKa/g4NdcikbNkT8/VasKOMOcdW5BjE3/q5zybep03v2exD/Je+vLctrux5D/ojY84DtGG/YfrF1Hmez2lvu28Z0X9VVqzW1vK24kOvg+fVHD13l/kNRVb89NNPn7755pvPNvPdd999rmv79uyXh7A+CWXJKiDOgDGD1nyHDrw8r4IKrMZC64Hj89wHwAxUBLD0Wa0hMuY81M31zfl6rujbss8FHee4yOu1AfNFr34O6JSgPYnMre8ReG+5PSZ7OPUK2aNcClbkm2TNKx0a1tn9z+WU3Pk9t1jtM2vofc6akLWyM8bHVtibuZboQtn6fnIs+I5tN9P/buW/PU/srGWcQ+ZZyW5fR/fWf+qc9/hc5LY/tAzGxW/OYbWnLQ9dV/LmOlbrbb1FLgUbxIZIZkhqfvzxx58Tm7Y9kUvYvuHIryCg4HAdcCarQDvfEyBgS2YHjgSgQFsCUYJyB5cOVN0XVvPxvjpEGNdjIePDDIq09VqB973gh4ytdtaevYDsb/rTNvcHfXpMs/o+9O01Ae8tI31S5hon6EC/+V0hOvSer3QIaVt9o1PsyYWV/axgj+c+dx3ztB3ETnr9vfdTVq/tXJ3k/ln5It8+dfyctvAY/ht7TNmSv4I5u/+cD33bftsvYKUz/VufaestI/7QvgRb58GcH7ou+s85qUPHvfWuvg1yem0iK3744YfPdkThGb799tvP70lsRB7C9g1HfkWC4QwozSpo8Z6gk/YUIDhQQgeSzNnBg/fIT5DroMRckZeAGfKeNRDcem5ANvIiuwPmDGQ9FyTo9R7NoNowvvcKeJ/rizz6tz5Ae/rzc66nyf73nNG54b2/wZzzHJAx5WY9c09WOgBrWfU/ly25Ifrwcw/2gH7Zk+wjBR3Zn54n720HwDqo7/2HtqvInmPleEw7WH3btgd+Xtt/se2H+g9kzvjI1DH2H5ir55s6o1d022LK4HnuS7c3zNPrz/yUyOAn74G+adtbb2T3ecHaGSOyBUnKtMHYEqX9R+RStm848gvicCmrIMLh3n0SSNphcWLqeW7Snj5Nj6d0gOl63tGr6zqIUXKxoDBPt3XJHHNNzBHmXCHrS+mg18zxKXvrXx14q0C9YvV9ej8osw/tsy5l6yLRzL2g9H7M77Mq85KQ/Tg1/5TT3w7m/p8KJr0W9pnx0WHPznre7OWE/i1/6irHZfrYtOfH9t8tH8tcGbM1N+OZq/0la8g7hXZk5J3nlc59nnVBV5gywvTXPfZ8NfQ83ba3Xpj666tyDv5FRh4LExmRExDEV8GauqcM4lw2+oJxFOaFSuSxwVcmJBldjy9T99gwx2oedLnF/CJPRZJj/x0ZuSYmMiIn6N+KNlsXkltxxITgqZM/eXngJ6uEf/6C4lb+tHWeoMsRfzEhci4kL0lc/K+WybUwkRHZgYvF6rdF1D9VIpGD/4iXnq1LnMhjga+sfDW2yOXpVpeozDX/QkS9v5EWEbkcExmRM+Dy0cUL+flwQcu++RtneQrw1/ZfylORX450OeJfV0VE7gETGRERERERORwmMiIiIiIicjhMZERERERE5HCYyIiIiIiIyOEwkRERERERkcNhIiMiIiIiIofDREZERERERA6HiYyIiIiIiBwOExkRERERETkcJjIiIiIicve8ffv206tXr35VXr9+/en9+/efn/kJPL958+bzc8Z9/Pjx87s8H0xkREREROTuISH58OHDl7ffYSLzcjGREREREZG7x0RGJiYyd0yc8jk4HgcPa1kdQPI8IbAQPESeM9g4tn5NuHzlAnYNri1P5KkwkZGJicyZ4AB75RqBDAd79+7d5+c4JEXH+x29L5QZnLt9dYlmL9N+7cvH15KDtkvTuqfkEjXru6z24RTY4dfIik4PmVueF9OuV5eQbn/pcKaxD9dKPK4tT+Qp4TwxkZHGqHEBcZKVI1wjSHB5TCIDe/O9VDistvYj+xX4Jn2RTiKQQ5C9vodkJnpNG8p62iYgSUbDmnptoS+Rl9hR71tAv1UA2YK9XcmRl8O01dhp2yLvuXhMH36p4GvXiCnh2vJEngpiyioOmci8XIwYFxAneQxHyGXWRGYb9mPvYpyDLMxLE2PneNp7zFOADluXjFwEW8dLEhlI27lJ20oGe3hp0mciI6sLdNsptjzbsZs+B18iq337Gq4tT14m+G7Klj11nwm+vdUGiVV7EFNWMQrZuTMlXvIcPRnHu/ep54eJzAXESaYjzMtagkaccpZAH97/4A/+4Fd9GNvzpS8lUM87/eKkfUFI/66HPbmtc9bVh0/qMjclsnsspfdpXr5PrW1F69GyIXPP+hxuQHueA+uZ3y9cuk8h4yiM2yP7MvVqaGcdYe4lRJ98iwk6nppnD8Zt7VNgn5iDgo7o3GOmTSKzx6QO+Jk66P2GU7rIfTDte9oRNkKfhvctv4m9IKftKXaf9/YXmHZ2KbFH5CKrdZ52ju6UnnPaa9v3aq2R0SBjS96K7ruSh97pM/drb73tixR5GbSNxLanTVGH7UBsKMQOYWWPcI49IWcV56YNy8vBU+gC4pg4ceC5HZLnODgFp6Mk6PZYoC3Q3gGjg0kHavrkIKEwT/rSj/Z26sxNn/SjTLnRGeZa6Zu2QJ+MT/9A3+iQ+dO+p0Ovv0GP6MKe0bf3bs4fkE+/7FfmCrRFz2ZPx719mu/0ixzaJmlP/xWzT/azQT/q5vpC2nvPLgEdtmTD3N/omPlW+5J9z9j57VtX2kPLlfuHb8U3W3036qZfrOwbYicUbCf2gi3FRyD9Ine+Rz7lHDti/JatUt9yogf1GTNtf+ULvFOiY9YUeM6cU4cVLSvztbzeP8g6YG+9yEobILPf5XnCuR57DdhEbAZ4bxuDtrN+nmOBsXsxJuBrq37a4cvl19FCNklAmGU6L+/UT3C0DpzIa4dkTBwdMl/3QXZkJMjMYEwdYxvmjqNvye110NZ95jv0vH1IQeYI8+A6tbZTZO1Z55wvZM/Tv+cD2rIvk4fsE/JW7TMIBObeawfkdZ9VEJh6TNJ+7v42zLu1R2H17bL3cMoeVmtqebRl/fx8yDrk6eD7UaYdURcfDitbCHx72ugTVv27z+ps4H3Ou0XmDPhSz992DvhCrzPj45v0PXVG0J4+1M99m3M0Uz60vNV+RAfWtbdeZGQdEFldJy8Dvn3bIM/tF8B77K7b+dk2xvscuwX2vbK3LX+Q588vTzPZJYd2Bxye94JGM513XsZoa2dezdeyE3DoFxKQpqP33KfkwkoOB0V0ZmzrOvWYzLWfo8MpkBl9Im8SnbNXc19o2zoAH7JPU97WvIG+c44J83WfuZcw9ZikPft1CczX33oFsuf3b3tpsuZeQ/YpMvjZa8keUPb2Su6LfNd+bv/obx5W9h2mncCqP++xWfry3naDDqdsulnZbJh2Ps+IqfM5Z0TLiP6rsmK1tpY35w+9Dp5Xc44O0JIAABBeSURBVPTcXeY3lOcPttJ2trKD9k36xwbbHrH7PJ8DclZxbmXT8jJYn4SyZBUQIYd/aCedxNmRMcfR1gfDar6WPQMk5MI6Hb0PlFNyYSUn4wB53UZ96zHp+eEcHU6BjOxh9G150HqtdGS++R3COTrOfco3yXvWPfUKzL3Sq+GA7kN67iVMPSbnzLMF692SG1ay+2IEuRyxF6s10Dd723sc8j0oW99M7gu+I986xD9iK9hEt0PbwWSOh5Ut8d5ye574yqW+kHlWstse0b31nzrnfe+MaBmMY45zWe1py0PXlby5jtV6W2952UwbwjamT8WGAmNiU6Gfsb+078WyVdvKpuVl8MvTX3bBSXGwDjhNAkUHjUmCCA4+nRHZHYBW87XsGSAhdR2QgPeMOyUX0I0+Wzp2X5hBEBib8fNAO0eHUyCz144O/Z41ZA70mzrS3mOah+4Tc1CX0m2TfK+tQzg6tI5zL2GlR0jbQw569Dtn3Or7dx0/e9/21sBap6x+X30XuU+wAb51gx2kjp/T51djQvzllD/w3jJiMylb8lcwZ/ef803bn2fESmf6tz7Tb1tG/GLa+/SRMOeHrov+c07q0HFvvatvg5xemzx/sL1pj7GfZvrKBJuMHcZHYW8cc0/bBWxTXibbFia/Io42HRhwojjxKpCEBKWV0yUgJpCs5mvZ1NO+dXikPv3mgbElF6LnPDASgGcwi8zWpQPtPJjO0WEPxs++kRlobz3nPtC2N985Os59Qubcm1Nknq319D7C3Es49b1m/3M5dz3RCZ0h+lCyZ23zvK90og/1cx0r2XL/xP7iQ/HB9qn+tvxcnY0h49MfVv7Ae+wWe5m+dQmZMzY5dcy5HWLvYep8jk9NGTzPfen2hnl6/ZmfEhn85D3QN217643s9k/Wzhh5GWArseUGG5l2jW1s2Sl9u3/3zRnfdhbot6qPjcrLw9vAmeBUpwokQFC2HAtnnQ4P1GVcnlNw3JY9y5Q3xyfQnJLLc4JVSh9aCXKrwDVlZxwHT9d///33v3hf6TCZOiFzResw9wSYK+1bByw8dJ9mXcqWvs1qHPOG7H0X5LZeq5LvEFrOKZC9+tYr+juzt4zNunvfKd2314iujJvQf2uM3Df93SjTntoeV98+TBvCR6fslZ2t/IaSuTJma27GMxc2nbFZQ94psfm887zS+dQZMWWEnp+yR59fyGAspel5um1vvTD1n+eLPF/41tjGithMg42t+uMXsy/2n7r4DT8n9FvVt6/Iy8JE5gnAsVeOeBTmASS/g++6+rbnfnP65IKwFTCuBXPd2yWEC1MudCLXYusy1fX4wjk++rUwx2qeo8cFed7gH/Nsnud1J7b83Eou6Dehf+rxhVUfMJGRiYnME3DkRIAD5LEv2Edm6zDlkO7fap4CG+Egf8zDmYBwiU63wMucXBt8aWXn1OXSBbc6l691RojciiQWq9I2y3Pq95KYrTOemJTx5/TpYiLzcjGRuTEEqyMnAluXAvndX1Pm96W+f2t1CX1oX2vfE2z6EncvGIzk2mDrqyQltha/3bo4XZPHOCNERF4yJjI3oH9LccRg1b+NuUWwPzL9rVNu9Zveo8L+ZK9EHgOSlvbJp7Q1zwgRkevhzUFERERERA6HiYyIiIiIiBwOExkRERERETkcJjIiIiIiInI4TGRERERERORwmMiIiIiIiMjhMJEREREREZHDYSIjIiIiIiKHw0RGREREREQOh4mMiIiIiIgcDhMZERERERE5HCYyIiIiInL3vH379tOrV69+VV6/fv3p/fv3n5/5CTy/efPm83PGffz48fO7PB9MZERERETk7iEh+fDhw5e332Ei83IxkRERERGRu8dERiYmMk8EzhUH+1pWsnBqHFeeNzm4PZxFngbOWc7ba3LN+ADXlifyVJjIyMRE5kxwgK1y7SB2CTgpOjxWkJprnYdAtz012Yu9wgGXA63L999//6u6WR4Ke8b4U4klul1iSzm0KR7Ocq/ERilb51T3eelc+0y/tjyRp8RERiZGjQuIk7Qj5JL6lA6Coz5GkHr37t3nsgVrzoGRvXlK2IM+4NCn9Z/rme3AYTgTDmTSd9X/FPTP2L1EJnZ0aVK8skmRe6HtOTY+zyrq7ukcuQeufaZfW57IU2EiIxMjxgVsXRpz0b30knstHitIsaYtWOuck4PkqfYA5tzzm/Dd+n31zVaJTKCNMatD9BR7coF29pOfl7BlkyJPDX4y7RJ/63OF93s7R+6Ba5/p15YnMmNh7kGzdEzjOfUrImMPExmZmMhcwCWJzHTqeYmd/QGH2+ufMi+7M0ihH/3izP2eiwRldRiE7re6VKwuG7xvBcvsBz9zoFDQLfpR5vjex7nuUzBmpXtYtTPH3PsQXbbWuMeeXHTg29B+zhp7/1Y2mTZK5PWYnoNn6rIPeY8+ItcEu5r2N32Q9y0fO3WW5b3ngD5jKJcSP0Muslpn6tpX0J3Sc05fijzKaq2R0bQPn+Ob3XclD73TZ+7X3nr7TKbIywNb4tvH72Blk9hNbCd2CCt7hHPsCTk9b5g2LC8HT6ELyOHOwd4kIKQ+AYz+kICbdp4pMxjmPYEi42nLITHboA+FzJ0+/d5zbB0kIQdF5qM0kd9knZOWgQ69LnTgJ6TfnDvv7EHk9N5tcarfqr33egXtjLuULbmsLfX8zF5sQZ/+btmP2FbPk/3LflM/dWdc9oD2vb4iXwt21T7X9hloX9neqbMsY9Ivcud75FPiK3swPn4ZWZmb+pYTPajPGOaljrGr94yhRMesKfCcOacOK1pW5mt5vX+QdcDeepGVNkBmv8vzB1vgu2MXic3QzwHbiJ3zHDviZ+wtIHMlY4Kvbc0lLxNvKheQgDBLBwjI4R9n42e/A+8dHHhv2un7GXosMH/rkPkTyGYwAp4vcfw5R8sPyJzrCNmDHsOB1DpMvaeOc19PQd9e82TVznx7lxvaGXcpW3J7T+d+TLKH7EOI7aSO8b2mucb5znPGMn+3tW4i12DaN/Z4yTmSM2Da8OzffeIjDe9z3i0yZ8APe/7p2/hNrzPjc27Rt31r5de0pw/1c9/mHM2UDy1vtR/RgXXtrRcZWQdEVtfJ8wXbiA2c+u7TbnmOHfGzbYz3tJ0C+17Nu+UP8vz55Wkmu+TQ7oADOBD1K0fE6WibTt/9+XmOE2b+OVcHKUggSqCe78B46s4lMsKUB3syVwcfe9Prnnqu5K3m3YK+vU+TVTv6oNcW+daXspLLe9vS3I8Jus529gJ9Wg6kfq5xztE6bY0RuQbT3gFbm/6M7VG/Yp4RsOrfNrzyEXzgEhunPzLmPEBb+9Gp83j6YNr7bGwZ7ZezrFitreXN+UOvg+fVHD13l/kN5XkSu1nF8wk22HaIbcUG2x6RkedzQM5q3pVNy8tgfRLKklVADDn404az5YBfOT3vcXJ+7jlh5k2Q6bHQhwLMwDnfgfHUXUL3R9/WAfqgmqz2gP697pWe/Z59WB1iK+g7dWxW7eiTfZ5kDZccumElF1lbpfcgoOu0k+xJ7C7vW7aSPWYtlNX+0J4icg2ws5VNX3qOnHuW8d5ye5748UqfPTLPSnb79rnncc6xyI0PQ8tg3PT7PVZ72vLQdSVvrmO13tZbXhbYQL59fGjPFrCntmmgLjYV+hn7S/uWbPqs2lY2LS8DbyoXQEDBwaZzAkEibekXVk7Pe4LDllzaqdsbCx2kIGNm4Mw7MJ66c0FGz8H4fgcOktarWe3BDKh7eqZ02ynov6UPrNrRp4N5k0O413Aue3LD3I/Jyk66Lvu3ZysQe2G+ljX1W40VuRRsdMuOqL/kHNk7I5ppu/GTlC35K5iz+8/5pm/Hv8JKZ/q3PvNMaRk5O9tXYfprmPND10X/OSd16Li33tW3QU6vTZ4ffOP+7rHJaUOB+mmDK+gTGfFRaJubYPerefdipzxv1pYiS+Joq4BC/QwU6Zf3dj7e+2DACdsRE0wYQ98Eirz32A5SwNgeM98hOp0Lfee6WyY/9w6S6N17wL7NNU+ZW8H6HJDV+zRZtaPPnDO6t26XspI7mfuxAh26D989uv3mN7/5hY4rWwHaqW+bAebvOuZ56HpFYOXD+HnXtc3yc88Hzj3L2u7xg2nrl5A5c3ZNHXnu9TBXzzd1Rq/pk5Mpg+e5L93eME+vP/NTIoOfvAf6pm1vvZGdNmDtjJHnC984NjTLyg7PsfHZhzkiK7Gr7SzQb1U//UNeDiYyZzKdd5YOZDDb8jz/D/I9ruvbKXHu1CegzeeMyQGQ0nNTODhm3SoIdTtlxSpArkjwS+G910SZeqPnrEvJYbfFXB+l17hqP/V/9l/NmTWwni3m2ilboNfePkLvOSVryfp6X3luW2mon3ojq/ecd5GHgg/HlmZpfzz3HFmdEdOXV+ff9JmUzJUxW3Mznrnat6J/3intbxSeVzqvzgRK/G3KCD0/ZY/ee2QwdnUGpE+37a0Xpv575588T2LX/FyBbbXNTBg37RH7T92efPqt6ttX5GVhIiN3CwfhKkhSd0/BMxeQI5ELnshLgIv5hMtQ13OmrC5I14Y5VvOgyy3mF/lasNOtRIO6maRMGDvB/1KfRHyFiYxMTGTkbtk6mDjEVgfZU4Aeq0vSvXMq0Ig8F7D1VdI+f1FyK5/YOtfQxV8uyBEg7u39xWTvF41b44CxtJ/bp4uJzMvFREbuEgI6hxOHVkP9vVzC0eOICQGJ116gEXlOcI6s/DQXn71L2bXJXPOXH9TPs05ERE5jIiN3DUG/i791eRi5QFGO+Bckka+Bc6PPEcpTkV/SdDniL0RERO4BExkRERERETkcJjIiIiIiInI4TGRERERERORwmMiIiIiIiMjhMJEREREREZHDYSIjIiIiIiKHw0RGREREREQOh4mMiIiIiIgcDhMZERERERE5HC8+kfmjP/qjX/1fli0Wi+UW5Y//+I+/nEQiIiJyKS8+kfnTP/3Tz5cJi8ViuXX5sz/7sy8nkYiIiFyK/2iZiIiIiIgcDhMZERERERE5HCYyIiIiIiJyOExkRERERETkcJjIiIiIiIjI4TCRERERERGRw2EiIyIiIiIih8NERkREREREDoeJjIiIiIiIHA4TGRERERERORwmMiIiIiIicjhMZERERERE5HCYyIiIiIiIyOEwkRERERERkcNhIiMiIiIiIofDREZERERERA6HiYyIiIiIiBwOExkRERERETkcJjIiIiIiInI4TGRERERERORwmMiIiIiIiMjhMJEREREREZHDYSIjIiIiIiKHw0RGREREREQOh4mMiIiIiIgcDhMZERERERE5HCYyIiIiIiJyOExkRERERETkcJjIiIiIiIjI4TCRERERERGRw2EiIyIiIiIih8NERkREREREDoeJjIiIiIiIHA4TGRERERERORwmMiIiIiIicjhMZERERERE5HCYyIiIiIiIyOEwkRERERERkcNhIiMiIiIiIofDREZERERERA6HiYyIiIiIiBwOExkRERERETkcJjIiIiIiInI4TGRERERERORwmMiIiIiIiMjhMJEREREREZHDYSIjIiIiIiKHw0RGREREREQOxqdP/z88IaGNqDCjhgAAAABJRU5ErkJggg==" /></p><p dir="ltr">The following medical product/combinations did not have a clinically significant effect on the<br />AUC ratio of Rosuvastatin at coadministration: Aleglitazar 0.3 mg 7 days dosing; Fenofibrate 67<br />mg 7 days TID dosing; Fluconazole 200mg 11 days OD dosing; Fosamprenavir 700 mg/ritonavir<br />100 mg 8 days BID dosing; Ketoconazole 200 mg 7 days BID dosing;<br />Rifampin 450 mg 7 days OD dosing; Silymarin 140 mg 5 days TID dosing.<br />Effect of rosuvastatin on co-administered medicinal products<br />Vitamin K antagonists: As with other HMG-CoA reductase inhibitors, the initiation of treatment<br />or dosage up-titration of rosuvastatin in patients treated concomitantly with vitamin K antagonists<br />(e.g. warfarin or another coumarin anticoagulant) may result in an increase in International<br />Normalised Ratio (INR). Discontinuation or down-titration of rosuvastatin may result in a decrease<br />in INR. In such situations, appropriate monitoring of INR is desirable.</p><p dir="ltr">Oral contraceptive/hormone replacement therapy (HRT): Concomitant use of rosuvastatin and<br />an oral contraceptive resulted in an increase in ethinylestradiol and norgestrel AUC of 26% and<br />34%, respectively. These increased plasma levels should be considered when selecting oral<br />contraceptive doses. There are no pharmacokinetic data available in subjects taking concomitant<br />rosuvastatin and HRT; therefore, a similar effect cannot be excluded. However, the combination<br />has been extensively used in women in clinical trials and was well tolerated.<br />Other medicinal products:<br />Digoxin: Based on data from specific interaction studies no clinically relevant interaction with<br />digoxin is expected.<br />Fusidic Acid: Interaction studies with rosuvastatin and fusidic acid have not been conducted. The<br />risk of myopathy, including rhabdomyolysis may be increased by the concomitant administration<br />of systemic fusidic acid with statins. The mechanism of this interaction (whether it is<br />pharmacodynamic or pharmacokinetic, or both) is yet unknown. There have been reports of<br />rhabdomyolysis (including some fatalities) in patients receiving this combination.<br />If treatment with systemic fusidic acid is necessary, Rosuvastatin treatment should be discontinued<br />throughout the duration of the fusidic acid treatment. Also see section 4.4.<br />Paediatric population<br />Interaction studies have only been performed in adults. The extent of interactions in the paediatric<br />population is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Rosuvastatin is contraindicated in pregnancy and lactation.<br />Women of child bearing potential should use appropriate contraceptive measures.<br />Since cholesterol and other products of cholesterol biosynthesis are essential for the development<br />of the foetus, the potential risk from inhibition of HMG-CoA reductase outweighs the advantage of<br />treatment during pregnancy. Animal studies provide limited evidence of reproductive toxicity (see<br />Section 5.3). If a patient becomes pregnant during use of this product, treatment should be<br />discontinued immediately.<br />Rosuvastatin is excreted in the milk of rats. There are no data with respect to excretion in milk in<br />humans. (See Section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Studies to determine the effect of Rosuvastatin on the ability to drive and use machines have not<br />been conducted.<br />However, based on its pharmacodynamic properties, Rosuvastatin is unlikely to affect this ability.<br />When driving vehicles or operating machines, it should be taken into account that dizziness may<br />occur during treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The adverse reactions seen with rosuvastatin are generally mild and transient. In controlled<br />clinical trials, less than 4% of rosuvastatin-treated patients were withdrawn due to adverse<br />reactions.<br />Tabulated list of adverse reactions<br />Based on data from clinical studies and extensive post-marketing experience, the following table<br />presents the adverse reaction profile for rosuvastatin. Adverse reactions listed below are classified<br />according to frequency and system organ class (SOC).<br />The frequencies of adverse reactions are ranked according to the following convention: Common<br />(&ge;1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to &lt;1/100); Rare (&ge;1/10,000 to &lt;1/1000); Very rare<br />(&lt;1/10,000); Not known (cannot be estimated from the available data).</p><p dir="ltr"><strong>Table 2. Adverse reactions based on data from clinical studies and post-marketing experience</strong></p><p dir="ltr">Common possible side effects: may affect up to 1 in 10 people<br />&bull; Headache<br />&bull; Stomach pain<br />&bull; Constipation<br />&bull; Feeling sick<br />&bull; Muscle pain<br />&bull; Feeling weak<br />&bull; Dizziness<br />&bull; An increase in the amount of protein in the urine &ndash; this usually returns to normal on its own without<br />having to stop taking your Rosuvastatin tablets (only Rosuvastatin 40 mg)<br />&bull; Diabetes. This is more likely if you have high levels of sugars and fats in your blood, are<br />overweight and have high blood pressure. Your doctor will monitor you while you are taking this<br />medicine.<br />Uncommon possible side effects: may affect up to 1 in 100 people<br />&bull; Rash, itching or other skin reactions<br />&bull; An increase in the amount of protein in the urine &ndash; this usually returns to normal on its own without<br />having to stop taking your Rosuvastatin tablets (only Rosuvastatin 5 mg, 10 mg and 20 mg).</p><p dir="ltr">Rare possible side effects: may affect up to 1 in 1,000 people<br />&bull; Severe allergic reaction &ndash; signs include swelling of the face, lips, tongue and/ or throat, difficulty in<br />swallowing and breathing, a severe itching of the skin (with raised lumps). If you think you are<br />having an allergic reaction, then stop taking Rosgan and seek medical help immediately<br />&bull; Muscle damage in adults &ndash; as a precaution, stop taking Rosgan and talk to your doctor<br />immediately if you have any unusual aches or pains in your muscles which go on for longer<br />than expected<br />&bull; A severe stomach pain (inflamed pancreas)<br />&bull; Increase in liver enzymes in the blood<br />&bull; Bleeding or bruising more easily than normal due to low level of blood platelets<br />&bull; Lupus-like disease syndrome (including rash, joint disorders and effects on blood cells).<br />Very rare possible side effects: may affect up to 1 in 10,000 people<br />&bull; Jaundice (yellowing of the skin and eyes)<br />&bull; Hepatitis (an inflamed liver)<br />&bull; Traces of blood in your urine<br />&bull; Damage to the nerves of your legs and arms (such as numbness)<br />&bull; Joint pain<br />&bull; Memory loss<br />&bull; Breast enlargement in men (gynaecomastia)<br />Side effects of not known frequency may include:<br />&bull; Diarrhoea (loose stools)<br />&bull; Cough<br />&bull; Shortness of breath<br />&bull; Oedema (swelling)<br />&bull; Sleep disturbances, including insomnia and nightmares<br />&bull; Sexual difficulties<br />&bull; Depression<br />&bull; Breathing problems, including persistent cough and/or shortness of breath or fever<br />&bull; Tendon injury<br />&bull; Muscle weakness that is constant</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">There is no specific treatment in the event of overdose. In the event of overdose, the patient should<br />be treated symptomatically and supportive measures instituted as required. Liver function and CK<br />levels should be monitored.<br />Haemodialysis is unlikely to be of benefit.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: HMG-CoA reductase inhibitors.<br />ATC Code: C10A A07<br />Mechanism of action<br />Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting<br />enzyme that converts 3- hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor for<br />cholesterol. The primary site of action of rosuvastatin is the liver, the target organ for cholesterol<br />lowering.<br />Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake<br />and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the total<br />number of VLDL and LDL particles.</p><p dir="ltr">Pharmacodynamic effects<br />Rosuvastatin reduces elevated LDL-cholesterol, total cholesterol and triglycerides and increases<br />HDL-cholesterol. It also lowers ApoB, non-HDL-C, VLDL-C, VLDL-TG and increases ApoA-I<br />(see Table3). Rosuvastatin also lowers the LDL-C/HDLC, total C/HDL-C and nonHDL-C/HDL-C<br />and the ApoB/ApoA-I ratios.<br />Table 3 Dose response in patients with primary hypercholesterolaemia (type IIa and IIb)<br />(adjusted mean percent change from baseline)</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p style="margin-right:40px"><strong>Dose</strong></p></td><td><p style="margin-right:40px"><strong>N</strong></p></td><td><p style="margin-right:40px"><strong>LDL-C</strong></p></td><td><p style="margin-right:40px"><strong>Tota</strong><strong>l-C</strong></p></td><td><p style="margin-right:40px"><strong>HD</strong><strong>L</strong><strong>-</strong><strong>C</strong></p></td><td><p style="margin-right:40px"><strong>TG</strong></p></td><td><p style="margin-right:40px"><strong>nonHDL-C</strong></p></td><td><p style="margin-right:40px"><strong>ApoB</strong></p></td><td><p style="margin-right:40px"><strong>ApoA-I</strong></p></td></tr><tr><td><p style="margin-right:40px">Placebo</p></td><td><p style="margin-right:40px">13</p></td><td><p style="margin-right:40px">-7</p></td><td><p style="margin-right:40px">-5</p></td><td><p style="margin-right:40px">3</p></td><td><p style="margin-right:40px">-3</p></td><td><p style="margin-right:40px">-7</p></td><td><p style="margin-right:40px">-3</p></td><td><p style="margin-right:40px">0</p></td></tr><tr><td><p style="margin-right:40px">5</p></td><td><p style="margin-right:40px">17</p></td><td><p style="margin-right:40px">-45</p></td><td><p style="margin-right:40px">-33</p></td><td><p style="margin-right:40px">13</p></td><td><p style="margin-right:40px">-35</p></td><td><p style="margin-right:40px">-44</p></td><td><p style="margin-right:40px">-38</p></td><td><p style="margin-right:40px">4</p></td></tr><tr><td><p style="margin-right:40px">10</p></td><td><p style="margin-right:40px">17</p></td><td><p style="margin-right:40px">-52</p></td><td><p style="margin-right:40px">-36</p></td><td><p style="margin-right:40px">14</p></td><td><p style="margin-right:40px">-10</p></td><td><p style="margin-right:40px">&nbsp;-48</p></td><td><p style="margin-right:40px">-42</p></td><td><p style="margin-right:40px">4</p></td></tr><tr><td><p style="margin-right:40px">20</p></td><td><p style="margin-right:40px">17</p></td><td><p style="margin-right:40px">-55</p></td><td><p style="margin-right:40px">-40</p></td><td><p style="margin-right:40px">8</p></td><td><p style="margin-right:40px">-23</p></td><td><p style="margin-right:40px">-51</p></td><td><p style="margin-right:40px">-46</p></td><td><p style="margin-right:40px">5</p></td></tr><tr><td><p style="margin-right:40px">40</p></td><td><p style="margin-right:40px">18</p></td><td><p style="margin-right:40px">-63</p></td><td><p style="margin-right:40px">-46</p></td><td><p style="margin-right:40px">10</p></td><td><p style="margin-right:40px">-28</p></td><td><p style="margin-right:40px">-60</p></td><td><p style="margin-right:40px">-54</p></td><td><p style="margin-right:40px">0</p><p style="margin-right:40px">&nbsp;</p></td></tr></tbody></table><p dir="ltr"><br />A therapeutic effect is obtained within 1 week following treatment initiation and 90% of<br />maximum response is achieved in 2 weeks. The maximum response is usually achieved by 4<br />weeks and is maintained after that.</p><p dir="ltr">Clinical efficacy and safety<br />Rosuvastatin is effective in adults with hypercholesterolaemia, with and without<br />hypertriglyceridaemia, regardless of race, sex, or age and in special populations such as diabetics,<br />or patients with familial hypercholesterolaemia.<br />From pooled phase III data, rosuvastatin has been shown to be effective at treating the majority of<br />patients with type IIa and IIb hypercholesterolaemia (mean baseline LDL-C about 4.8 mmol/l) to<br />recognised European Atherosclerosis Society (EAS; 1998) guideline targets; about 80% of<br />patients treated with 10 mg reached the EAS targets for LDL-C levels (&lt;3 mmol/l).<br />In a large study, 435 patients with heterozygous familial hypercholesterolaemia were given<br />rosuvastatin from 20 mg to 80 mg in a force-titration design. All doses showed a beneficial effect<br />on lipid parameters and treatment to target goals.<br />Following titration to a daily dose of 40 mg (12 weeks of treatment), LDL-C was reduced by<br />53%. Thirty three percent (33%) of patients reached EAS guidelines for LDL-C levels (&lt;3<br />mmol/l).<br />In a force-titration, open label trial, 42 patients (including 8 paediatric patients) with homozygous<br />familial hypercholesterolaemia were evaluated for their response to rosuvastatin 20 - 40 mg. In<br />the overall population, the mean LDL-C reduction was 22%.</p><p dir="ltr">In clinical studies with a limited number of patients, rosuvastatin has been shown to have additive<br />efficacy in lowering triglycerides when used in combination with fenofibrate and in increasing<br />HDL-C levels when used in combination with niacin (see Section 4.4).<br />In a multi-centre, double-blind, placebo-controlled clinical study (METEOR), 984 patients<br />between 45 and 70 years of age and at low risk for coronary heart disease (defined as<br />Framingham risk &lt;10% over 10 years), with a mean LDL-C of 4.0 mmol/l (154.5 mg/dL), but<br />with subclinical atherosclerosis (detected by Carotid Intima Media Thickness) were randomised<br />to 40 mg rosuvastatin once daily or placebo for 2 years. Rosuvastatin significantly slowed the<br />rate of progression of the maximum CIMT for the 12 carotid artery sites compared to placebo by<br />-0.0145 mm/year [95% confidence interval -0.0196, -0.0093; p&lt;0.0001]. The change from<br />baseline was -0.0014 mm/year (-0.12%/year (nonsignificant)) for rosuvastatin compared to a<br />progression of +0.0131 mm/year (1.12%/year (p&lt;0.0001)) for placebo. No direct correlation<br />between CIMT decrease and reduction of the risk of cardiovascular events has yet been<br />demonstrated.<br />The population studied in METEOR is low risk for coronary heart disease and does not represent<br />the target population of rosuvastatin 40mg. The 40mg dose should only be prescribed in patients<br />with severe hypercholesterolaemia at high cardiovascular risk (see Section 4.2).<br />In the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating<br />Rosuvastatin (JUPITER) study, the effect of rosuvastatin on the occurrence of major<br />atherosclerotic cardiovascular disease events was assessed in 17,802 men (&ge;50 years) and women<br />(&ge;60 years).<br />Study participants were randomly assigned to placebo (n=8901) or rosuvastatin 20 mg once daily<br />(n=8901) and were followed for a mean duration of 2 years.<br />LDL-cholesterol concentration was reduced by 45% (p&lt;0.001) in the rosuvastatin group<br />compared to the placebo group.<br />In a post-hoc analysis of a high-risk subgroup of subjects with a baseline Framingham risk<br />score&gt;20% (1558 subjects) there was a significant reduction in the combined end-point of<br />cardiovascular death, stroke and myocardial infarction (p=0.028) on rosuvastatin treatment versus<br />placebo. The absolute risk reduction in the event rate per 1000 patient-years was 8.8. Total<br />mortality was unchanged in this high risk group (p=0.193). In a post-hoc analysis of a high-risk<br />subgroup of subjects (9302 subjects total) with a baseline SCORE risk &ge;5% (extrapolated to<br />include subjects above 65 yrs) there was a significant reduction in the combined end-point of<br />cardiovascular death, stroke and myocardial infarction (p=0.0003) on rosuvastatin treatment<br />versus placebo. The absolute risk reduction in the event rate was 5.1 per 1000 patient-years. Total<br />mortality was unchanged in this high risk group (p=0.076).</p><p dir="ltr">In the JUPITER trial, there were 6.6% of rosuvastatin and 6.2% of placebo subjects who<br />discontinued use of study medication due to an adverse event. The most common adverse events<br />that led to treatment discontinuation were: myalgia (0.3% rosuvastatin, 0.2% placebo), abdominal<br />pain (0.03% rosuvastatin, 0.02% placebo) and rash (0.02% rosuvastatin, 0.03% placebo). The<br />most common adverse events at a rate greater than or equal to placebo were urinary tract<br />infection (8.7% rosuvastatin, 8.6% placebo), nasopharyngitis (7.6% rosuvastatin, 7.2% placebo),<br />back pain (7.6% rosuvastatin, 6.9% placebo) and myalgia (7.6% rosuvastatin, 6.6% placebo).<br />Paediatric population<br />In a double-blind, randomized, multi-centre, placebo-controlled, 12-week study (n=176, 97 male<br />and 79 female) followed by a 40-week (n=173, 96 male and 77 female), open-label, rosuvastatin<br />dose-titration phase, patients 10 to17 years of age (Tanner stage II-V, females at least 1 year postmenarche)<br />with heterozygous familial hypercholesterolaemia received rosuvastatin 5, 10 or 20<br />mg or placebo daily for 12 weeks and then all received rosuvastatin daily for 40 weeks. At study<br />entry, approximately 30% of the patients were 10 to13 years and approximately 17%, 18%, 40%,<br />and 25% were Tanner stage II, III, IV, and V, respectively.<br />LDL-C was reduced 38.3%, 44.6%, and 50.0% by rosuvastatin 5, 10 and 20 mg, respectively,<br />compared to 0.7% for placebo.<br />At the end of the 40-week, open-label, titration to goal, dosing up to a maximum of 20 mg once<br />daily, 70 of 173 patients (40.5%) had achieved the LDL-C goal of less than 2.8 mmol/l.<br />After 52 weeks of study treatment, no effect on growth, weight, BMI or sexual maturation was<br />detected (see Section 4.4). This trial (n=176) was not suited for comparison of rare adverse drug<br />events.<br />Rosuvastatin was also studied in a 2-year open-label, titration-to-goal study in 198 children with<br />heterozygous familial hypercholesterolaemia aged 6 to 17 years (88 male and 110 female, Tanner<br />stage &lt;II-V). The starting dose for all patients was 5 mg rosuvastatin once daily. Patients aged 6<br />to 9 years (n=64) could titrate to a maximum dose of 10 mg once daily and patients aged 10 to 17<br />years (n=134) to a maximum dose of 20 mg once daily.<br />After 24 months of treatment with rosuvastatin, the LS mean percent reduction from the baseline<br />value in LDL-C was -43% (Baseline: 236 mg/dL, Month 24: 133 mg/dL). For each age group, the<br />LS mean percent reductions from baseline values in LDL-C were -43% (Baseline: 234 mg/dL,<br />Month 24: 124 mg/dL), -45% (Baseline: 234 mg/dL, Month 24: 124 mg/dL ), and -35%<br />(Baseline: 241 mg/dL, Month 24: 153 mg/dL) in the 6 to &lt;10, 10 to &lt;14, and 14 to &lt;18 age<br />groups, respectively.</p><p dir="ltr">Rosuvastatin 5 mg, 10 mg, and 20 mg also achieved statistically significant mean changes from<br />baseline for the following secondary lipid and lipoprotein variables: HDL-C, TC, non-HDLC,<br />LDL-C/HDL-C, TC/HDL-C, TG/HDL-C, non-HDL, C/HDL-C, ApoB, ApoB/ApoA-1. These<br />changes were each in the direction of improved lipid responses and were sustained over 2 years.<br />No effect on growth, weight, BMI or sexual maturation was detected after 24 months of treatment<br />(see Section 4.4).<br />Rosuvastatin was studied in a randomised, double-blind, placebo-controlled, multicenter, crossover<br />study with 20 mg once daily versus placebo in 14 children and adolescents (aged from 6 to<br />17 years) with homozygous familial hypercholesterolaemia. The study included an active 4-week<br />dietary lead-in phase during which patients were treated with rosuvastatin 10 mg, a cross-over<br />phase that consisted of a 6-week treatment period with rosuvastatin 20 mg preceded or followed<br />by a 6-week placebo treatment period, and a 12-week maintenance phase during which all<br />patients were treated with rosuvastatin 20 mg. Patients who entered the study on ezetimibe or<br />apheresis therapy continued the treatment throughout the entire study.<br />A statistically significant (p=0.005) reduction in LDL-C (22.3%, 85.4 mg/dL or 2.2 mmol/L) was<br />observed following 6 weeks of treatment with rosuvastatin 20 mg versus placebo. Statistically<br />significant reductions in Total-C (20.1%, p=0.003), non-HDL-C (22.9%, p=0.003), and ApoB<br />(17.1%, p=0.024) were observed. Reductions were also seen in TG, LDL-C/HDL-C, Total-<br />C/HDL-C, non-HDL-C/HDL-C, and ApoB/ApoA-1 following 6 weeks of treatment with<br />rosuvastatin 20 mg versus placebo. The reduction in LDL-C after 6 weeks of treatment with<br />rosuvastatin 20 mg following 6 weeks of treatment with placebo was maintained over 12 weeks<br />of continuous therapy. One patient had a further reduction in LDLC (8.0%), Total-C (6.7%) and<br />non-HDL-C (7.4%) following 6 weeks of treatment with 40 mg after up-titration. During an<br />extended open-label treatment in 9 of these patients with 20 mg rosuvastatin for up to 90 weeks,<br />the LDL-C reduction was maintained in the range of -12.1% to -21.3%.<br />In the 7 evaluable children and adolescent patients (aged from 8 to 17 years) from the force<br />titration open-label study with homozygous familial hypercholesterolaemia (see above), the<br />percent reduction in LDL-C (21.0%), Total-C (19.2%), and non-HDL-C (21.0%) from baseline<br />following 6 weeks of treatment with rosuvastatin 20 mg was consistent with that observed in the<br />aforementioned study in children and adolescents with homozygous familial<br />hypercholesterolaemia.<br />The European Medicines Agency has waived the obligation to submit the results of studies with<br />rosuvastatin in all subsets of the paediatric population in the treatment of homozygous familial<br />hypercholesterolaemia, primary combined (mixed) dyslipidaemia and in the (see section 4.2 for<br />information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Absorption<br />Maximum rosuvastatin plasma concentrations are achieved approximately 5 hours after oral<br />administration. The absolute bioavailability is approximately 20%.<br />Distribution<br />Rosuvastatin is taken up extensively by the liver which is the primary site of cholesterol synthesis<br />and LDL-C clearance. The volume of distribution of rosuvastatin is approximately 134 L.<br />Approximately 90% of rosuvastatin is bound to plasma proteins, mainly to albumin.<br />Biotransformation<br />Rosuvastatin undergoes limited metabolism (approximately 10%). In vitro metabolism studies<br />using human hepatocytes indicate that rosuvastatin is a poor substrate for cytochrome P450-based<br />metabolism. CYP2C9 was the principal isoenzyme involved, with 2C19, 3A4 and 2D6 involved to<br />a lesser extent. The main metabolites identified are the Ndesmethyl and lactone metabolites. The<br />N-desmethyl metabolite is approximately 50% less active than Rosuvastatin whereas the lactone<br />form is considered clinically inactive. Rosuvastatin accounts for greater than 90% of the<br />circulating HMG-CoA reductase inhibitor activity.<br />Elimination<br />Approximately 90% of the rosuvastatin dose is excreted unchanged in the faeces (consisting of<br />absorbed and nonabsorbed active substance) and the remaining part is excreted in urine.<br />Approximately 5% is excreted unchanged in urine. The plasma elimination half-life is<br />approximately 19 hours. The elimination half-life does not increase at higher doses. The geometric<br />mean plasma clearance is approximately 50 litres/hour (coefficient of variation 21.7%). As with<br />other HMG-CoA reductase inhibitors, the hepatic uptake of rosuvastatin involves the membrane<br />transporter OATP-C. This transporter is important in the hepatic elimination of rosuvastatin.</p><p dir="ltr">Linearity<br />Systemic exposure of rosuvastatin increases in proportion to dose. There are no changes in<br />pharmacokinetic parameters following multiple daily doses.<br />Special populations<br />Age and sex: There was no clinically relevant effect of age or sex on the pharmacokinetics of<br />rosuvastatin in adults. The exposure in in children and adolescents with heterozygous familial<br />hypercholesterolaemia appears to be similar to or lower than that in adult patients with<br />dyslipidaemia (see &ldquo;Paediatric population&rdquo; below).<br />Race: Pharmacokinetic studies show an approximate 2-fold elevation in median AUC and Cmax<br />in Asian subjects (Japanese, Chinese, Filipino, Vietnamese and Koreans) compared with<br />Caucasians; Asian-Indians show an approximate 1.3-fold elevation in median AUC and Cmax. A<br />population pharmacokinetic analysis revealed no clinically relevant differences in<br />pharmacokinetics between Caucasian and Black groups.<br />Renal insufficiency: In a study in subjects with varying degrees of renal impairment, mild to<br />moderate renal disease had no influence on plasma concentration of rosuvastatin or the Ndesmethyl<br />metabolite. Subjects with severe impairment (CrCl &lt;30 ml/min) had a 3-fold increase<br />in plasma concentration and a 9-fold increase in the N-desmethyl metabolite concentration<br />compared to healthy volunteers. Steady-state plasma concentrations of rosuvastatin in subjects<br />undergoing haemodialysis were approximately 50% greater compared to healthy volunteers.<br />Hepatic insufficiency: In a study with subjects with varying degrees of hepatic impairment there<br />was no evidence of increased exposure to rosuvastatin in subjects with Child-Pugh scores of 7 or<br />below. However, two subjects with Child- Pugh scores of 8 and 9 showed an increase in systemic<br />exposure of at least 2-fold compared to subjects with lower Child-Pugh scores. There is no<br />experience in subjects with Child-Pugh scores above 9.<br />Genetic polymorphisms: Disposition of HMG-CoA reductase inhibitors, including rosuvastatin,<br />involves OATP1B1 and BCRP transporter proteins. In patients with SLCO1B1 (OATP1B1)<br />and/or ABCG2 (BCRP) genetic polymorphisms there is a risk of increased rosuvastatin exposure.<br />Individual polymorphisms of SLCO1B1 c.521CC and ABCG2 c.421AA are associated with a<br />higher rosuvastatin exposure (AUC) compared to the SLCO1B1 c.521TT or ABCG2 c.421CC<br />genotypes. This specific genotyping is not established in clinical practice, but for patients who are<br />known to have these types of polymorphisms, a lower daily dose of rosuvastatin is recommended.</p><p dir="ltr">Paediatric population<br />Two pharmacokinetic studies with rosuvastatin (given as tablets) in paediatric patients with<br />heterozygous familial hypercholesterolaemia 10 to 17 or 6 to17 years of age (total of 214 patients)<br />demonstrated that exposure in paediatric patients appears comparable to or lower than that in adult<br />patients. Rosuvastatin exposure was predictable with respect to dose and time over a 2-year<br />period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Preclinical data reveal no special hazard for humans based on conventional studies of safety<br />pharmacology, genotoxicity and carcinogenicity potential. Specific tests for effects on hERG have<br />not been evaluated. Adverse reactions not observed in clinical studies, but seen in animals at<br />exposure levels similar to clinical exposure levels were as follows: In repeated-dose toxicity<br />studies histopathologic liver changes likely due to the pharmacologic action of rosuvastatin were<br />observed in mouse, rat, and to a lesser extent with effects in the gall bladder in dogs, but not in<br />monkeys. In addition, testicular toxicity was observed in monkeys and dogs at higher dosages.<br />Reproductive toxicity was evident in rats, with reduced litter sizes, litter weight and pup survival<br />observed at maternally toxic doses, where systemic exposures were several times above the<br />therapeutic exposure level.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Tablet Core<br />Lactose monohydrate<br />Calcium Hydrogen Phosphate Anhydrous<br />Microcrystalline cellulose<br />Crospovidone (type B)<br />Magnesium stearate<br />Film-coating<br />Hypromellose (15cP) (E464)<br />Lactose monohydrate<br />Titanium dioxide (E171)<br />Allura red AC aluminium lake (E129)<br />Sunset Yellow FCF (E110)<br />Indigo carmine aluminium lake (E132)<br />Triacetin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Rosgan tablets are supplied in blister pack of 30&rsquo;s (10&rsquo;s Blister x 3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aurobindo Pharma Saudi Arabia Limited,
Jeddah, Saudi Arabia.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aug 2022.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>